



## Clinical trial results:

### A Randomized, Double-blind, Parallel-group, Placebo- and Active-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder

#### Summary

|                          |                                                          |
|--------------------------|----------------------------------------------------------|
| EudraCT number           | 2012-005735-91                                           |
| Trial protocol           | GB BE DE NL CZ HU LV SE IT EE FI SK SI DK ES LT PL GR BG |
| Global end of trial date | 22 October 2015                                          |

#### Results information

|                                |                  |
|--------------------------------|------------------|
| Result version number          | v1               |
| This version publication date  | 04 November 2016 |
| First version publication date | 04 November 2016 |

#### Trial information

##### Trial identification

|                       |            |
|-----------------------|------------|
| Sponsor protocol code | 178-CL-101 |
|-----------------------|------------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT01972841 |
| WHO universal trial number (UTN)   | -           |

Notes:

#### Sponsors

|                              |                                                                                                    |
|------------------------------|----------------------------------------------------------------------------------------------------|
| Sponsor organisation name    | Astellas Pharma Europe B.V.                                                                        |
| Sponsor organisation address | Sylviusweg 62, Leiden, Netherlands, 2333 BE                                                        |
| Public contact               | Clinical Trial Disclosure, Astellas Pharma Europe B.V.,<br>astellas.resultsdisclosure@astellas.com |
| Scientific contact           | Clinical Trial Disclosure, Astellas Pharma Europe B.V.,<br>astellas.resultsdisclosure@astellas.com |

Notes:

#### Paediatric regulatory details

|                                                                      |    |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|                                                      |                 |
|------------------------------------------------------|-----------------|
| Analysis stage                                       | Final           |
| Date of interim/final analysis                       | 22 October 2015 |
| Is this the analysis of the primary completion data? | No              |
| Global end of trial reached?                         | Yes             |
| Global end of trial date                             | 22 October 2015 |
| Was the trial ended prematurely?                     | No              |

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the efficacy of 2 dose combinations of solifenacin and mirabegron (5 + 25 mg and 5 + 50 mg) compared to solifenacin (5 mg) and mirabegron (25 mg and 50 mg) monotherapy.

Protection of trial subjects:

This clinical study was written, conducted and reported in accordance with the protocol, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) Guidelines, and applicable local regulations, including the European Directive 2001/20/EC, on the protection of human rights, and with the ethical principles that have their origin in the Declaration of Helsinki.

Astellas ensures that the use and disclosure of protected health information (PHI) obtained during a research study complies with the federal, national and/or regional legislation related to the privacy and protection of personal information.

Background therapy: -

Evidence for comparator: -

|                                                           |                  |
|-----------------------------------------------------------|------------------|
| Actual start date of recruitment                          | 05 November 2013 |
| Long term follow-up planned                               | No               |
| Independent data monitoring committee (IDMC) involvement? | Yes              |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                     |
|--------------------------------------|---------------------|
| Country: Number of subjects enrolled | Argentina: 5        |
| Country: Number of subjects enrolled | Australia: 56       |
| Country: Number of subjects enrolled | Belgium: 5          |
| Country: Number of subjects enrolled | Bulgaria: 116       |
| Country: Number of subjects enrolled | Canada: 133         |
| Country: Number of subjects enrolled | China: 118          |
| Country: Number of subjects enrolled | Czech Republic: 184 |
| Country: Number of subjects enrolled | Denmark: 7          |
| Country: Number of subjects enrolled | Estonia: 12         |
| Country: Number of subjects enrolled | Finland: 6          |
| Country: Number of subjects enrolled | France: 18          |
| Country: Number of subjects enrolled | Germany: 159        |
| Country: Number of subjects enrolled | Greece: 1           |
| Country: Number of subjects enrolled | Hong Kong: 4        |
| Country: Number of subjects enrolled | Hungary: 114        |
| Country: Number of subjects enrolled | Italy: 25           |
| Country: Number of subjects enrolled | Latvia: 29          |

|                                      |                         |
|--------------------------------------|-------------------------|
| Country: Number of subjects enrolled | Lithuania: 55           |
| Country: Number of subjects enrolled | Malaysia: 8             |
| Country: Number of subjects enrolled | Mexico: 19              |
| Country: Number of subjects enrolled | New Zealand: 16         |
| Country: Number of subjects enrolled | Norway: 40              |
| Country: Number of subjects enrolled | Peru: 14                |
| Country: Number of subjects enrolled | Philippines: 20         |
| Country: Number of subjects enrolled | Poland: 317             |
| Country: Number of subjects enrolled | Romania: 68             |
| Country: Number of subjects enrolled | Russian Federation: 108 |
| Country: Number of subjects enrolled | Singapore: 17           |
| Country: Number of subjects enrolled | Slovakia: 158           |
| Country: Number of subjects enrolled | Slovenia: 6             |
| Country: Number of subjects enrolled | South Africa: 36        |
| Country: Number of subjects enrolled | Korea, Republic of: 211 |
| Country: Number of subjects enrolled | Spain: 48               |
| Country: Number of subjects enrolled | Sweden: 79              |
| Country: Number of subjects enrolled | Taiwan: 8               |
| Country: Number of subjects enrolled | Thailand: 50            |
| Country: Number of subjects enrolled | Turkey: 5               |
| Country: Number of subjects enrolled | Ukraine: 325            |
| Country: Number of subjects enrolled | United Kingdom: 23      |
| Country: Number of subjects enrolled | United States: 873      |
| Country: Number of subjects enrolled | Netherlands: 31         |
| Worldwide total number of subjects   | 3527                    |
| EEA total number of subjects         | 1501                    |

Notes:

### Subjects enrolled per age group

|                                           |      |
|-------------------------------------------|------|
| In utero                                  | 0    |
| Preterm newborn - gestational age < 37 wk | 0    |
| Newborns (0-27 days)                      | 0    |
| Infants and toddlers (28 days-23 months)  | 0    |
| Children (2-11 years)                     | 0    |
| Adolescents (12-17 years)                 | 0    |
| Adults (18-64 years)                      | 2383 |
| From 65 to 84 years                       | 1134 |
| 85 years and over                         | 10   |

## Subject disposition

### Recruitment

Recruitment details:

Patients who had symptoms of "wet" overactive bladder (OAB) (urgency, urinary frequency and urgency incontinence) for  $\geq 3$  months were enrolled in 435 centers globally. Eligible participants went into a single-blind, 4-week placebo run-in period and completed a micturition diary 7 days prior to each study visit.

### Pre-assignment

Screening details:

A total of 6991 participants were screened, 6275 participants received placebo run-in treatment and 3527 participants were randomized into 1 of 6 treatment arms in a 1:1:1:1:2:2 ratio in the 12-week double-blind treatment period. A total of 953 participants were also enrolled in an ambulatory blood pressure monitoring (ABPM) substudy.

### Period 1

|                              |                                 |
|------------------------------|---------------------------------|
| Period 1 title               | Overall period (overall period) |
| Is this the baseline period? | Yes                             |
| Allocation method            | Randomised - controlled         |
| Blinding used                | Double blind                    |
| Roles blinded                | Subject, Investigator           |

### Arms

|                              |         |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes     |
| <b>Arm title</b>             | Placebo |

Arm description:

Participants who received matching placebo once a day for 12 weeks.

|                                        |                        |
|----------------------------------------|------------------------|
| Arm type                               | Placebo                |
| Investigational medicinal product name | Placebo to solifenacin |
| Investigational medicinal product code |                        |
| Other name                             |                        |
| Pharmaceutical forms                   | Tablet                 |
| Routes of administration               | Oral use               |

Dosage and administration details:

Participants received placebo to match solifenacin 5 mg orally once a day at the same time each day.

|                                        |                       |
|----------------------------------------|-----------------------|
| Investigational medicinal product name | Placebo to mirabegron |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Tablet                |
| Routes of administration               | Oral use              |

Dosage and administration details:

Participants received placebo to match mirabegron 25 mg or 50 mg orally once a day at the same time each day.

|                  |                  |
|------------------|------------------|
| <b>Arm title</b> | Mirabegron 25 mg |
|------------------|------------------|

Arm description:

Participants who received mirabegron 25 mg once a day for 12 weeks.

|                                        |                                        |
|----------------------------------------|----------------------------------------|
| Arm type                               | Active comparator                      |
| Investigational medicinal product name | Mirabegron                             |
| Investigational medicinal product code | YM178                                  |
| Other name                             | Myrbetriq, Myrbetric, Betanis, Betmiga |
| Pharmaceutical forms                   | Tablet                                 |
| Routes of administration               | Oral use                               |

Dosage and administration details:

Participants received mirabegron 25 mg orally once a day at the same time each day.

|                  |                  |
|------------------|------------------|
| <b>Arm title</b> | Mirabegron 50 mg |
|------------------|------------------|

Arm description:

Participants who received mirabegron 50 mg once a day for 12 weeks.

|                                        |                                        |
|----------------------------------------|----------------------------------------|
| Arm type                               | Active comparator                      |
| Investigational medicinal product name | Mirabegron                             |
| Investigational medicinal product code | YM178                                  |
| Other name                             | Myrbetriq, Myrbetric, Betanis, Betmiga |
| Pharmaceutical forms                   | Tablet                                 |
| Routes of administration               | Oral use                               |

Dosage and administration details:

Participants received mirabegron 50 mg orally once a day at the same time each day.

|                  |                  |
|------------------|------------------|
| <b>Arm title</b> | Solifenacin 5 mg |
|------------------|------------------|

Arm description:

Participants who received solifenacin 5 mg once a day for 12 weeks.

|                                        |                                          |
|----------------------------------------|------------------------------------------|
| Arm type                               | Active comparator                        |
| Investigational medicinal product name | Solifenacin succinate                    |
| Investigational medicinal product code | YM905                                    |
| Other name                             | Solifenacin, Vesicare, Vesikur, Vesitrim |
| Pharmaceutical forms                   | Tablet                                   |
| Routes of administration               | Oral use                                 |

Dosage and administration details:

Participants received solifenacin succinate 5 mg orally once a day at the same time each day.

|                  |                                     |
|------------------|-------------------------------------|
| <b>Arm title</b> | Solifenacin 5 mg + mirabegron 25 mg |
|------------------|-------------------------------------|

Arm description:

Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.

|                                        |                                          |
|----------------------------------------|------------------------------------------|
| Arm type                               | Experimental                             |
| Investigational medicinal product name | Solifenacin succinate                    |
| Investigational medicinal product code | YM905                                    |
| Other name                             | Solifenacin, Vesicare, Vesikur, Vesitrim |
| Pharmaceutical forms                   | Tablet                                   |
| Routes of administration               | Oral use                                 |

Dosage and administration details:

Participants received solifenacin succinate 5 mg orally once a day at the same time each day.

|                                        |                                        |
|----------------------------------------|----------------------------------------|
| Investigational medicinal product name | Mirabegron                             |
| Investigational medicinal product code | YM178                                  |
| Other name                             | Myrbetriq, Myrbetric, Betanis, Betmiga |
| Pharmaceutical forms                   | Tablet                                 |
| Routes of administration               | Oral use                               |

Dosage and administration details:

Participants received mirabegron 25 mg orally once a day at the same time each day.

|                  |                                     |
|------------------|-------------------------------------|
| <b>Arm title</b> | Solifenacin 5 mg + mirabegron 50 mg |
|------------------|-------------------------------------|

Arm description:

Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.

|          |              |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

|                                        |                                          |
|----------------------------------------|------------------------------------------|
| Investigational medicinal product name | Solifenacin succinate                    |
| Investigational medicinal product code | YM905                                    |
| Other name                             | Solifenacin, Vesicare, Vesikur, Vesitrim |
| Pharmaceutical forms                   | Tablet                                   |
| Routes of administration               | Oral use                                 |

Dosage and administration details:

Participants received solifenacin succinate 5 mg orally once a day at the same time each day.

|                                        |                                        |
|----------------------------------------|----------------------------------------|
| Investigational medicinal product name | Mirabegron                             |
| Investigational medicinal product code | YM178                                  |
| Other name                             | Myrbetriq, Myrbetric, Betanis, Betmiga |
| Pharmaceutical forms                   | Tablet                                 |
| Routes of administration               | Oral use                               |

Dosage and administration details:

Participants received mirabegron 50 mg orally once a day at the same time each day.

| <b>Number of subjects in period 1</b>            | Placebo | Mirabegron 25 mg | Mirabegron 50 mg |
|--------------------------------------------------|---------|------------------|------------------|
| Started                                          | 447     | 441              | 437              |
| Treated                                          | 444     | 436              | 433              |
| Safety Analysis Set (SAF)                        | 429     | 423              | 422              |
| Full Analysis Set (FAS)                          | 418     | 410              | 411              |
| Completed                                        | 404     | 397              | 387              |
| Not completed                                    | 43      | 44               | 50               |
| Randomized but never received double-blind tdrug | 2       | 5                | 4                |
| Protocol violation                               | 2       | 2                | 3                |
| Did not have a treatment page                    | -       | -                | -                |
| Miscellaneous                                    | -       | -                | 4                |
| Adverse event                                    | 13      | 8                | 12               |
| Lost to follow-up                                | 4       | 2                | 4                |
| Lack of efficacy                                 | 1       | -                | -                |
| Withdrawal by patient                            | 21      | 27               | 23               |

| <b>Number of subjects in period 1</b>            | Solifenacin 5 mg | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |
|--------------------------------------------------|------------------|-------------------------------------|-------------------------------------|
| Started                                          | 434              | 885                                 | 883                                 |
| Treated                                          | 432              | 878                                 | 871                                 |
| Safety Analysis Set (SAF)                        | 423              | 853                                 | 848                                 |
| Full Analysis Set (FAS)                          | 415              | 827                                 | 827                                 |
| Completed                                        | 397              | 802                                 | 798                                 |
| Not completed                                    | 37               | 83                                  | 85                                  |
| Randomized but never received double-blind tdrug | 2                | 6                                   | 13                                  |
| Protocol violation                               | 5                | 9                                   | 4                                   |
| Did not have a treatment page                    | -                | 1                                   | -                                   |

|                       |    |    |    |
|-----------------------|----|----|----|
| Miscellaneous         | 1  | -  | 4  |
| Adverse event         | 9  | 21 | 26 |
| Lost to follow-up     | 2  | 9  | 3  |
| Lack of efficacy      | 2  | 4  | 1  |
| Withdrawal by patient | 16 | 33 | 34 |

## Baseline characteristics

### Reporting groups

|                                                                                          |                                     |
|------------------------------------------------------------------------------------------|-------------------------------------|
| Reporting group title                                                                    | Placebo                             |
| Reporting group description:                                                             |                                     |
| Participants who received matching placebo once a day for 12 weeks.                      |                                     |
| Reporting group title                                                                    | Mirabegron 25 mg                    |
| Reporting group description:                                                             |                                     |
| Participants who received mirabegron 25 mg once a day for 12 weeks.                      |                                     |
| Reporting group title                                                                    | Mirabegron 50 mg                    |
| Reporting group description:                                                             |                                     |
| Participants who received mirabegron 50 mg once a day for 12 weeks.                      |                                     |
| Reporting group title                                                                    | Solifenacin 5 mg                    |
| Reporting group description:                                                             |                                     |
| Participants who received solifenacin 5 mg once a day for 12 weeks.                      |                                     |
| Reporting group title                                                                    | Solifenacin 5 mg + mirabegron 25 mg |
| Reporting group description:                                                             |                                     |
| Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks. |                                     |
| Reporting group title                                                                    | Solifenacin 5 mg + mirabegron 50 mg |
| Reporting group description:                                                             |                                     |
| Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks. |                                     |

| Reporting group values | Placebo | Mirabegron 25 mg | Mirabegron 50 mg |
|------------------------|---------|------------------|------------------|
| Number of subjects     | 447     | 441              | 437              |
| Age categorical        |         |                  |                  |
| Units: Subjects        |         |                  |                  |

|                                                                                |        |         |         |
|--------------------------------------------------------------------------------|--------|---------|---------|
| Age continuous                                                                 |        |         |         |
| Randomized analysis set (RAS), comprised of all randomized participants.       |        |         |         |
| Units: years                                                                   |        |         |         |
| arithmetic mean                                                                | 57.46  | 56.77   | 56.69   |
| standard deviation                                                             | ± 13.2 | ± 13.46 | ± 13.28 |
| Gender categorical                                                             |        |         |         |
| RAS                                                                            |        |         |         |
| Units:                                                                         |        |         |         |
| Male                                                                           | 102    | 98      | 99      |
| Female                                                                         | 345    | 343     | 338     |
| Mean Number of Incontinence Episodes per 24 Hours                              |        |         |         |
| RAS; data only available for 3490 participants [444, 434, 433, 432, 877, 870]. |        |         |         |
| Units: incontinence episodes                                                   |        |         |         |
| arithmetic mean                                                                | 3.32   | 3.33    | 3.16    |
| standard deviation                                                             | ± 3.32 | ± 3.36  | ± 3.44  |
| Mean Number of Micturations per 24 Hours                                       |        |         |         |
| RAS; data only available for 3490 participants [444, 434, 433, 432, 877, 870]. |        |         |         |
| Units: micturations                                                            |        |         |         |
| arithmetic mean                                                                | 10.9   | 10.79   | 11.14   |
| standard deviation                                                             | ± 2.81 | ± 2.61  | ± 3.22  |

|                                                                                                                                                                   |         |         |         |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|---------|---------|
| Mean Volume Voided per Micturition                                                                                                                                |         |         |         |
| RAS; data only available for 3475 participants [440, 433, 431, 430, 873, 868].                                                                                    |         |         |         |
| Units: mL                                                                                                                                                         |         |         |         |
| arithmetic mean                                                                                                                                                   | 157.53  | 151.79  | 155.36  |
| standard deviation                                                                                                                                                | ± 58.53 | ± 60.39 | ± 59.7  |
| Number of Incontinence Episodes per Week                                                                                                                          |         |         |         |
| RAS; data only available for 3490 participants [444, 434, 433, 432, 877, 870].                                                                                    |         |         |         |
| Units: incontinence episodes                                                                                                                                      |         |         |         |
| arithmetic mean                                                                                                                                                   | 22.99   | 22.85   | 21.58   |
| standard deviation                                                                                                                                                | ± 23.2  | ± 23.31 | ± 23.53 |
| Mean Number of Urgency Incontinence Episodes per 24 Hours                                                                                                         |         |         |         |
| RAS; data only available for 3469 participants [441, 432, 427, 431, 872, 866]. Only participants with ≥ 1 urgency incontinence episode at baseline were included. |         |         |         |
| Units: urgency incontinence episodes                                                                                                                              |         |         |         |
| arithmetic mean                                                                                                                                                   | 3.07    | 2.92    | 2.88    |
| standard deviation                                                                                                                                                | ± 3.18  | ± 3.05  | ± 3.28  |
| Number of Urgency Incontinence Episodes per Week                                                                                                                  |         |         |         |
| RAS; data only available for 3469 participants [441, 432, 427, 431, 872, 866]. Only participants with ≥ 1 urgency incontinence episode at baseline were included. |         |         |         |
| Units: urgency incontinence episodes                                                                                                                              |         |         |         |
| arithmetic mean                                                                                                                                                   | 21.25   | 20.03   | 19.73   |
| standard deviation                                                                                                                                                | ± 22.2  | ± 21.09 | ± 22.43 |
| Mean Number of Urgency Episodes (Grade 3 or 4) per 24 Hours                                                                                                       |         |         |         |
| RAS; data only available for 3488 participants [442, 434, 433, 432, 876, 870]. Only participants with ≥ 1 urgency episode at baseline were included.              |         |         |         |
| Units: urgency episodes                                                                                                                                           |         |         |         |
| arithmetic mean                                                                                                                                                   | 6.66    | 6.35    | 6.58    |
| standard deviation                                                                                                                                                | ± 4.02  | ± 3.88  | ± 4.83  |
| Mean Number of Nocturia Episodes per 24 Hours                                                                                                                     |         |         |         |
| RAS; data only available for 3002 participants [393, 366, 377, 367, 754, 745]. Only participants with ≥ 1 nocturia episode at baseline were included.             |         |         |         |
| Units: nocturia episodes                                                                                                                                          |         |         |         |
| arithmetic mean                                                                                                                                                   | 1.57    | 1.53    | 1.59    |
| standard deviation                                                                                                                                                | ± 1.04  | ± 1.01  | ± 1.08  |
| Number of Nocturia Episodes per Week                                                                                                                              |         |         |         |
| RAS; data only available for 3002 participants [393, 366, 377, 367, 754, 745]. Only participants with ≥ 1 nocturia episode at baseline were included.             |         |         |         |
| Units: nocturia episodes                                                                                                                                          |         |         |         |
| arithmetic mean                                                                                                                                                   | 10.83   | 10.57   | 10.98   |
| standard deviation                                                                                                                                                | ± 7.26  | ± 7.06  | ± 7.52  |
| Mean Number of Pads Used per 24 Hours                                                                                                                             |         |         |         |
| RAS; data only available for 2203 participants [281, 272, 270, 278, 554, 548]. Only participants with ≥ 1 pad used at baseline were included.                     |         |         |         |
| Units: pads                                                                                                                                                       |         |         |         |
| arithmetic mean                                                                                                                                                   | 2.79    | 2.74    | 2.56    |
| standard deviation                                                                                                                                                | ± 2.91  | ± 2.63  | ± 3.11  |
| Number of Pads Used per Week                                                                                                                                      |         |         |         |
| RAS; data only available for 2203 participants [281, 272, 270, 278, 554, 548]. Only participants with ≥ 1 pad used at baseline were included.                     |         |         |         |
| Units: pads                                                                                                                                                       |         |         |         |

|                    |         |         |         |
|--------------------|---------|---------|---------|
| arithmetic mean    | 19.29   | 18.78   | 17.5    |
| standard deviation | ± 20.38 | ± 18.21 | ± 21.17 |

| <b>Reporting group values</b> | Solifenacin 5 mg | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |
|-------------------------------|------------------|-------------------------------------|-------------------------------------|
| Number of subjects            | 434              | 885                                 | 883                                 |
| Age categorical               |                  |                                     |                                     |
| Units: Subjects               |                  |                                     |                                     |

|                                                                                                                                                                   |         |         |         |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|---------|---------|
| Age continuous                                                                                                                                                    |         |         |         |
| Randomized analysis set (RAS), comprised of all randomized participants.                                                                                          |         |         |         |
| Units: years                                                                                                                                                      |         |         |         |
| arithmetic mean                                                                                                                                                   | 57.88   | 56.94   | 57.3    |
| standard deviation                                                                                                                                                | ± 12.92 | ± 13.78 | ± 13.46 |
| Gender categorical                                                                                                                                                |         |         |         |
| RAS                                                                                                                                                               |         |         |         |
| Units:                                                                                                                                                            |         |         |         |
| Male                                                                                                                                                              | 92      | 199     | 199     |
| Female                                                                                                                                                            | 342     | 686     | 684     |
| Mean Number of Incontinence Episodes per 24 Hours                                                                                                                 |         |         |         |
| RAS; data only available for 3490 participants [444, 434, 433, 432, 877, 870].                                                                                    |         |         |         |
| Units: incontinence episodes                                                                                                                                      |         |         |         |
| arithmetic mean                                                                                                                                                   | 3.56    | 3.15    | 3.11    |
| standard deviation                                                                                                                                                | ± 3.51  | ± 3.15  | ± 3.05  |
| Mean Number of Micturations per 24 Hours                                                                                                                          |         |         |         |
| RAS; data only available for 3490 participants [444, 434, 433, 432, 877, 870].                                                                                    |         |         |         |
| Units: micturations                                                                                                                                               |         |         |         |
| arithmetic mean                                                                                                                                                   | 10.77   | 10.72   | 10.74   |
| standard deviation                                                                                                                                                | ± 2.64  | ± 2.85  | ± 2.35  |
| Mean Volume Voided per Micturition                                                                                                                                |         |         |         |
| RAS; data only available for 3475 participants [440, 433, 431, 430, 873, 868].                                                                                    |         |         |         |
| Units: mL                                                                                                                                                         |         |         |         |
| arithmetic mean                                                                                                                                                   | 152.09  | 159.47  | 153.74  |
| standard deviation                                                                                                                                                | ± 59.57 | ± 58.15 | ± 59.38 |
| Number of Incontinence Episodes per Week                                                                                                                          |         |         |         |
| RAS; data only available for 3490 participants [444, 434, 433, 432, 877, 870].                                                                                    |         |         |         |
| Units: incontinence episodes                                                                                                                                      |         |         |         |
| arithmetic mean                                                                                                                                                   | 24.64   | 21.57   | 21.41   |
| standard deviation                                                                                                                                                | ± 24.46 | ± 21.6  | ± 21.1  |
| Mean Number of Urgency Incontinence Episodes per 24 Hours                                                                                                         |         |         |         |
| RAS; data only available for 3469 participants [441, 432, 427, 431, 872, 866]. Only participants with ≥ 1 urgency incontinence episode at baseline were included. |         |         |         |
| Units: urgency incontinence episodes                                                                                                                              |         |         |         |
| arithmetic mean                                                                                                                                                   | 3.21    | 2.79    | 2.76    |
| standard deviation                                                                                                                                                | ± 3.32  | ± 2.8   | ± 2.63  |
| Number of Urgency Incontinence Episodes per Week                                                                                                                  |         |         |         |
| RAS; data only available for 3469 participants [441, 432, 427, 431, 872, 866]. Only participants with ≥ 1 urgency incontinence episode at baseline were included. |         |         |         |

|                                                                                                                                                       |         |         |         |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|---------|---------|---------|
| Units: urgency incontinence episodes                                                                                                                  |         |         |         |
| arithmetic mean                                                                                                                                       | 22.23   | 19.15   | 18.99   |
| standard deviation                                                                                                                                    | ± 23.19 | ± 19.26 | ± 18.11 |
| Mean Number of Urgency Episodes<br>(Grade 3 or 4) per 24 Hours                                                                                        |         |         |         |
| RAS; data only available for 3488 participants [442, 434, 433, 432, 876, 870]. Only participants with ≥ 1 urgency episode at baseline were included.  |         |         |         |
| Units: urgency episodes                                                                                                                               |         |         |         |
| arithmetic mean                                                                                                                                       | 6.6     | 6.34    | 6.33    |
| standard deviation                                                                                                                                    | ± 3.87  | ± 3.72  | ± 3.59  |
| Mean Number of Nocturia Episodes per<br>24 Hours                                                                                                      |         |         |         |
| RAS; data only available for 3002 participants [393, 366, 377, 367, 754, 745]. Only participants with ≥ 1 nocturia episode at baseline were included. |         |         |         |
| Units: nocturia episdes                                                                                                                               |         |         |         |
| arithmetic mean                                                                                                                                       | 1.61    | 1.57    | 1.54    |
| standard deviation                                                                                                                                    | ± 0.95  | ± 1.06  | ± 0.97  |
| Number of Nocturia Episodes per Week                                                                                                                  |         |         |         |
| RAS; data only available for 3002 participants [393, 366, 377, 367, 754, 745]. Only participants with ≥ 1 nocturia episode at baseline were included. |         |         |         |
| Units: nocturia episodes                                                                                                                              |         |         |         |
| arithmetic mean                                                                                                                                       | 11.13   | 10.82   | 10.62   |
| standard deviation                                                                                                                                    | ± 6.6   | ± 7.38  | ± 6.74  |
| Mean Number of Pads Used per 24<br>Hours                                                                                                              |         |         |         |
| RAS; data only available for 2203 participants [281, 272, 270, 278, 554, 548]. Only participants with ≥ 1 pad used at baseline were included.         |         |         |         |
| Units: pads                                                                                                                                           |         |         |         |
| arithmetic mean                                                                                                                                       | 2.84    | 2.44    | 2.55    |
| standard deviation                                                                                                                                    | ± 3.08  | ± 2.56  | ± 2.37  |
| Number of Pads Used per Week                                                                                                                          |         |         |         |
| RAS; data only available for 2203 participants [281, 272, 270, 278, 554, 548]. Only participants with ≥ 1 pad used at baseline were included.         |         |         |         |
| Units: pads                                                                                                                                           |         |         |         |
| arithmetic mean                                                                                                                                       | 19.62   | 16.72   | 17.5    |
| standard deviation                                                                                                                                    | ± 21.39 | ± 17.58 | ± 16.34 |

|                               |       |  |  |
|-------------------------------|-------|--|--|
| <b>Reporting group values</b> | Total |  |  |
| Number of subjects            | 3527  |  |  |
| Age categorical               |       |  |  |
| Units: Subjects               |       |  |  |

|                                                                          |      |  |  |
|--------------------------------------------------------------------------|------|--|--|
| Age continuous                                                           |      |  |  |
| Randomized analysis set (RAS), comprised of all randomized participants. |      |  |  |
| Units: years                                                             |      |  |  |
| arithmetic mean                                                          |      |  |  |
| standard deviation                                                       | -    |  |  |
| Gender categorical                                                       |      |  |  |
| RAS                                                                      |      |  |  |
| Units:                                                                   |      |  |  |
| Male                                                                     | 789  |  |  |
| Female                                                                   | 2738 |  |  |

|                                                                                                                                                                        |   |  |  |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|--|--|
| Mean Number of Incontinence Episodes per 24 Hours                                                                                                                      |   |  |  |
| RAS; data only available for 3490 participants [444, 434, 433, 432, 877, 870].                                                                                         |   |  |  |
| Units: incontinence episodes<br>arithmetic mean<br>standard deviation                                                                                                  | - |  |  |
| Mean Number of Micturitions per 24 Hours                                                                                                                               |   |  |  |
| RAS; data only available for 3490 participants [444, 434, 433, 432, 877, 870].                                                                                         |   |  |  |
| Units: micturitions<br>arithmetic mean<br>standard deviation                                                                                                           | - |  |  |
| Mean Volume Voided per Micturition                                                                                                                                     |   |  |  |
| RAS; data only available for 3475 participants [440, 433, 431, 430, 873, 868].                                                                                         |   |  |  |
| Units: mL<br>arithmetic mean<br>standard deviation                                                                                                                     | - |  |  |
| Number of Incontinence Episodes per Week                                                                                                                               |   |  |  |
| RAS; data only available for 3490 participants [444, 434, 433, 432, 877, 870].                                                                                         |   |  |  |
| Units: incontinence episodes<br>arithmetic mean<br>standard deviation                                                                                                  | - |  |  |
| Mean Number of Urgency Incontinence Episodes per 24 Hours                                                                                                              |   |  |  |
| RAS; data only available for 3469 participants [441, 432, 427, 431, 872, 866]. Only participants with $\geq 1$ urgency incontinence episode at baseline were included. |   |  |  |
| Units: urgency incontinence episodes<br>arithmetic mean<br>standard deviation                                                                                          | - |  |  |
| Number of Urgency Incontinence Episodes per Week                                                                                                                       |   |  |  |
| RAS; data only available for 3469 participants [441, 432, 427, 431, 872, 866]. Only participants with $\geq 1$ urgency incontinence episode at baseline were included. |   |  |  |
| Units: urgency incontinence episodes<br>arithmetic mean<br>standard deviation                                                                                          | - |  |  |
| Mean Number of Urgency Episodes (Grade 3 or 4) per 24 Hours                                                                                                            |   |  |  |
| RAS; data only available for 3488 participants [442, 434, 433, 432, 876, 870]. Only participants with $\geq 1$ urgency episode at baseline were included.              |   |  |  |
| Units: urgency episodes<br>arithmetic mean<br>standard deviation                                                                                                       | - |  |  |
| Mean Number of Nocturia Episodes per 24 Hours                                                                                                                          |   |  |  |
| RAS; data only available for 3002 participants [393, 366, 377, 367, 754, 745]. Only participants with $\geq 1$ nocturia episode at baseline were included.             |   |  |  |
| Units: nocturia episodes<br>arithmetic mean<br>standard deviation                                                                                                      | - |  |  |
| Number of Nocturia Episodes per Week                                                                                                                                   |   |  |  |
| RAS; data only available for 3002 participants [393, 366, 377, 367, 754, 745]. Only participants with $\geq 1$ nocturia episode at baseline were included.             |   |  |  |
| Units: nocturia episodes<br>arithmetic mean                                                                                                                            |   |  |  |

|                                                                                                                                                    |   |  |  |
|----------------------------------------------------------------------------------------------------------------------------------------------------|---|--|--|
| standard deviation                                                                                                                                 | - |  |  |
| Mean Number of Pads Used per 24 Hours                                                                                                              |   |  |  |
| RAS; data only available for 2203 participants [281, 272, 270, 278, 554, 548]. Only participants with $\geq 1$ pad used at baseline were included. |   |  |  |
| Units: pads                                                                                                                                        |   |  |  |
| arithmetic mean                                                                                                                                    |   |  |  |
| standard deviation                                                                                                                                 | - |  |  |
| Number of Pads Used per Week                                                                                                                       |   |  |  |
| RAS; data only available for 2203 participants [281, 272, 270, 278, 554, 548]. Only participants with $\geq 1$ pad used at baseline were included. |   |  |  |
| Units: pads                                                                                                                                        |   |  |  |
| arithmetic mean                                                                                                                                    |   |  |  |
| standard deviation                                                                                                                                 | - |  |  |

## End points

### End points reporting groups

|                                                                                                                          |                                     |
|--------------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| Reporting group title                                                                                                    | Placebo                             |
| Reporting group description:<br>Participants who received matching placebo once a day for 12 weeks.                      |                                     |
| Reporting group title                                                                                                    | Mirabegron 25 mg                    |
| Reporting group description:<br>Participants who received mirabegron 25 mg once a day for 12 weeks.                      |                                     |
| Reporting group title                                                                                                    | Mirabegron 50 mg                    |
| Reporting group description:<br>Participants who received mirabegron 50 mg once a day for 12 weeks.                      |                                     |
| Reporting group title                                                                                                    | Solifenacin 5 mg                    |
| Reporting group description:<br>Participants who received solifenacin 5 mg once a day for 12 weeks.                      |                                     |
| Reporting group title                                                                                                    | Solifenacin 5 mg + mirabegron 25 mg |
| Reporting group description:<br>Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks. |                                     |
| Reporting group title                                                                                                    | Solifenacin 5 mg + mirabegron 50 mg |
| Reporting group description:<br>Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks. |                                     |

### Primary: Change from Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes per 24 Hours

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Change from Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes per 24 Hours |
| End point description:<br>An incontinence episode is defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period. The analysis population was the Full Analysis Set (FAS), which was comprised of all randomized participants who took $\geq 1$ dose of double-blind treatment, reported $\geq 1$ micturition in the baseline diary and $\geq 1$ micturition postbaseline, reported $\geq 1$ incontinence episode in the baseline diary and excluded participants from site 10153. Last observation carried forward (LOCF) for EoT was used. |                                                                                                     |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Primary                                                                                             |
| End point timeframe:<br>Baseline and Week 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                     |

| End point values                    | Placebo             | Mirabegron 25 mg   | Mirabegron 50 mg    | Solifenacin 5 mg    |
|-------------------------------------|---------------------|--------------------|---------------------|---------------------|
| Subject group type                  | Reporting group     | Reporting group    | Reporting group     | Reporting group     |
| Number of subjects analysed         | 412                 | 409                | 406                 | 413                 |
| Units: incontinence episodes        |                     |                    |                     |                     |
| least squares mean (standard error) | -1.34 ( $\pm 0.1$ ) | -1.7 ( $\pm 0.1$ ) | -1.76 ( $\pm 0.1$ ) | -1.79 ( $\pm 0.1$ ) |

|                                     |                                     |                                     |  |  |
|-------------------------------------|-------------------------------------|-------------------------------------|--|--|
| <b>End point values</b>             | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
| Subject group type                  | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed         | 823                                 | 816                                 |  |  |
| Units: incontinence episodes        |                                     |                                     |  |  |
| least squares mean (standard error) | -2.04 (± 0.07)                      | -1.98 (± 0.07)                      |  |  |

## Statistical analyses

|                                   |                                     |
|-----------------------------------|-------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Solifenacin 5 mg (1) |
|-----------------------------------|-------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (< 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1236                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority <sup>[1]</sup>                             |
| P-value                                 | = 0.072 <sup>[2]</sup>                                 |
| Method                                  | Stratified rank ANCOVA                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.25                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -0.49                                                  |
| upper limit                             | -0.01                                                  |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.12                                                   |

Notes:

[1] - Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure. No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.

[2] - Nominal p-value

|                                   |                                     |
|-----------------------------------|-------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Solifenacin 5 mg (2) |
|-----------------------------------|-------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (< 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                   |                                                        |
|-------------------|--------------------------------------------------------|
| Comparison groups | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
|-------------------|--------------------------------------------------------|

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1229                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority <sup>[3]</sup>    |
| P-value                                 | = 0.033                       |
| Method                                  | Stratified rank ANCOVA        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | -0.2                          |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | -0.44                         |
| upper limit                             | 0.04                          |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 0.12                          |

Notes:

[3] - Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure. No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.

|                                   |                                 |
|-----------------------------------|---------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg |
|-----------------------------------|---------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 25 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (< 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1232                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority <sup>[4]</sup>                             |
| P-value                                 | = 0.001 <sup>[5]</sup>                                 |
| Method                                  | Stratified rank ANCOVA                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.34                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -0.58                                                  |
| upper limit                             | -0.1                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.12                                                   |

Notes:

[4] - Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure. No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.

[5] - Nominal p-value

|                                   |                                 |
|-----------------------------------|---------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 50 mg |
|-----------------------------------|---------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 50 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (< 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                   |                                                        |
|-------------------|--------------------------------------------------------|
| Comparison groups | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
|-------------------|--------------------------------------------------------|

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1222                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority <sup>[6]</sup>    |
| P-value                                 | = 0.052                       |
| Method                                  | Stratified rank ANCOVA        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | -0.23                         |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | -0.47                         |
| upper limit                             | 0.01                          |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 0.12                          |

Notes:

[6] - Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure. No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.

### **Primary: Change from Baseline to EoT in Mean Number of Micturitions per 24 Hours**

|                                                                                                                                                                                                                                                                                                                                    |                                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                    | Change from Baseline to EoT in Mean Number of Micturitions per 24 Hours |
| End point description:                                                                                                                                                                                                                                                                                                             |                                                                         |
| A micturition is defined as any voluntary micturition (excluding incontinence only episodes). The mean number of micturitions per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period. The analysis population was the FAS. LOCF for EoT was used. |                                                                         |
| End point type                                                                                                                                                                                                                                                                                                                     | Primary                                                                 |
| End point timeframe:                                                                                                                                                                                                                                                                                                               |                                                                         |
| Baseline and Week 12                                                                                                                                                                                                                                                                                                               |                                                                         |

| <b>End point values</b>             | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|-------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                  | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed         | 412             | 409              | 406              | 413              |
| Units: micturitions                 |                 |                  |                  |                  |
| least squares mean (standard error) | -1.64 (± 0.12)  | -2 (± 0.12)      | -2.03 (± 0.12)   | -2.2 (± 0.12)    |

| <b>End point values</b>             | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|-------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                  | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed         | 823                                 | 816                                 |  |  |
| Units: micturitions                 |                                     |                                     |  |  |
| least squares mean (standard error) | -2.49 (± 0.08)                      | -2.59 (± 0.08)                      |  |  |

## Statistical analyses

| Statistical analysis title | Difference vs. Solifenacin 5 mg (1) |
|----------------------------|-------------------------------------|
|----------------------------|-------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (< 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1236                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority <sup>[7]</sup>                             |
| P-value                                 | = 0.04 <sup>[8]</sup>                                  |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.29                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -0.57                                                  |
| upper limit                             | -0.01                                                  |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.14                                                   |

Notes:

[7] - Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure. No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.

[8] - Nominal p-value

| Statistical analysis title | Difference vs. Solifenacin 5 mg (2) |
|----------------------------|-------------------------------------|
|----------------------------|-------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (< 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1229                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority <sup>[9]</sup>                             |
| P-value                                 | = 0.006 <sup>[10]</sup>                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.39                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -0.67                                                  |
| upper limit                             | -0.11                                                  |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.14                                                   |

Notes:

[9] - Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure. No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                                | Difference vs. Mirabegron 25 mg                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                                         |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 25 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (< 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                         | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                                   | 1232                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                                    | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                                             | superiority <sup>[11]</sup>                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                                   | = 0.001 <sup>[12]</sup>                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                                    | ANCOVA                                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                                        | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                                            | -0.48                                                  |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                                       |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                                     | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                                     | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                               | -0.76                                                  |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                               | -0.21                                                  |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                                      | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                                          | 0.14                                                   |

Notes:

[11] - Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure. No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.

[12] - Nominal p-value

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                                | Difference vs. Mirabegron 50 mg                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                                         |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 50 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (< 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                         | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                                   | 1222                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                                    | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                                             | superiority <sup>[13]</sup>                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                                   | < 0.001 <sup>[14]</sup>                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                                    | ANCOVA                                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                                        | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                                            | -0.56                                                  |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                                       |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                                     | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                                     | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                               | -0.84                                                  |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                               | -0.28                                                  |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                                      | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                                          | 0.14                                                   |

Notes:

[13] - Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure. No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.

[14] - Nominal p-value

## Secondary: Change from Baseline to EoT in Mean Volume Voided per Micturition

|                 |                                                                   |
|-----------------|-------------------------------------------------------------------|
| End point title | Change from Baseline to EoT in Mean Volume Voided per Micturition |
|-----------------|-------------------------------------------------------------------|

End point description:

The mean volume voided per micturition was calculated from the data recorded by the participant during 3 consecutive days with volume measurements during the 7-day micturition diary period. The analysis population was the FAS. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 12

| End point values                    | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|-------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                  | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed         | 413             | 407              | 408              | 411              |
| Units: mL                           |                 |                  |                  |                  |
| least squares mean (standard error) | 8.44 (± 2.55)   | 13.32 (± 2.57)   | 21.99 (± 2.57)   | 30.99 (± 2.56)   |

| End point values                    | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|-------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                  | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed         | 821                                 | 821                                 |  |  |
| Units: mL                           |                                     |                                     |  |  |
| least squares mean (standard error) | 34.84 (± 1.81)                      | 39.73 (± 1.81)                      |  |  |

## Statistical analyses

|                            |                                     |
|----------------------------|-------------------------------------|
| Statistical analysis title | Difference vs. Solifenacin 5 mg (1) |
|----------------------------|-------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (< 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                   |                                                        |
|-------------------|--------------------------------------------------------|
| Comparison groups | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
|-------------------|--------------------------------------------------------|

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1232                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority <sup>[15]</sup>   |
| P-value                                 | = 0.219 <sup>[16]</sup>       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | 3.85                          |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | -2.29                         |
| upper limit                             | 10                            |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 3.13                          |

Notes:

[15] - Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure. No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.

[16] - Nominal p-value

|                                   |                                     |
|-----------------------------------|-------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Solifenacin 5 mg (2) |
|-----------------------------------|-------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (< 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1232                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority <sup>[17]</sup>                            |
| P-value                                 | = 0.005 <sup>[18]</sup>                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | 8.75                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 2.61                                                   |
| upper limit                             | 14.89                                                  |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 3.13                                                   |

Notes:

[17] - Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure. No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.

[18] - Nominal p-value

|                                   |                                 |
|-----------------------------------|---------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg |
|-----------------------------------|---------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 25 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (< 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                   |                                                        |
|-------------------|--------------------------------------------------------|
| Comparison groups | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
|-------------------|--------------------------------------------------------|

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1228                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority <sup>[19]</sup>   |
| P-value                                 | < 0.001 <sup>[20]</sup>       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | 21.52                         |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | 15.35                         |
| upper limit                             | 27.68                         |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 3.14                          |

Notes:

[19] - Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure. No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.

[20] - Nominal p-value

|                                   |                                 |
|-----------------------------------|---------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 50 mg |
|-----------------------------------|---------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 50 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (< 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1229                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority <sup>[21]</sup>                            |
| P-value                                 | < 0.001 <sup>[22]</sup>                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | 17.74                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 11.58                                                  |
| upper limit                             | 23.9                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 3.14                                                   |

Notes:

[21] - Adjustment for multiplicity across primary and the first secondary endpoint as well as across the 2 combination doses was made using a sequential Bonferroni-based testing procedure. No adjustment for multiplicity was needed for testing combination therapy vs. its 2 monotherapy components.

[22] - Nominal p-value

## Secondary: Change from Baseline to EoT in OAB Questionnaire (OAB-q) Symptom Bother Score

|                 |                                                                               |
|-----------------|-------------------------------------------------------------------------------|
| End point title | Change from Baseline to EoT in OAB Questionnaire (OAB-q) Symptom Bother Score |
|-----------------|-------------------------------------------------------------------------------|

End point description:

The OAB-q is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion consists of 8 items, rated on a 6-point Likert scale

(1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicates an improvement. The analysis population was the FAS. LOCF for EoT was used.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Baseline and Week 12 |           |

| End point values                    | Placebo              | Mirabegron 25 mg     | Mirabegron 50 mg     | Solifenacin 5 mg     |
|-------------------------------------|----------------------|----------------------|----------------------|----------------------|
| Subject group type                  | Reporting group      | Reporting group      | Reporting group      | Reporting group      |
| Number of subjects analysed         | 400                  | 392                  | 398                  | 399                  |
| Units: units on a scale             |                      |                      |                      |                      |
| least squares mean (standard error) | -19.45 ( $\pm$ 0.98) | -23.93 ( $\pm$ 0.99) | -26.14 ( $\pm$ 0.98) | -26.44 ( $\pm$ 0.98) |

| End point values                    | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|-------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                  | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed         | 800                                 | 795                                 |  |  |
| Units: units on a scale             |                                     |                                     |  |  |
| least squares mean (standard error) | -31.06 ( $\pm$ 0.69)                | -32.24 ( $\pm$ 0.7)                 |  |  |

## Statistical analyses

|                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                                     | Difference vs. Solifenacin 5 mg (1)                    |
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                                              |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (< 65, $\geq$ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                              | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                                        | 1199                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                                         | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                                                  | superiority <sup>[23]</sup>                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                                        | < 0.001                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                                         | ANCOVA                                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                                             | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                                                 | -4.63                                                  |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                                            |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                                          | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                                          | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                                    | -6.98                                                  |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                                    | -2.27                                                  |

|                      |                            |
|----------------------|----------------------------|
| Variability estimate | Standard error of the mean |
| Dispersion value     | 1.2                        |

Notes:

[23] - No adjustment for multiplicity was made for this comparison.

|                                   |                                     |
|-----------------------------------|-------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Solifenacin 5 mg (2) |
|-----------------------------------|-------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (< 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1194                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority <sup>[24]</sup>                            |
| P-value                                 | < 0.001                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -5.8                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -8.17                                                  |
| upper limit                             | -3.44                                                  |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 1.21                                                   |

Notes:

[24] - No adjustment for multiplicity was made for this comparison.

|                                   |                                 |
|-----------------------------------|---------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg |
|-----------------------------------|---------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 25 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (< 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1192                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority <sup>[25]</sup>                            |
| P-value                                 | < 0.001                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -7.13                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -9.5                                                   |
| upper limit                             | -4.76                                                  |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 1.21                                                   |

Notes:

[25] - No adjustment for multiplicity was made for this comparison.

|                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                                         | Difference vs. Mirabegron 50 mg                        |
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                                         |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 50 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (< 65, ≥ 65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                         | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                                   | 1193                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                                    | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                                             | superiority <sup>[26]</sup>                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                                   | < 0.001                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                                    | ANCOVA                                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                                        | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                                            | -6.1                                                   |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                                       |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                                     | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                                     | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                               | -8.46                                                  |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                               | -3.74                                                  |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                                      | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                                          | 1.2                                                    |

Notes:

[26] - No adjustment for multiplicity was made for this comparison.

### Secondary: Change from Baseline to EoT in Treatment Satisfaction-Visual Analogue Scale (TS-VAS)

|                                                                                                                                                                                                                                                                                                                                                         |                                                                                      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                         | Change from Baseline to EoT in Treatment Satisfaction-Visual Analogue Scale (TS-VAS) |
| End point description:                                                                                                                                                                                                                                                                                                                                  |                                                                                      |
| The TS-VAS is a visual analogue scale which asks participants to rate their satisfaction with the treatment by placing a vertical mark on a line that runs from 0 (No, not at all) on the left to 10 (Yes, completely) on the right. A positive change from baseline indicates improvement. The analysis population was the FAS. LOCF for EoT was used. |                                                                                      |
| End point type                                                                                                                                                                                                                                                                                                                                          | Secondary                                                                            |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                    |                                                                                      |
| Baseline and Week 12                                                                                                                                                                                                                                                                                                                                    |                                                                                      |

| End point values                    | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|-------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                  | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed         | 399             | 391              | 398              | 399              |
| Units: units on a scale             |                 |                  |                  |                  |
| least squares mean (standard error) | 1.42 (± 0.11)   | 2.16 (± 0.11)    | 2.18 (± 0.11)    | 2.28 (± 0.11)    |

|                                     |                                     |                                     |  |  |
|-------------------------------------|-------------------------------------|-------------------------------------|--|--|
| <b>End point values</b>             | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
| Subject group type                  | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed         | 798                                 | 794                                 |  |  |
| Units: units on a scale             |                                     |                                     |  |  |
| least squares mean (standard error) | 2.53 ( $\pm$ 0.08)                  | 2.55 ( $\pm$ 0.08)                  |  |  |

## Statistical analyses

|                                   |                                     |
|-----------------------------------|-------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Solifenacin 5 mg (1) |
|-----------------------------------|-------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (< 65,  $\geq$  65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1197                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority <sup>[27]</sup>                            |
| P-value                                 | = 0.077 <sup>[28]</sup>                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | 0.25                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -0.03                                                  |
| upper limit                             | 0.52                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.14                                                   |

Notes:

[27] - No adjustment for multiplicity was made for this comparison.

[28] - P < 0.05 indicates statistical significance at the 0.05 level.

|                                   |                                     |
|-----------------------------------|-------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Solifenacin 5 mg (2) |
|-----------------------------------|-------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (< 65,  $\geq$  65 years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1193                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority <sup>[29]</sup>                            |
| P-value                                 | = 0.05 <sup>[30]</sup>                                 |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | 0.27                                                   |

|                      |                            |
|----------------------|----------------------------|
| Confidence interval  |                            |
| level                | 95 %                       |
| sides                | 2-sided                    |
| lower limit          | 0                          |
| upper limit          | 0.55                       |
| Variability estimate | Standard error of the mean |
| Dispersion value     | 0.14                       |

Notes:

[29] - No adjustment for multiplicity was made for this comparison.

[30] -  $P < 0.05$  indicates statistical significance at the 0.05 level.

|                                   |                                 |
|-----------------------------------|---------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg |
|-----------------------------------|---------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 25 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group ( $< 65$ ,  $\geq 65$  years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1189                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority <sup>[31]</sup>                            |
| P-value                                 | = 0.008 <sup>[32]</sup>                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | 0.37                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 0.1                                                    |
| upper limit                             | 0.65                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.14                                                   |

Notes:

[31] - No adjustment for multiplicity was made for this comparison.

[32] -  $P < 0.05$  indicates statistical significance at the 0.05 level.

|                                   |                                 |
|-----------------------------------|---------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 50 mg |
|-----------------------------------|---------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 50 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group ( $< 65$ ,  $\geq 65$  years), previous overactive bladder medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1192                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority <sup>[33]</sup>                            |
| P-value                                 | = 0.007 <sup>[34]</sup>                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | 0.37                                                   |

|                      |                            |
|----------------------|----------------------------|
| Confidence interval  |                            |
| level                | 95 %                       |
| sides                | 2-sided                    |
| lower limit          | 0.1                        |
| upper limit          | 0.65                       |
| Variability estimate | Standard error of the mean |
| Dispersion value     | 0.14                       |

Notes:

[33] - No adjustment for multiplicity was made for this comparison.

[34] -  $P < 0.05$  indicates statistical significance at the 0.05 level.

### Secondary: Number of Incontinence Episodes at Weeks 4, 8, 12 and EoT

|                                                                                                                                                                                                                                                                                               |                                                           |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                               | Number of Incontinence Episodes at Weeks 4, 8, 12 and EoT |
| End point description:                                                                                                                                                                                                                                                                        |                                                           |
| The number of incontinence episodes is the number of times a participant records an incontinence episode during the 7-day micturition diary period prior to each visit. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. |                                                           |
| End point type                                                                                                                                                                                                                                                                                | Secondary                                                 |
| End point timeframe:                                                                                                                                                                                                                                                                          |                                                           |
| Weeks 4, 8 and 12                                                                                                                                                                                                                                                                             |                                                           |

| End point values                         | Placebo             | Mirabegron 25 mg    | Mirabegron 50 mg    | Solifenacin 5 mg    |
|------------------------------------------|---------------------|---------------------|---------------------|---------------------|
| Subject group type                       | Reporting group     | Reporting group     | Reporting group     | Reporting group     |
| Number of subjects analysed              | 418                 | 410                 | 411                 | 415                 |
| Units: incontinence episodes             |                     |                     |                     |                     |
| least squares mean (standard error)      |                     |                     |                     |                     |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | 18.09 ( $\pm$ 1.17) | 15.65 ( $\pm$ 1.08) | 12.9 ( $\pm$ 1.06)  | 15.31 ( $\pm$ 1.11) |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | 14.45 ( $\pm$ 1.12) | 12.84 ( $\pm$ 1.05) | 11.31 ( $\pm$ 1.09) | 12.19 ( $\pm$ 1.06) |
| Week 12 [N=374, 369, 369, 379, 754, 750] | 14.06 ( $\pm$ 1.17) | 10.6 ( $\pm$ 0.98)  | 9.5 ( $\pm$ 0.98)   | 11.25 ( $\pm$ 1.03) |
| Eot [N=412, 409, 406, 413, 823, 816]     | 13.7 ( $\pm$ 1.08)  | 11.19 ( $\pm$ 0.95) | 9.79 ( $\pm$ 0.94)  | 11.21 ( $\pm$ 0.98) |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: incontinence episodes             |                                     |                                     |  |  |
| least squares mean (standard error)      |                                     |                                     |  |  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | 12.51 ( $\pm$ 0.67)                 | 11.44 ( $\pm$ 0.7)                  |  |  |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | 9.7 ( $\pm$ 0.65)                   | 9.33 ( $\pm$ 0.68)                  |  |  |
| Week 12 [N=374, 369, 369, 379, 754, 750] | 7.62 ( $\pm$ 0.57)                  | 8.21 ( $\pm$ 0.68)                  |  |  |
| Eot [N=412, 409, 406, 413, 823, 816]     | 8.02 ( $\pm$ 0.55)                  | 8.18 ( $\pm$ 0.64)                  |  |  |

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Rate ratio vs. Solifenacin 5 mg (1) (EoT)              |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                        |
| Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (<65, ≥65 years), geographic region and previous OAB medication (yes, no) as factors, log(number of incontinence episodes used divided by number of valid diary days) at baseline included as a covariate and number of valid diary days at EoT as the offset variable. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | = 0.135                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Negative binomial regression                           |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Rate ratio                                             |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 0.87                                                   |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.72                                                   |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 1.04                                                   |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 0.09                                                   |

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Rate ratio vs. Solifenacin 5 mg (2) (EoT)              |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                        |
| Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (<65, ≥65 years), geographic region and previous OAB medication (yes, no) as factors, log(number of incontinence episodes used divided by number of valid diary days) at baseline included as a covariate and number of valid diary days at EoT as the offset variable. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | = 0.282                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Negative binomial regression                           |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Rate ratio                                             |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 0.9                                                    |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.75                                                   |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 1.09                                                   |

|                      |                            |
|----------------------|----------------------------|
| Variability estimate | Standard error of the mean |
| Dispersion value     | 0.09                       |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Rate ratio vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (<65, ≥65 years), geographic region and previous OAB medication (yes, no) as factors, log(number of incontinence episodes used divided by number of valid diary days) at baseline included as a covariate and number of valid diary days at EoT as the offset variable.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | Negative binomial regression                           |
| Parameter estimate                      | Rate ratio                                             |
| Point estimate                          | 0.71                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 0.59                                                   |
| upper limit                             | 0.85                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.09                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Rate ratio vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (<65, ≥65 years), geographic region and previous OAB medication (yes, no) as factors, log(number of incontinence episodes used divided by number of valid diary days) at baseline included as a covariate and number of valid diary days at EoT as the offset variable.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.172                                                |
| Method                                  | Negative binomial regression                           |
| Parameter estimate                      | Rate ratio                                             |
| Point estimate                          | 0.88                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 0.73                                                   |
| upper limit                             | 1.06                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.1                                                    |

## Secondary: Change from Baseline to Weeks 4, 8, 12 and EoT in Number of Incontinence Episodes

|                 |                                                                                   |
|-----------------|-----------------------------------------------------------------------------------|
| End point title | Change from Baseline to Weeks 4, 8, 12 and EoT in Number of Incontinence Episodes |
|-----------------|-----------------------------------------------------------------------------------|

End point description:

The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 8, 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: incontinence episodes             |                 |                  |                  |                  |
| least squares mean (standard error)      |                 |                  |                  |                  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | -5.23 (± 0.66)  | -7.59 (± 0.66)   | -8.99 (± 0.67)   | -8.92 (± 0.67)   |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | -8.79 (± 0.71)  | -10.57 (± 0.72)  | -10.97 (± 0.72)  | -11.89 (± 0.72)  |
| Week 12 [N=374, 369, 369, 379, 754, 750] | -9.05 (± 0.72)  | -12.33 (± 0.72)  | -12.58 (± 0.72)  | -12.75 (± 0.71)  |
| EoT [N=412, 409, 406, 413, 823, 816]     | -9.42 (± 0.68)  | -11.93 (± 0.68)  | -12.39 (± 0.68)  | -12.65 (± 0.68)  |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 823                                 | 816                                 |  |  |
| Units: incontinence episodes             |                                     |                                     |  |  |
| least squares mean (standard error)      |                                     |                                     |  |  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | -9.62 (± 0.47)                      | -10.51 (± 0.47)                     |  |  |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | -12.53 (± 0.5)                      | -12.78 (± 0.51)                     |  |  |
| Week 12 [N=374, 369, 369, 379, 754, 750] | -14.5 (± 0.51)                      | -13.94 (± 0.51)                     |  |  |
| EoT [N=412, 409, 406, 413, 823, 816]     | -14.29 (± 0.48)                     | -13.98 (± 0.48)                     |  |  |

## Statistical analyses

|                                                                                                                                                                                                                                                                                                                                                                                                           |                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                         | Difference vs. Solifenacin 5 mg (1) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                         |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                         | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                   | 1238                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                    | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                             | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                   | = 0.074                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                    | Stratified rank ANCOVA                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                        | least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                            | -1.64                                                  |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                       |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                     | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                     | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                               | -3.27                                                  |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                               | -0.01                                                  |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                      | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                          | 0.83                                                   |

|                                                                                                                                                                                                                                                                                                                                                                                                           |                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                         | Difference vs. Solifenacin 5 mg (2) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                         |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the solifenacin 5 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                         | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                   | 1231                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                    | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                             | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                   | = 0.025                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                    | Stratified rank ANCOVA                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                        | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                            | -1.33                                                  |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                       |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                     | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                     | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                               | -2.96                                                  |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                               | 0.3                                                    |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                      | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                          | 0.83                                                   |

|                                                                                                                                                                                                      |                                       |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                    | Difference vs. Mirabegron 25 mg (EoT) |
| Statistical analysis description:                                                                                                                                                                    |                                       |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 25 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron |                                       |

25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1233                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | Stratified rank ANCOVA                                 |
| Parameter estimate                      | least square mean difference                           |
| Point estimate                          | -2.36                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -4                                                     |
| upper limit                             | -0.73                                                  |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.83                                                   |

|                                                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                        | Difference vs. Mirabegron 50 mg (EoT)                  |
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the mirabegron 50 mg monotherapy group from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                        | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                  | 1227                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                   | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                            | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                  | = 0.024                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                   | Stratified rank ANCOVA                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                       | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                           | -1.59                                                  |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                      |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                    | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                    | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                              | -3.23                                                  |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                              | 0.05                                                   |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                     | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                         | 0.84                                                   |

## Secondary: Change from Baseline to Weeks 4, 8 and 12 in Mean Number of Incontinence Episodes per 24 Hours

|                                                                                                                       |                                                                                                |
|-----------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| End point title                                                                                                       | Change from Baseline to Weeks 4, 8 and 12 in Mean Number of Incontinence Episodes per 24 Hours |
| End point description:                                                                                                |                                                                                                |
| The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. |                                                                                                |
| End point type                                                                                                        | Secondary                                                                                      |

End point timeframe:

Baseline and Weeks 4, 8, 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: incontinence episodes             |                 |                  |                  |                  |
| least squares mean (standard error)      |                 |                  |                  |                  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | -0.74 (± 0.1)   | -1.07 (± 0.1)    | -1.24 (± 0.1)    | -1.24 (± 0.1)    |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | -1.2 (± 0.1)    | -1.51 (± 0.1)    | -1.57 (± 0.1)    | -1.66 (± 0.1)    |
| Week 12 [N=374, 369, 369, 379, 754, 750] | -1.3 (± 0.11)   | -1.76 (± 0.11)   | -1.81 (± 0.11)   | -1.8 (± 0.1)     |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: incontinence episodes             |                                     |                                     |  |  |
| least squares mean (standard error)      |                                     |                                     |  |  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | -1.38 (± 0.07)                      | -1.5 (± 0.07)                       |  |  |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | -1.79 (± 0.07)                      | -1.84 (± 0.07)                      |  |  |
| Week 12 [N=374, 369, 369, 379, 754, 750] | -2.08 (± 0.07)                      | -1.98 (± 0.07)                      |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to Weeks 4, 8 and 12 in Mean Number of Micturitions per 24 Hours

|                 |                                                                                       |
|-----------------|---------------------------------------------------------------------------------------|
| End point title | Change from Baseline to Weeks 4, 8 and 12 in Mean Number of Micturitions per 24 Hours |
|-----------------|---------------------------------------------------------------------------------------|

End point description:

The analysis population was the FAS. N is the number of participants analyzed with data available at each time point.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 8, 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: micturations                      |                 |                  |                  |                  |
| least squares mean (standard error)      |                 |                  |                  |                  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | -1.02 (± 0.11)  | -1.46 (± 0.11)   | -1.44 (± 0.11)   | -1.39 (± 0.11)   |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | -1.43 (± 0.11)  | -1.95 (± 0.12)   | -1.89 (± 0.12)   | -1.84 (± 0.12)   |
| Week 12 [N=374, 369, 369, 379, 754, 750] | -1.51 (± 0.12)  | -2.01 (± 0.12)   | -2.03 (± 0.12)   | -2.22 (± 0.12)   |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: micturations                      |                                     |                                     |  |  |
| least squares mean (standard error)      |                                     |                                     |  |  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | -1.67 (± 0.08)                      | -1.91 (± 0.08)                      |  |  |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | -2.23 (± 0.08)                      | -2.42 (± 0.08)                      |  |  |
| Week 12 [N=374, 369, 369, 379, 754, 750] | -2.47 (± 0.08)                      | -2.6 (± 0.08)                       |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to Weeks 4, 8 and 12 in Mean Volume Voided per Micturition

|                                                                                                                                                 |                                                                                 |
|-------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| End point title                                                                                                                                 | Change from Baseline to Weeks 4, 8 and 12 in Mean Volume Voided per Micturition |
| End point description:<br>The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. |                                                                                 |
| End point type                                                                                                                                  | Secondary                                                                       |
| End point timeframe:<br>Baseline and Weeks 4, 8, 12                                                                                             |                                                                                 |

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: mL                                |                 |                  |                  |                  |
| least squares mean (standard error)      |                 |                  |                  |                  |
| Week 4 [N=403, 398, 399, 395, 798, 802]  | 6.95 (± 2.13)   | 10.08 (± 2.14)   | 15.52 (± 2.14)   | 24.23 (± 2.15)   |
| Week 8 [N=395, 382, 380, 387, 770, 771]  | 9 (± 2.48)      | 10.96 (± 2.52)   | 17.73 (± 2.53)   | 27.55 (± 2.5)    |
| Week 12 [N=373, 362, 364, 378, 750, 750] | 8.7 (± 2.7)     | 12.88 (± 2.74)   | 22.4 (± 2.73)    | 31.89 (± 2.68)   |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: mL                                |                                     |                                     |  |  |
| least squares mean (standard error)      |                                     |                                     |  |  |
| Week 4 [N=403, 398, 399, 395, 798, 802]  | 25.54 (± 1.51)                      | 28.99 (± 1.51)                      |  |  |
| Week 8 [N=395, 382, 380, 387, 770, 771]  | 32.94 (± 1.78)                      | 36.51 (± 1.77)                      |  |  |
| Week 12 [N=373, 362, 364, 378, 750, 750] | 35.52 (± 1.9)                       | 41.28 (± 1.9)                       |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to EoT in Corrected Micturition Frequency

|                 |                                                                |
|-----------------|----------------------------------------------------------------|
| End point title | Change from Baseline to EoT in Corrected Micturition Frequency |
|-----------------|----------------------------------------------------------------|

End point description:

Corrected micturition frequency is defined as the mean number of micturitions per 24 hours that participants had at end of treatment if their fluid intake had remained unchanged since baseline. The analysis population was the FAS. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 12

| End point values                    | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|-------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                  | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed         | 412             | 409              | 406              | 413              |
| Units: micturitions                 |                 |                  |                  |                  |
| least squares mean (standard error) | 0.15 (± 0.24)   | -0.17 (± 0.24)   | -0.97 (± 0.24)   | -1.28 (± 0.24)   |

| End point values                    | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|-------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                  | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed         | 823                                 | 816                                 |  |  |
| Units: micturitions                 |                                     |                                     |  |  |
| least squares mean (standard error) | -1.1 (± 0.17)                       | -1.52 (± 0.17)                      |  |  |

## Statistical analyses

| Statistical analysis title | Difference vs. Solifenacin 5 mg (1) (EoT) |
|----------------------------|-------------------------------------------|
|----------------------------|-------------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline mean number of micturitions per 24 hours as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1236                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.52                                                 |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | 0.19                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -0.39                                                  |
| upper limit                             | 0.76                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.29                                                   |

| Statistical analysis title | Difference vs. Solifenacin 5 mg (2) (EoT) |
|----------------------------|-------------------------------------------|
|----------------------------|-------------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline mean number of

micturitions per 24 hours as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1229                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.413                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.24                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -0.82                                                  |
| upper limit                             | 0.34                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.29                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline mean number of micturitions per 24 hours as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1232                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.002                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.92                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -1.5                                                   |
| upper limit                             | -0.34                                                  |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.29                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline mean number of micturitions per 24 hours as a covariate.

|                   |                                                        |
|-------------------|--------------------------------------------------------|
| Comparison groups | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
|-------------------|--------------------------------------------------------|

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1222                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | = 0.06                        |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | -0.56                         |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | -1.13                         |
| upper limit                             | 0.02                          |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 0.3                           |

### Secondary: Number of Urgency Incontinence Episodes at Weeks 4, 8, 12 and EOT

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Number of Urgency Incontinence Episodes at Weeks 4, 8, 12 and EOT |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                   |
| An urgency incontinence episode is defined as the involuntary leakage of urine accompanied by or immediately preceded by urgency. The number of urgency incontinence episodes is number of times a participant records an urgency incontinence episode during the 7-day micturition diary period prior to each visit. The analysis population was the FAS. Only participants with $\geq 1$ urgency incontinence episode at baseline were included in the analysis. N is the number of participants analyzed with data available at each time point. LOCF for EOT was used. |                                                                   |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Secondary                                                         |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                   |
| Weeks 4, 8 and 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                   |

| End point values                         | Placebo              | Mirabegron 25 mg     | Mirabegron 50 mg     | Solifenacin 5 mg     |
|------------------------------------------|----------------------|----------------------|----------------------|----------------------|
| Subject group type                       | Reporting group      | Reporting group      | Reporting group      | Reporting group      |
| Number of subjects analysed              | 418                  | 410                  | 411                  | 415                  |
| Units: urgency incontinence episodes     |                      |                      |                      |                      |
| least squares mean (standard error)      |                      |                      |                      |                      |
| Week 4 [N=403, 404, 396, 401, 813, 806]  | 15.76 ( $\pm 1.1$ )  | 13.36 ( $\pm 0.99$ ) | 11.46 ( $\pm 1$ )    | 13.19 ( $\pm 1.06$ ) |
| Week 8 [N=394, 383, 380, 385, 780, 765]  | 12.77 ( $\pm 1.07$ ) | 10.65 ( $\pm 0.94$ ) | 10.09 ( $\pm 1.02$ ) | 10.41 ( $\pm 1$ )    |
| Week 12 [N=371, 367, 363, 378, 750, 746] | 12 ( $\pm 1.09$ )    | 8.84 ( $\pm 0.89$ )  | 8.32 ( $\pm 0.94$ )  | 9.29 ( $\pm 0.96$ )  |
| EOT [N=409, 407, 400, 412, 819, 812]     | 11.69 ( $\pm 1$ )    | 9.37 ( $\pm 0.86$ )  | 8.63 ( $\pm 0.89$ )  | 9.29 ( $\pm 0.91$ )  |

| End point values | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------|-------------------------------------|-------------------------------------|--|--|
|------------------|-------------------------------------|-------------------------------------|--|--|

|                                          |                     |                    |  |  |
|------------------------------------------|---------------------|--------------------|--|--|
| Subject group type                       | Reporting group     | Reporting group    |  |  |
| Number of subjects analysed              | 827                 | 827                |  |  |
| Units: urgency incontinence episodes     |                     |                    |  |  |
| least squares mean (standard error)      |                     |                    |  |  |
| Week 4 [N=403, 404, 396, 401, 813, 806]  | 10.22 ( $\pm$ 0.58) | 9.33 ( $\pm$ 0.58) |  |  |
| Week 8 [N=394, 383, 380, 385, 780, 765]  | 7.58 ( $\pm$ 0.53)  | 7.31 ( $\pm$ 0.54) |  |  |
| Week 12 [N=371, 367, 363, 378, 750, 746] | 5.86 ( $\pm$ 0.46)  | 6.27 ( $\pm$ 0.49) |  |  |
| EOT [N=409, 407, 400, 412, 819, 812]     | 6.25 ( $\pm$ 0.45)  | 6.15 ( $\pm$ 0.47) |  |  |

## Statistical analyses

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Rate ratio vs. Solifenacin 5 mg (1) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                        |
| Rate ratio of number of urgency incontinence episodes during the 7-day diary bet. the given combination group & the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (<65, $\geq$ 65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of urgency incontinence episodes used divided by number of valid diary days) included as a covariate & postbaseline number of valid diary days as offset variable. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | = 0.11                                                 |
| Method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Negative binomial regression                           |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Rate ratio                                             |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 0.85                                                   |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0.7                                                    |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 1.04                                                   |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.1                                                    |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Rate ratio vs. Solifenacin 5 mg (2) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                        |
| Rate ratio of number of urgency incontinence episodes during the 7-day diary bet. the given combination group & the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (<65, $\geq$ 65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of urgency incontinence episodes used divided by number of valid diary days) included as a covariate & postbaseline number of valid diary days as offset variable. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |

|                                         |                              |
|-----------------------------------------|------------------------------|
| Number of subjects included in analysis | 1242                         |
| Analysis specification                  | Pre-specified                |
| Analysis type                           | superiority                  |
| P-value                                 | = 0.288                      |
| Method                                  | Negative binomial regression |
| Parameter estimate                      | Rate ratio                   |
| Point estimate                          | 0.9                          |
| Confidence interval                     |                              |
| level                                   | 95 %                         |
| sides                                   | 2-sided                      |
| lower limit                             | 0.73                         |
| upper limit                             | 1.1                          |
| Variability estimate                    | Standard error of the mean   |
| Dispersion value                        | 0.1                          |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Rate ratio vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Rate ratio of number of urgency incontinence episodes during the 7-day diary bet. the given combination group & the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (<65, ≥ 65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of urgency incontinence episodes used divided by number of valid diary days) included as a covariate & postbaseline number of valid diary days as offset variable.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | Negative binomial regression                           |
| Parameter estimate                      | Rate ratio                                             |
| Point estimate                          | 0.65                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 0.53                                                   |
| upper limit                             | 0.79                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.1                                                    |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Rate ratio vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Rate ratio of number of urgency incontinence episodes during the 7-day diary bet. the given combination group & the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (<65, ≥ 65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of urgency incontinence episodes used divided by number of valid diary days) included as a covariate & postbaseline number of valid diary days as offset variable.

|                   |                                                        |
|-------------------|--------------------------------------------------------|
| Comparison groups | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
|-------------------|--------------------------------------------------------|

|                                         |                              |
|-----------------------------------------|------------------------------|
| Number of subjects included in analysis | 1238                         |
| Analysis specification                  | Pre-specified                |
| Analysis type                           | superiority                  |
| P-value                                 | = 0.084                      |
| Method                                  | Negative binomial regression |
| Parameter estimate                      | Rate ratio                   |
| Point estimate                          | 0.84                         |
| Confidence interval                     |                              |
| level                                   | 95 %                         |
| sides                                   | 2-sided                      |
| lower limit                             | 0.68                         |
| upper limit                             | 1.02                         |
| Variability estimate                    | Standard error of the mean   |
| Dispersion value                        | 0.1                          |

### Secondary: Change from Baseline to Weeks 4, 8, 12 and EoT in Number of Urgency Incontinence Episodes

|                                                                                                                                                                                                                                                      |                                                                                           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                      | Change from Baseline to Weeks 4, 8, 12 and EoT in Number of Urgency Incontinence Episodes |
| End point description:                                                                                                                                                                                                                               |                                                                                           |
| The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. Only participants with $\geq 1$ urgency incontinence episode at baseline were included in the analysis. LOCF for EoT was used. |                                                                                           |
| End point type                                                                                                                                                                                                                                       | Secondary                                                                                 |
| End point timeframe:                                                                                                                                                                                                                                 |                                                                                           |
| Baseline and Weeks 4, 8, 12                                                                                                                                                                                                                          |                                                                                           |

| End point values                         | Placebo             | Mirabegron 25 mg     | Mirabegron 50 mg     | Solifenacin 5 mg     |
|------------------------------------------|---------------------|----------------------|----------------------|----------------------|
| Subject group type                       | Reporting group     | Reporting group      | Reporting group      | Reporting group      |
| Number of subjects analysed              | 418                 | 410                  | 411                  | 415                  |
| Units: urgency incontinence episodes     |                     |                      |                      |                      |
| least squares mean (standard error)      |                     |                      |                      |                      |
| Week 4 [N=403, 404, 396, 401, 813, 806]  | -5.49 ( $\pm$ 0.63) | -7.07 ( $\pm$ 0.63)  | -8.39 ( $\pm$ 0.63)  | -8.53 ( $\pm$ 0.63)  |
| Week 8 [N=394, 383, 380, 385, 780, 765]  | -8.3 ( $\pm$ 0.66)  | -9.93 ( $\pm$ 0.67)  | -10.07 ( $\pm$ 0.67) | -11.1 ( $\pm$ 0.67)  |
| Week 12 [N=371, 367, 363, 378, 750, 746] | -8.96 ( $\pm$ 0.65) | -11.39 ( $\pm$ 0.66) | -11.66 ( $\pm$ 0.66) | -12.1 ( $\pm$ 0.65)  |
| EoT [N=409, 407, 400, 412, 819, 812]     | -9.26 ( $\pm$ 0.62) | -11.03 ( $\pm$ 0.62) | -11.44 ( $\pm$ 0.62) | -12.03 ( $\pm$ 0.62) |

|                  |                                     |                                     |  |  |
|------------------|-------------------------------------|-------------------------------------|--|--|
| End point values | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------|-------------------------------------|-------------------------------------|--|--|

|                                          |                 |                 |  |  |
|------------------------------------------|-----------------|-----------------|--|--|
| Subject group type                       | Reporting group | Reporting group |  |  |
| Number of subjects analysed              | 827             | 827             |  |  |
| Units: urgency incontinence episodes     |                 |                 |  |  |
| least squares mean (standard error)      |                 |                 |  |  |
| Week 4 [N=403, 404, 396, 401, 813, 806]  | -9.44 (± 0.44)  | -10.23 (± 0.44) |  |  |
| Week 8 [N=394, 383, 380, 385, 780, 765]  | -12.18 (± 0.47) | -12.38 (± 0.47) |  |  |
| Week 12 [N=371, 367, 363, 378, 750, 746] | -13.87 (± 0.46) | -13.53 (± 0.46) |  |  |
| EoT [N=409, 407, 400, 412, 819, 812]     | -13.64 (± 0.44) | -13.64 (± 0.44) |  |  |

## Statistical analyses

|                                                                                                                                                                                                                                                                                                                                                                                                            |                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                          | Difference vs. Solifenacin 5 mg (1) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                    | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                     | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                              | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                    | = 0.114                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                     | ANCOVA                                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                         | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                             | -1.61                                                  |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                      | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                      | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                | -3.09                                                  |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                | -0.13                                                  |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                       | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                           | 0.76                                                   |

|                                                                                                                                                                                                                                                                                                                                                                                                            |                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                          | Difference vs. Solifenacin 5 mg (2) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1242                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | = 0.034                       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | -1.62                         |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | -3.1                          |
| upper limit                             | -0.13                         |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 0.76                          |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -2.61                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -4.09                                                  |
| upper limit                             | -1.12                                                  |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.76                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                   |                                                        |
|-------------------|--------------------------------------------------------|
| Comparison groups | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
|-------------------|--------------------------------------------------------|

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1238                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | = 0.012                       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | -2.21                         |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | -3.7                          |
| upper limit                             | -0.71                         |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 0.76                          |

### Secondary: Change from Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Incontinence Episodes per 24 Hours

|                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title        | Change from Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Incontinence Episodes per 24 Hours                                                                                                                                                                                                                                                                                                                                           |
| End point description: | The mean number of urgency incontinence episodes was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. Only participants with $\geq 1$ urgency incontinence episode at baseline were included in the analysis. LOCF for EoT was used. |
| End point type         | Secondary                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| End point timeframe:   | Baseline and Weeks 4, 8, 12                                                                                                                                                                                                                                                                                                                                                                                                                           |

| End point values                         | Placebo             | Mirabegron 25 mg    | Mirabegron 50 mg    | Solifenacin 5 mg    |
|------------------------------------------|---------------------|---------------------|---------------------|---------------------|
| Subject group type                       | Reporting group     | Reporting group     | Reporting group     | Reporting group     |
| Number of subjects analysed              | 418                 | 410                 | 411                 | 415                 |
| Units: urgency incontinence episodes     |                     |                     |                     |                     |
| least squares mean (standard error)      |                     |                     |                     |                     |
| Week 4 [N=403, 404, 396, 401, 813, 806]  | -0.78 ( $\pm$ 0.09) | -1 ( $\pm$ 0.09)    | -1.15 ( $\pm$ 0.09) | -1.19 ( $\pm$ 0.09) |
| Week 8 [N=394, 383, 380, 385, 780, 765]  | -1.15 ( $\pm$ 0.1)  | -1.43 ( $\pm$ 0.1)  | -1.44 ( $\pm$ 0.1)  | -1.56 ( $\pm$ 0.1)  |
| Week 12 [N=371, 367, 363, 378, 750, 746] | -1.29 ( $\pm$ 0.1)  | -1.63 ( $\pm$ 0.1)  | -1.67 ( $\pm$ 0.1)  | -1.72 ( $\pm$ 0.1)  |
| EoT [N=409, 407, 400, 412, 819, 812]     | -1.33 ( $\pm$ 0.09) | -1.58 ( $\pm$ 0.09) | -1.62 ( $\pm$ 0.09) | -1.71 ( $\pm$ 0.09) |

| End point values | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------|-------------------------------------|-------------------------------------|--|--|
|------------------|-------------------------------------|-------------------------------------|--|--|

|                                          |                 |                 |  |  |
|------------------------------------------|-----------------|-----------------|--|--|
| Subject group type                       | Reporting group | Reporting group |  |  |
| Number of subjects analysed              | 827             | 827             |  |  |
| Units: urgency incontinence episodes     |                 |                 |  |  |
| least squares mean (standard error)      |                 |                 |  |  |
| Week 4 [N=403, 404, 396, 401, 813, 806]  | -1.35 (± 0.06)  | -1.47 (± 0.06)  |  |  |
| Week 8 [N=394, 383, 380, 385, 780, 765]  | -1.74 (± 0.07)  | -1.79 (± 0.07)  |  |  |
| Week 12 [N=371, 367, 363, 378, 750, 746] | -1.99 (± 0.07)  | -1.93 (± 0.07)  |  |  |
| EoT [N=409, 407, 400, 412, 819, 812]     | -1.95 (± 0.06)  | -1.94 (± 0.06)  |  |  |

## Statistical analyses

|                                                                                                                                                                                                                                                                                                                                                                                                            |                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                          | Difference vs. Solifenacin 5 mg (1) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                    | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                     | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                              | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                    | = 0.134                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                     | Stratified rank ANCOVA                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                         | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                             | -0.24                                                  |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                      | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                      | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                | -0.46                                                  |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                | -0.02                                                  |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                       | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                           | 0.11                                                   |

|                                                                                                                                                                                                                                                                                                                                                                                                            |                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                          | Difference vs. Solifenacin 5 mg (2) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1242                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | = 0.043                       |
| Method                                  | Stratified rank ANCOVA        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | -0.23                         |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | -0.45                         |
| upper limit                             | -0.02                         |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 0.11                          |

|                                   |                                           |
|-----------------------------------|-------------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg (2) (EoT) |
|-----------------------------------|-------------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | Stratified rank ANCOVA                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.37                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -0.59                                                  |
| upper limit                             | -0.15                                                  |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.11                                                   |

|                                   |                                           |
|-----------------------------------|-------------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg (2) (EoT) |
|-----------------------------------|-------------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                   |                                                        |
|-------------------|--------------------------------------------------------|
| Comparison groups | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
|-------------------|--------------------------------------------------------|

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1238                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | = 0.019                       |
| Method                                  | Stratified rank ANCOVA        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | -0.32                         |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | -0.54                         |
| upper limit                             | -0.1                          |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 0.11                          |

### Secondary: Change from Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Episodes (Grade 3 or 4) per 24 Hours

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Change from Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Episodes (Grade 3 or 4) per 24 Hours |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                               |
| An urgency episode is a complaint of a sudden, compelling desire to pass urine, which is difficult to defer; it is recorded when a micturition or incontinence episode is recorded and the severity of urinary urgency recorded is 3 (severe urgency) or 4 (urgency incontinence) according to the Patient Perception of Intensity of Urgency Scale (PPIUS). The mean number of urgency episodes was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. Only participants with $\geq 1$ urgency episode at baseline were included in the analysis. LOCF for EoT was used. |                                                                                                               |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Secondary                                                                                                     |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                               |
| Baseline and Weeks 4, 8, 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                               |

| End point values                         | Placebo             | Mirabegron 25 mg    | Mirabegron 50 mg    | Solifenacin 5 mg    |
|------------------------------------------|---------------------|---------------------|---------------------|---------------------|
| Subject group type                       | Reporting group     | Reporting group     | Reporting group     | Reporting group     |
| Number of subjects analysed              | 418                 | 410                 | 411                 | 415                 |
| Units: urgency episodes                  |                     |                     |                     |                     |
| least squares mean (standard error)      |                     |                     |                     |                     |
| Week 4 [N=405, 406, 402, 402, 817, 810]  | -1.34 ( $\pm$ 0.15) | -1.95 ( $\pm$ 0.14) | -1.91 ( $\pm$ 0.15) | -2.14 ( $\pm$ 0.15) |
| Week 8 [N=396, 385, 386, 386, 784, 769]  | -1.85 ( $\pm$ 0.15) | -2.54 ( $\pm$ 0.15) | -2.43 ( $\pm$ 0.15) | -2.9 ( $\pm$ 0.15)  |
| Week 12 [N=373, 369, 369, 379, 754, 750] | -2.05 ( $\pm$ 0.16) | -2.85 ( $\pm$ 0.16) | -2.7 ( $\pm$ 0.16)  | -3.11 ( $\pm$ 0.16) |
| EoT [N=411, 409, 406, 413, 823, 816]     | -2.06 ( $\pm$ 0.15) | -2.74 ( $\pm$ 0.15) | -2.63 ( $\pm$ 0.15) | -3.05 ( $\pm$ 0.15) |

| End point values | Solifenacin 5 mg + | Solifenacin 5 mg + |  |  |
|------------------|--------------------|--------------------|--|--|
|------------------|--------------------|--------------------|--|--|

|                                          | mirabegron 25 mg | mirabegron 50 mg |  |  |
|------------------------------------------|------------------|------------------|--|--|
| Subject group type                       | Reporting group  | Reporting group  |  |  |
| Number of subjects analysed              | 827              | 827              |  |  |
| Units: urgency episodes                  |                  |                  |  |  |
| least squares mean (standard error)      |                  |                  |  |  |
| Week 4 [N=405, 406, 402, 817, 810]       | -2.42 (± 0.1)    | -2.66 (± 0.1)    |  |  |
| Week 8 [N=396, 385, 386, 784, 769]       | -3.13 (± 0.11)   | -3.28 (± 0.11)   |  |  |
| Week 12 [N=373, 369, 369, 379, 754, 750] | -3.45 (± 0.11)   | -3.5 (± 0.11)    |  |  |
| EoT [N=411, 409, 406, 413, 823, 816]     | -3.38 (± 0.11)   | -3.51 (± 0.11)   |  |  |

## Statistical analyses

|                                   |                                           |
|-----------------------------------|-------------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Solifenacin 5 mg (1) (EoT) |
|-----------------------------------|-------------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1242                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.074                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.33                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -0.69                                                  |
| upper limit                             | 0.03                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.18                                                   |

|                                   |                                           |
|-----------------------------------|-------------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Solifenacin 5 mg (2) (EoT) |
|-----------------------------------|-------------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                   |                                                        |
|-------------------|--------------------------------------------------------|
| Comparison groups | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
|-------------------|--------------------------------------------------------|

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1242                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | = 0.014                       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | -0.45                         |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | -0.82                         |
| upper limit                             | -0.09                         |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 0.18                          |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.65                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -1.01                                                  |
| upper limit                             | -0.28                                                  |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.18                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                   |                                                        |
|-------------------|--------------------------------------------------------|
| Comparison groups | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
|-------------------|--------------------------------------------------------|

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1238                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | < 0.001                       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | -0.87                         |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | -1.24                         |
| upper limit                             | 0.51                          |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 0.19                          |

### Secondary: Number of Nocturia Episodes at Weeks 4, 8, 12 and EoT

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                       |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Number of Nocturia Episodes at Weeks 4, 8, 12 and EoT |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                       |
| A nocturia episode is defined as waking at night 1 or more times to void (i.e., any voiding associated with sleep disturbance between the time the participant goes to bed with the intention to sleep until the time the patients gets up in the morning with the intention to stay awake). The number of nocturia episodes is the number of times a participant records a nocturia episode during the 7-day micturition diary period prior to each visit. The analysis population was the FAS. Only participants with $\geq 1$ nocturia episode at baseline were included in the analysis. N is the number of participants analyzed with data available at each time point. LOCF for EOT was used. |                                                       |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Secondary                                             |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                       |
| Weeks 4, 8 and 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                       |

| End point values                         | Placebo            | Mirabegron 25 mg   | Mirabegron 50 mg   | Solifenacin 5 mg   |
|------------------------------------------|--------------------|--------------------|--------------------|--------------------|
| Subject group type                       | Reporting group    | Reporting group    | Reporting group    | Reporting group    |
| Number of subjects analysed              | 418                | 410                | 411                | 415                |
| Units: nocturia episodes                 |                    |                    |                    |                    |
| least squares mean (standard error)      |                    |                    |                    |                    |
| Week 4 [N=359, 341, 349, 341, 705, 693]  | 9.62 ( $\pm$ 0.43) | 8.46 ( $\pm$ 0.36) | 9.11 ( $\pm$ 0.47) | 9.22 ( $\pm$ 0.42) |
| Week 8 [N=349, 327, 336, 329, 676, 655]  | 8.99 ( $\pm$ 0.44) | 8.07 ( $\pm$ 0.34) | 8.61 ( $\pm$ 0.45) | 8.37 ( $\pm$ 0.38) |
| Week 12 [N=336, 312, 321, 320, 652, 641] | 8.91 ( $\pm$ 0.43) | 7.99 ( $\pm$ 0.37) | 8.34 ( $\pm$ 0.48) | 8.17 ( $\pm$ 0.39) |
| EoT [N=363, 344, 353, 350, 708, 697]     | 8.83 ( $\pm$ 0.42) | 7.79 ( $\pm$ 0.35) | 8.14 ( $\pm$ 0.45) | 8.12 ( $\pm$ 0.37) |

| End point values | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------|-------------------------------------|-------------------------------------|--|--|
|------------------|-------------------------------------|-------------------------------------|--|--|

|                                          |                    |                    |  |  |
|------------------------------------------|--------------------|--------------------|--|--|
| Subject group type                       | Reporting group    | Reporting group    |  |  |
| Number of subjects analysed              | 827                | 827                |  |  |
| Units: nocturia episodes                 |                    |                    |  |  |
| least squares mean (standard error)      |                    |                    |  |  |
| Week 4 [N=359, 341, 349, 341, 705, 693]  | 8.4 ( $\pm$ 0.25)  | 8.09 ( $\pm$ 0.25) |  |  |
| Week 8 [N=349, 327, 336, 329, 676, 655]  | 7.63 ( $\pm$ 0.25) | 7.11 ( $\pm$ 0.24) |  |  |
| Week 12 [N=336, 312, 321, 320, 652, 641] | 7.26 ( $\pm$ 0.24) | 6.67 ( $\pm$ 0.23) |  |  |
| EoT [N=363, 344, 353, 350, 708, 697]     | 7.33 ( $\pm$ 0.24) | 6.67 ( $\pm$ 0.22) |  |  |

## Statistical analyses

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Rate ratio vs. Solifenacin 5 mg (1) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                        |
| Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (<65, >=65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of nocturia episodes used divided by number of valid diary days) included as a covariate and postbaseline number of valid diary days as offset variable. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | = 0.006                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Negative binomial regression                           |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Rate ratio                                             |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.88                                                   |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 0.81                                                   |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 0.96                                                   |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.05                                                   |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Rate ratio vs. Solifenacin 5 mg (2) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                        |
| Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (<65, >=65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of nocturia episodes used divided by number of valid diary days) included as a covariate and postbaseline number of valid diary days as offset variable. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |

|                                         |                              |
|-----------------------------------------|------------------------------|
| Number of subjects included in analysis | 1242                         |
| Analysis specification                  | Pre-specified                |
| Analysis type                           | superiority                  |
| P-value                                 | < 0.001                      |
| Method                                  | Negative binomial regression |
| Parameter estimate                      | Rate ratio                   |
| Point estimate                          | 0.81                         |
| Confidence interval                     |                              |
| level                                   | 95 %                         |
| sides                                   | 2-sided                      |
| lower limit                             | 0.74                         |
| upper limit                             | 0.88                         |
| Variability estimate                    | Standard error of the mean   |
| Dispersion value                        | 0.05                         |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Rate ratio vs. Mirabgeron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (<65, >=65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of nocturia episodes used divided by number of valid diary days) included as a covariate and postbaseline number of valid diary days as offset variable.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.049                                                |
| Method                                  | Negative binomial regression                           |
| Parameter estimate                      | Rate ratio                                             |
| Point estimate                          | 0.91                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 0.84                                                   |
| upper limit                             | 1                                                      |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.05                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Rate ratio vs. Mirabgeron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (<65, >=65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of nocturia episodes used divided by number of valid diary days) included as a covariate and postbaseline number of valid diary days as offset variable.

|                   |                                                        |
|-------------------|--------------------------------------------------------|
| Comparison groups | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
|-------------------|--------------------------------------------------------|

|                                         |                              |
|-----------------------------------------|------------------------------|
| Number of subjects included in analysis | 1238                         |
| Analysis specification                  | Pre-specified                |
| Analysis type                           | superiority                  |
| P-value                                 | = 0.001                      |
| Method                                  | Negative binomial regression |
| Parameter estimate                      | Rate ratio                   |
| Point estimate                          | 0.86                         |
| Confidence interval                     |                              |
| level                                   | 95 %                         |
| sides                                   | 2-sided                      |
| lower limit                             | 0.79                         |
| upper limit                             | 0.94                         |
| Variability estimate                    | Standard error of the mean   |
| Dispersion value                        | 0.05                         |

### Secondary: Change from Baseline to Weeks 4, 8, 12 and EoT in Number of Nocturia Episodes

|                                                                                                                                                                                                                                                                    |                                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                    | Change from Baseline to Weeks 4, 8, 12 and EoT in Number of Nocturia Episodes |
| End point description:<br>The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. Only participants with $\geq 1$ nocturia episode at baseline were included in the analysis. LOCF for EoT was used. |                                                                               |
| End point type                                                                                                                                                                                                                                                     | Secondary                                                                     |
| End point timeframe:<br>Baseline and Weeks 4, 8, 12                                                                                                                                                                                                                |                                                                               |

| End point values                         | Placebo             | Mirabegron 25 mg    | Mirabegron 50 mg    | Solifenacin 5 mg    |
|------------------------------------------|---------------------|---------------------|---------------------|---------------------|
| Subject group type                       | Reporting group     | Reporting group     | Reporting group     | Reporting group     |
| Number of subjects analysed              | 418                 | 410                 | 411                 | 415                 |
| Units: nocturia episodes                 |                     |                     |                     |                     |
| least squares mean (standard error)      |                     |                     |                     |                     |
| Week 4 [N=359, 341, 349, 341, 705, 693]  | -1.27 ( $\pm$ 0.27) | -2.25 ( $\pm$ 0.28) | -1.8 ( $\pm$ 0.27)  | -1.79 ( $\pm$ 0.28) |
| Week 8 [N=349, 327, 336, 329, 676, 655]  | -1.94 ( $\pm$ 0.27) | -2.7 ( $\pm$ 0.28)  | -2.41 ( $\pm$ 0.28) | -2.6 ( $\pm$ 0.28)  |
| Week 12 [N=336, 312, 321, 320, 652, 641] | -1.95 ( $\pm$ 0.29) | -2.77 ( $\pm$ 0.3)  | -2.73 ( $\pm$ 0.29) | -2.89 ( $\pm$ 0.29) |
| EoT [N=363, 344, 353, 350, 708, 697]     | -2.05 ( $\pm$ 0.27) | -2.91 ( $\pm$ 0.28) | -2.75 ( $\pm$ 0.28) | -2.81 ( $\pm$ 0.28) |

| End point values            | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|-----------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type          | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed | 827                                 | 827                                 |  |  |

|                                          |                |                |  |  |
|------------------------------------------|----------------|----------------|--|--|
| Units: nocturia episodes                 |                |                |  |  |
| least squares mean (standard error)      |                |                |  |  |
| Week 4 [N=359, 341, 349, 341, 705, 693]  | -2.39 (± 0.19) | -2.5 (± 0.19)  |  |  |
| Week 8 [N=349, 327, 336, 329, 676, 655]  | -3.13 (± 0.2)  | -3.48 (± 0.2)  |  |  |
| Week 12 [N=336, 312, 321, 320, 652, 641] | -3.49 (± 0.21) | -3.96 (± 0.21) |  |  |
| EoT [N=363, 344, 353, 350, 708, 697]     | -3.42 (± 0.2)  | -3.96 (± 0.2)  |  |  |

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                 | Difference vs. Solifenacin 5 mg (1) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                    | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                     | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                              | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                    | = 0.073                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                     | ANCOVA                                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                         | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                             | -0.61                                                  |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                      | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                      | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                | -1.28                                                  |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                | 0.06                                                   |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                       | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                           | 0.34                                                   |

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                 | Difference vs. Solifenacin 5 mg (2) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                    | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                     | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                              | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                    | = 0.001                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                     | ANCOVA                                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                         | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                             | -1.16                                                  |

|                      |                            |
|----------------------|----------------------------|
| Confidence interval  |                            |
| level                | 95 %                       |
| sides                | 2-sided                    |
| lower limit          | -1.83                      |
| upper limit          | -0.48                      |
| Variability estimate | Standard error of the mean |
| Dispersion value     | 0.34                       |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.14                                                 |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.51                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -1.18                                                  |
| upper limit                             | 0.17                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.34                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -1.21                                                  |

|                      |                            |
|----------------------|----------------------------|
| Confidence interval  |                            |
| level                | 95 %                       |
| sides                | 2-sided                    |
| lower limit          | -1.88                      |
| upper limit          | -0.54                      |
| Variability estimate | Standard error of the mean |
| Dispersion value     | 0.34                       |

## Secondary: Change from Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Nocturia Episodes per 24 Hours

|                 |                                                                                                 |
|-----------------|-------------------------------------------------------------------------------------------------|
| End point title | Change from Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Nocturia Episodes per 24 Hours |
|-----------------|-------------------------------------------------------------------------------------------------|

End point description:

The mean number of nocturia episodes was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. Only participants with  $\geq 1$  nocturia episode at baseline were included in the analysis. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 8, 12

| End point values                         | Placebo             | Mirabegron 25 mg    | Mirabegron 50 mg    | Solifenacin 5 mg    |
|------------------------------------------|---------------------|---------------------|---------------------|---------------------|
| Subject group type                       | Reporting group     | Reporting group     | Reporting group     | Reporting group     |
| Number of subjects analysed              | 418                 | 410                 | 411                 | 415                 |
| Units: nocturia episodes                 |                     |                     |                     |                     |
| least squares mean (standard error)      |                     |                     |                     |                     |
| Week 4 [N=359, 341, 349, 341, 705, 693]  | -0.17 ( $\pm$ 0.04) | -0.31 ( $\pm$ 0.04) | -0.25 ( $\pm$ 0.04) | -0.24 ( $\pm$ 0.04) |
| Week 8 [N=349, 327, 336, 329, 676, 655]  | -0.27 ( $\pm$ 0.04) | -0.37 ( $\pm$ 0.04) | -0.35 ( $\pm$ 0.04) | -0.36 ( $\pm$ 0.04) |
| Week 12 [N=336, 312, 321, 320, 652, 641] | -0.26 ( $\pm$ 0.04) | -0.38 ( $\pm$ 0.04) | -0.39 ( $\pm$ 0.04) | -0.41 ( $\pm$ 0.04) |
| EoT [N=363, 344, 353, 350, 708, 697]     | -0.27 ( $\pm$ 0.04) | -0.4 ( $\pm$ 0.04)  | -0.39 ( $\pm$ 0.04) | -0.39 ( $\pm$ 0.04) |

| End point values                        | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|-----------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                      | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed             | 827                                 | 827                                 |  |  |
| Units: nocturia episodes                |                                     |                                     |  |  |
| least squares mean (standard error)     |                                     |                                     |  |  |
| Week 4 [N=359, 341, 349, 341, 705, 693] | -0.33 ( $\pm$ 0.03)                 | -0.35 ( $\pm$ 0.03)                 |  |  |
| Week 8 [N=349, 327, 336, 329, 676, 655] | -0.44 ( $\pm$ 0.03)                 | -0.5 ( $\pm$ 0.03)                  |  |  |

|                                          |                |                |  |  |
|------------------------------------------|----------------|----------------|--|--|
| Week 12 [N=336, 312, 321, 320, 652, 641] | -0.49 (± 0.03) | -0.56 (± 0.03) |  |  |
| EoT [N=363, 344, 353, 350, 708, 697]     | -0.48 (± 0.03) | -0.56 (± 0.03) |  |  |

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                 | Difference vs. Solifenacin 5 mg (1) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                    | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                     | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                              | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                    | = 0.065                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                     | ANCOVA                                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                         | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                             | -0.09                                                  |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                      | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                      | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                | -0.19                                                  |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                | 0.01                                                   |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                       | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                           | 0.05                                                   |

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                 | Difference vs. Solifenacin 5 mg (2) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                    | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                     | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                              | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                    | = 0.001                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                     | ANCOVA                                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                         | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                             | -0.17                                                  |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                      | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                      | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                | -0.26                                                  |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                | -0.07                                                  |

|                      |                            |
|----------------------|----------------------------|
| Variability estimate | Standard error of the mean |
| Dispersion value     | 0.05                       |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.1                                                  |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.08                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -0.18                                                  |
| upper limit                             | 0.02                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.05                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.001                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.17                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -0.26                                                  |
| upper limit                             | -0.07                                                  |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.05                                                   |

**Secondary: Number of Pads Used at Weeks 4, 8, 12 and EoT**

|                                                                                                                                                                                                                                                                                                                                                                                                               |                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                               | Number of Pads Used at Weeks 4, 8, 12 and EoT |
| End point description:<br>The number of pads used is the number of times a participant records a new pad used during the 7-day micturition diary period prior to each visit. The analysis population was the FAS. Only participants with $\geq 1$ pad used at baseline were included in the analysis. N is the number of participants analyzed with data available at each time point. LOCF for EOT was used. |                                               |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                | Secondary                                     |
| End point timeframe:<br>Weeks 4, 8 and 12                                                                                                                                                                                                                                                                                                                                                                     |                                               |

| End point values                         | Placebo              | Mirabegron 25 mg     | Mirabegron 50 mg     | Solifenacin 5 mg     |
|------------------------------------------|----------------------|----------------------|----------------------|----------------------|
| Subject group type                       | Reporting group      | Reporting group      | Reporting group      | Reporting group      |
| Number of subjects analysed              | 418                  | 410                  | 411                  | 415                  |
| Units: pads                              |                      |                      |                      |                      |
| least squares mean (standard error)      |                      |                      |                      |                      |
| Week 4 [N=248, 250, 247, 257, 506, 499]  | 15.62 ( $\pm 1.33$ ) | 13.46 ( $\pm 1.24$ ) | 10.05 ( $\pm 1.21$ ) | 11.41 ( $\pm 1.23$ ) |
| Week 8 [N=239, 237, 240, 243, 485, 472]  | 12.75 ( $\pm 1.22$ ) | 10.79 ( $\pm 1.05$ ) | 9.53 ( $\pm 1.39$ )  | 8.45 ( $\pm 1.03$ )  |
| Week 12 [N=226, 225, 229, 241, 468, 461] | 12.62 ( $\pm 1.21$ ) | 9.65 ( $\pm 1$ )     | 8.44 ( $\pm 1.26$ )  | 8.21 ( $\pm 0.95$ )  |
| EoT [N=252, 252, 249, 262, 510, 502]     | 12.29 ( $\pm 1.11$ ) | 10.15 ( $\pm 0.97$ ) | 8.16 ( $\pm 1.17$ )  | 8.53 ( $\pm 0.94$ )  |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: pads                              |                                     |                                     |  |  |
| least squares mean (standard error)      |                                     |                                     |  |  |
| Week 4 [N=248, 250, 247, 257, 506, 499]  | 9.71 ( $\pm 0.7$ )                  | 9.34 ( $\pm 0.68$ )                 |  |  |
| Week 8 [N=239, 237, 240, 243, 485, 472]  | 8.07 ( $\pm 0.65$ )                 | 7.58 ( $\pm 0.62$ )                 |  |  |
| Week 12 [N=226, 225, 229, 241, 468, 461] | 6.6 ( $\pm 0.58$ )                  | 6.64 ( $\pm 0.61$ )                 |  |  |
| EoT [N=252, 252, 249, 262, 510, 502]     | 7.04 ( $\pm 0.56$ )                 | 6.8 ( $\pm 0.59$ )                  |  |  |

**Statistical analyses**

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Rate ratio vs. Solifenacin 5 mg (1) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (<65, >=65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of pads used divided by number of valid diary days) included as a covariate and postbaseline number of valid diary days as offset variable. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | = 0.938                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Negative binomial regression                           |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Rate ratio                                             |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 1.01                                                   |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.8                                                    |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 1.27                                                   |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.12                                                   |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Rate ratio vs. Solifenacin 5 mg (2) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (<65, >=65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of pads used divided by number of valid diary days) included as a covariate and postbaseline number of valid diary days as offset variable. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | = 0.967                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Negative binomial regression                           |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Rate ratio                                             |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 1                                                      |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.79                                                   |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 1.25                                                   |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.12                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Rate ratio vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

**Statistical analysis description:**

Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (<65, >=65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of pads used divided by number of valid diary days) included as a covariate and postbaseline number of valid diary days as offset variable.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.008                                                |
| Method                                  | Negative binomial regression                           |
| Parameter estimate                      | Rate ratio                                             |
| Point estimate                          | 0.73                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 0.58                                                   |
| upper limit                             | 0.92                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.12                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Rate ratio vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

**Statistical analysis description:**

Rate ratio of number of incontinence episodes during the 7-day diary between the given combination group and the given monotherapy group calculated from a negative binomial regression model incl. treatment group, sex, age group (<65, >=65 years), geographic region and previous OAB medication (yes, no) as factors, baseline log(number of pads used divided by number of valid diary days) included as a covariate and postbaseline number of valid diary days as offset variable.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.069                                                |
| Method                                  | Negative binomial regression                           |
| Parameter estimate                      | Rate ratio                                             |
| Point estimate                          | 0.8                                                    |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 0.64                                                   |
| upper limit                             | 1.02                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.12                                                   |

**Secondary: Change from Baseline to Weeks 4, 8, 12 and EoT in Number of Pads Used**

|                 |                                                                       |
|-----------------|-----------------------------------------------------------------------|
| End point title | Change from Baseline to Weeks 4, 8, 12 and EoT in Number of Pads Used |
|-----------------|-----------------------------------------------------------------------|

End point description:

The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. Only participants with  $\geq 1$  pad used at baseline were included in the analysis. LOCF for EoT was used.

|                             |           |
|-----------------------------|-----------|
| End point type              | Secondary |
| End point timeframe:        |           |
| Baseline and Weeks 4, 8, 12 |           |

| End point values                         | Placebo             | Mirabegron 25 mg    | Mirabegron 50 mg    | Solifenacin 5 mg     |
|------------------------------------------|---------------------|---------------------|---------------------|----------------------|
| Subject group type                       | Reporting group     | Reporting group     | Reporting group     | Reporting group      |
| Number of subjects analysed              | 418                 | 410                 | 411                 | 415                  |
| Units: pads                              |                     |                     |                     |                      |
| least squares mean (standard error)      |                     |                     |                     |                      |
| Week 4 [N=248, 250, 247, 257, 506, 499]  | -3.69 ( $\pm$ 0.71) | -5.68 ( $\pm$ 0.71) | -7.83 ( $\pm$ 0.71) | -8.23 ( $\pm$ 0.7)   |
| Week 8 [N=239, 237, 240, 243, 485, 472]  | -6.24 ( $\pm$ 0.77) | -8.44 ( $\pm$ 0.77) | -8.43 ( $\pm$ 0.76) | -10.67 ( $\pm$ 0.76) |
| Week 12 [N=226, 225, 229, 241, 468, 461] | -6.29 ( $\pm$ 0.75) | -9.06 ( $\pm$ 0.75) | -9.41 ( $\pm$ 0.75) | -10.8 ( $\pm$ 0.73)  |
| EoT [N=252, 252, 249, 262, 510, 502]     | -6.6 ( $\pm$ 0.71)  | -8.76 ( $\pm$ 0.71) | -9.8 ( $\pm$ 0.72)  | -10.63 ( $\pm$ 0.7)  |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: pads                              |                                     |                                     |  |  |
| least squares mean (standard error)      |                                     |                                     |  |  |
| Week 4 [N=248, 250, 247, 257, 506, 499]  | -7.61 ( $\pm$ 0.5)                  | -8.58 ( $\pm$ 0.5)                  |  |  |
| Week 8 [N=239, 237, 240, 243, 485, 472]  | -9.49 ( $\pm$ 0.54)                 | -10.59 ( $\pm$ 0.54)                |  |  |
| Week 12 [N=226, 225, 229, 241, 468, 461] | -10.66 ( $\pm$ 0.52)                | -11.23 ( $\pm$ 0.53)                |  |  |
| EoT [N=252, 252, 249, 262, 510, 502]     | -10.67 ( $\pm$ 0.5)                 | -11.21 ( $\pm$ 0.5)                 |  |  |

## Statistical analyses

|                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                       | Difference vs. Solifenacin 5 mg (1) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, $\geq$ 65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1242                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | = 0.958                       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | -0.04                         |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | -1.73                         |
| upper limit                             | 1.64                          |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 0.86                          |

|                                   |                                           |
|-----------------------------------|-------------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Solifenacin 5 mg (2) (EoT) |
|-----------------------------------|-------------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1242                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.5                                                  |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.58                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -2.27                                                  |
| upper limit                             | 1.11                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.86                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabgeron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                   |                                                        |
|-------------------|--------------------------------------------------------|
| Comparison groups | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
|-------------------|--------------------------------------------------------|

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1237                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | = 0.028                       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | -1.91                         |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | -3.62                         |
| upper limit                             | -0.2                          |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 0.87                          |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.108                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -1.41                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -3.13                                                  |
| upper limit                             | 0.31                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.88                                                   |

**Secondary: Change from Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Pads Used per 24 Hours**

|                 |                                                                                         |
|-----------------|-----------------------------------------------------------------------------------------|
| End point title | Change from Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Pads Used per 24 Hours |
|-----------------|-----------------------------------------------------------------------------------------|

End point description:

The mean number of pads used was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. Only participants with ≥ 1 pads used at baseline were included in the analysis. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 8, 12

| <b>End point values</b>                  | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: pads                              |                 |                  |                  |                  |
| least squares mean (standard error)      |                 |                  |                  |                  |
| Week 4 [N=248, 250, 247, 257, 506, 499]  | -0.52 (± 0.1)   | -0.81 (± 0.1)    | -1.12 (± 0.1)    | -1.19 (± 0.1)    |
| Week 8 [N=239, 237, 240, 243, 485, 472]  | -0.82 (± 0.11)  | -1.2 (± 0.11)    | -1.24 (± 0.11)   | -1.53 (± 0.11)   |
| Week 12 [N=226, 225, 229, 241, 468, 461] | -0.92 (± 0.11)  | -1.3 (± 0.11)    | -1.37 (± 0.11)   | -1.56 (± 0.11)   |
| EoT [N=252, 252, 249, 262, 510, 502]     | -0.94 (± 0.1)   | -1.26 (± 0.1)    | -1.41 (± 0.1)    | -1.53 (± 0.1)    |

| <b>End point values</b>                  | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: pads                              |                                     |                                     |  |  |
| least squares mean (standard error)      |                                     |                                     |  |  |
| Week 4 [N=248, 250, 247, 257, 506, 499]  | -1.09 (± 0.07)                      | -1.23 (± 0.07)                      |  |  |
| Week 8 [N=239, 237, 240, 243, 485, 472]  | -1.36 (± 0.08)                      | -1.51 (± 0.08)                      |  |  |
| Week 12 [N=226, 225, 229, 241, 468, 461] | -1.54 (± 0.08)                      | -1.59 (± 0.08)                      |  |  |
| EoT [N=252, 252, 249, 262, 510, 502]     | -1.53 (± 0.07)                      | -1.58 (± 0.07)                      |  |  |

## Statistical analyses

| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                          | Difference vs. Solifenacin 5 mg (1) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                    | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                     | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                              | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                    | = 0.993                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                     | ANCOVA                                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                         | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                             | 0                                                      |

|                      |                            |
|----------------------|----------------------------|
| Confidence interval  |                            |
| level                | 95 %                       |
| sides                | 2-sided                    |
| lower limit          | -0.25                      |
| upper limit          | 0.25                       |
| Variability estimate | Standard error of the mean |
| Dispersion value     | 0.13                       |

|                                   |                                           |
|-----------------------------------|-------------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Solifenacin 5 mg (2) (EoT) |
|-----------------------------------|-------------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1242                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.65                                                 |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.06                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -0.3                                                   |
| upper limit                             | 0.19                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.13                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.035                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.27                                                  |

|                      |                            |
|----------------------|----------------------------|
| Confidence interval  |                            |
| level                | 95 %                       |
| sides                | 2-sided                    |
| lower limit          | -0.52                      |
| upper limit          | -0.02                      |
| Variability estimate | Standard error of the mean |
| Dispersion value     | 0.13                       |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.169                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.18                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -0.43                                                  |
| upper limit                             | 0.08                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.13                                                   |

### **Secondary: Number of Incontinence-Free Days at Weeks 4, 8, 12 and EoT**

|                 |                                                            |
|-----------------|------------------------------------------------------------|
| End point title | Number of Incontinence-Free Days at Weeks 4, 8, 12 and EoT |
|-----------------|------------------------------------------------------------|

End point description:

The number of incontinence-free days is the number of valid diary days during the 7-day micturition diary period with no incontinence episodes recorded. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EOT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Weeks 4, 8 and 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: incontinence-free days            |                 |                  |                  |                  |
| arithmetic mean (standard error)         |                 |                  |                  |                  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | 2.25 (± 0.13)   | 2.48 (± 0.13)    | 2.98 (± 0.13)    | 2.74 (± 0.14)    |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | 2.92 (± 0.14)   | 3.17 (± 0.14)    | 3.63 (± 0.15)    | 3.31 (± 0.14)    |
| Week 12 [N=374, 369, 369, 379, 754, 750] | 3.19 (± 0.15)   | 3.69 (± 0.15)    | 3.96 (± 0.15)    | 3.68 (± 0.14)    |
| EoT [N=412, 409, 406, 413, 823, 816]     | 3.16 (± 0.14)   | 3.51 (± 0.14)    | 3.89 (± 0.14)    | 3.61 (± 0.14)    |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: incontinence-free days            |                                     |                                     |  |  |
| arithmetic mean (standard error)         |                                     |                                     |  |  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | 3.08 (± 0.1)                        | 3.37 (± 0.1)                        |  |  |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | 3.88 (± 0.1)                        | 4.01 (± 0.1)                        |  |  |
| Week 12 [N=374, 369, 369, 379, 754, 750] | 4.33 (± 0.1)                        | 4.25 (± 0.1)                        |  |  |
| EoT [N=412, 409, 406, 413, 823, 816]     | 4.2 (± 0.1)                         | 4.23 (± 0.1)                        |  |  |

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                                                               | Odds ratio vs. Solifenacin 5 mg (1) (EoT)              |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                        |                                                        |
| Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline logarithm of mean number of incontinence episodes per 24 hours as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                        | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                  | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                   | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                            | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                  | = 0.003                                                |
| Method                                                                                                                                                                                                                                                                                                   | Overdispersed binomial regression                      |
| Parameter estimate                                                                                                                                                                                                                                                                                       | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                                           | 1.37                                                   |
| Confidence interval                                                                                                                                                                                                                                                                                      |                                                        |
| level                                                                                                                                                                                                                                                                                                    | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                    | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                              | 1.11                                                   |
| upper limit                                                                                                                                                                                                                                                                                              | 1.68                                                   |

|                                                                                                                                                                                                                                                                                                                                               |                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                             | Odds ratio vs. Solifenacin 5 mg (2) (EoT)              |
| Statistical analysis description:<br>Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline logarithm of mean number of incontinence episodes per 24 hours as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                             | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                       | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                        | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                 | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                       | = 0.004                                                |
| Method                                                                                                                                                                                                                                                                                                                                        | Overdispersed binomial regression                      |
| Parameter estimate                                                                                                                                                                                                                                                                                                                            | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                                                                                | 1.36                                                   |
| Confidence interval                                                                                                                                                                                                                                                                                                                           |                                                        |
| level                                                                                                                                                                                                                                                                                                                                         | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                         | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                   | 1.11                                                   |
| upper limit                                                                                                                                                                                                                                                                                                                                   | 1.68                                                   |

|                                                                                                                                                                                                                                                                                                                                               |                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                             | Odds ratio vs. Mirabegron 25 mg (EoT)                  |
| Statistical analysis description:<br>Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline logarithm of mean number of incontinence episodes per 24 hours as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                             | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                       | 1237                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                        | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                 | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                       | < 0.001                                                |
| Method                                                                                                                                                                                                                                                                                                                                        | Overdispersed binomial regression                      |
| Parameter estimate                                                                                                                                                                                                                                                                                                                            | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                                                                                | 1.59                                                   |
| Confidence interval                                                                                                                                                                                                                                                                                                                           |                                                        |
| level                                                                                                                                                                                                                                                                                                                                         | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                         | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                   | 1.29                                                   |
| upper limit                                                                                                                                                                                                                                                                                                                                   | 1.95                                                   |

|                                                                                                                                                                                                                                                                                                                                               |                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                             | Odds ratio vs. Mirabegron 50 mg (EoT)                  |
| Statistical analysis description:<br>Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline logarithm of mean number of incontinence episodes per 24 hours as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                             | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |

|                                         |                                   |
|-----------------------------------------|-----------------------------------|
| Number of subjects included in analysis | 1238                              |
| Analysis specification                  | Pre-specified                     |
| Analysis type                           | superiority                       |
| P-value                                 | = 0.004                           |
| Method                                  | Overdispersed binomial regression |
| Parameter estimate                      | Odds ratio (OR)                   |
| Point estimate                          | 1.36                              |
| Confidence interval                     |                                   |
| level                                   | 95 %                              |
| sides                                   | 2-sided                           |
| lower limit                             | 1.1                               |
| upper limit                             | 1.68                              |

### Secondary: Number of Days with < 8 Micturations at Weeks 4, 8, 12 and EoT

|                                                                                                                                                                                                                                                                                                          |                                                                |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                          | Number of Days with < 8 Micturations at Weeks 4, 8, 12 and EoT |
| End point description:                                                                                                                                                                                                                                                                                   |                                                                |
| The number of days with < 8 micturations is the number of valid diary days during the 7-day micturition diary period with less than 8 micturations per day. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EOT was used. |                                                                |
| End point type                                                                                                                                                                                                                                                                                           | Secondary                                                      |
| End point timeframe:                                                                                                                                                                                                                                                                                     |                                                                |
| Weeks 4, 8 and 12                                                                                                                                                                                                                                                                                        |                                                                |

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: days                              |                 |                  |                  |                  |
| arithmetic mean (standard error)         |                 |                  |                  |                  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | 1.49 (± 0.1)    | 1.74 (± 0.1)     | 1.55 (± 0.1)     | 1.86 (± 0.11)    |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | 1.69 (± 0.1)    | 2.08 (± 0.12)    | 1.99 (± 0.11)    | 2.22 (± 0.12)    |
| Week 12 [N=374, 369, 369, 379, 754, 750] | 1.76 (± 0.11)   | 2.31 (± 0.13)    | 2.25 (± 0.12)    | 2.49 (± 0.13)    |
| EoT [N=412, 409, 406, 413, 823, 816]     | 1.8 (± 0.11)    | 2.28 (± 0.12)    | 2.22 (± 0.12)    | 2.49 (± 0.12)    |

| End point values                 | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|----------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type               | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed      | 827                                 | 827                                 |  |  |
| Units: days                      |                                     |                                     |  |  |
| arithmetic mean (standard error) |                                     |                                     |  |  |

|                                          |                    |                    |  |  |
|------------------------------------------|--------------------|--------------------|--|--|
| Week 4 [N=406, 406, 402, 402, 817, 810]  | 2.07 ( $\pm$ 0.08) | 2.11 ( $\pm$ 0.08) |  |  |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | 2.59 ( $\pm$ 0.09) | 2.7 ( $\pm$ 0.09)  |  |  |
| Week 12 [N=374, 369, 369, 379, 754, 750] | 2.87 ( $\pm$ 0.09) | 2.95 ( $\pm$ 0.1)  |  |  |
| EoT [N=412, 409, 406, 413, 823, 816]     | 2.84 ( $\pm$ 0.09) | 2.92 ( $\pm$ 0.09) |  |  |

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                                         | Odds ratio vs. Solifenacin 5 mg (1) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                  |                                                        |
| Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                  | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                            | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                             | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                      | superiority                                            |
| P-value                                                                                                                                                                                                                                                                            | = 0.039                                                |
| Method                                                                                                                                                                                                                                                                             | Overdispersed binomial regression                      |
| Parameter estimate                                                                                                                                                                                                                                                                 | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                     | 1.23                                                   |
| Confidence interval                                                                                                                                                                                                                                                                |                                                        |
| level                                                                                                                                                                                                                                                                              | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                              | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                        | 1.01                                                   |
| upper limit                                                                                                                                                                                                                                                                        | 1.5                                                    |

| Statistical analysis title                                                                                                                                                                                                                                                         | Odds ratio vs. Solifenacin 5 mg (2) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                  |                                                        |
| Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                  | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                            | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                             | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                      | superiority                                            |
| P-value                                                                                                                                                                                                                                                                            | = 0.009                                                |
| Method                                                                                                                                                                                                                                                                             | Overdispersed binomial regression                      |
| Parameter estimate                                                                                                                                                                                                                                                                 | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                     | 1.3                                                    |
| Confidence interval                                                                                                                                                                                                                                                                |                                                        |
| level                                                                                                                                                                                                                                                                              | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                              | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                        | 1.07                                                   |
| upper limit                                                                                                                                                                                                                                                                        | 1.59                                                   |

|                                                                                                                                                                                                                                                                                    |                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                  | Odds ratio vs. Mirabegron 25 mg (EoT)                  |
| Statistical analysis description:                                                                                                                                                                                                                                                  |                                                        |
| Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                  | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                            | 1237                                                   |
| Analysis specification                                                                                                                                                                                                                                                             | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                      | superiority                                            |
| P-value                                                                                                                                                                                                                                                                            | < 0.001                                                |
| Method                                                                                                                                                                                                                                                                             | overdispersed binomial regression                      |
| Parameter estimate                                                                                                                                                                                                                                                                 | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                     | 1.45                                                   |
| Confidence interval                                                                                                                                                                                                                                                                |                                                        |
| level                                                                                                                                                                                                                                                                              | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                              | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                        | 1.19                                                   |
| upper limit                                                                                                                                                                                                                                                                        | 1.77                                                   |

|                                                                                                                                                                                                                                                                                   |                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                 | Odds ratio vs. Mirabegron 50 mg (EoT)                  |
| Statistical analysis description:                                                                                                                                                                                                                                                 |                                                        |
| Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                 | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                           | 1238                                                   |
| Analysis specification                                                                                                                                                                                                                                                            | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                     | superiority                                            |
| P-value                                                                                                                                                                                                                                                                           | < 0.001                                                |
| Method                                                                                                                                                                                                                                                                            | Overdispersed binomial regression                      |
| Parameter estimate                                                                                                                                                                                                                                                                | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                    | 1.5                                                    |
| Confidence interval                                                                                                                                                                                                                                                               |                                                        |
| level                                                                                                                                                                                                                                                                             | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                             | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                       | 1.23                                                   |
| upper limit                                                                                                                                                                                                                                                                       | 1.84                                                   |

## Secondary: Number of Incontinence-Free Days with < 8 micturitions per day at Weeks 4, 8 and 12 and EoT

|                 |                                                                                             |
|-----------------|---------------------------------------------------------------------------------------------|
| End point title | Number of Incontinence-Free Days with < 8 micturitions per day at Weeks 4, 8 and 12 and EoT |
|-----------------|---------------------------------------------------------------------------------------------|

End point description:

The number of incontinence-free days with < 8 micturitions per day is the number of valid diary days during the 7-day micturition diary period with no incontinence episodes recorded and with < 8

micturitions per day. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EOT was used.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Weeks 4, 8 and 12    |           |

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: days                              |                 |                  |                  |                  |
| arithmetic mean (standard error)         |                 |                  |                  |                  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | 0.64 (± 0.07)   | 0.84 (± 0.08)    | 0.87 (± 0.08)    | 0.91 (± 0.08)    |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | 0.85 (± 0.08)   | 1.2 (± 0.1)      | 1.23 (± 0.1)     | 1.31 (± 0.1)     |
| Week 12 [N=374, 369, 369, 379, 754, 750] | 0.98 (± 0.09)   | 1.47 (± 0.11)    | 1.5 (± 0.11)     | 1.6 (± 0.11)     |
| EoT [N=412, 409, 406, 413, 823, 816]     | 1.01 (± 0.08)   | 1.4 (± 0.1)      | 1.47 (± 0.1)     | 1.59 (± 0.1)     |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: days                              |                                     |                                     |  |  |
| arithmetic mean (standard error)         |                                     |                                     |  |  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | 1.21 (± 0.07)                       | 1.32 (± 0.07)                       |  |  |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | 1.75 (± 0.08)                       | 1.89 (± 0.08)                       |  |  |
| Week 12 [N=374, 369, 369, 379, 754, 750] | 2.12 (± 0.09)                       | 2.15 (± 0.09)                       |  |  |
| EoT [N=412, 409, 406, 413, 823, 816]     | 2.04 (± 0.08)                       | 2.12 (± 0.09)                       |  |  |

## Statistical analyses

|                                                                                                                                                                                                                                                                                    |                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis title                                                                                                                                                                                                                                                         | Odds ratio vs. Solifenacin 5 mg (1) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                  |                                                        |
| Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                  | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |

|                                         |                                   |
|-----------------------------------------|-----------------------------------|
| Number of subjects included in analysis | 1242                              |
| Analysis specification                  | Pre-specified                     |
| Analysis type                           | superiority                       |
| P-value                                 | = 0.011                           |
| Method                                  | Overdispersed binomial regression |
| Parameter estimate                      | Odds ratio (OR)                   |
| Point estimate                          | 1.32                              |
| Confidence interval                     |                                   |
| level                                   | 95 %                              |
| sides                                   | 2-sided                           |
| lower limit                             | 1.07                              |
| upper limit                             | 1.64                              |

|                                   |                                           |
|-----------------------------------|-------------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Solifenacin 5 mg (2) (EoT) |
|-----------------------------------|-------------------------------------------|

Statistical analysis description:

Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1242                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.002                                                |
| Method                                  | Overdispersed binomial regression                      |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.41                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.14                                                   |
| upper limit                             | 1.75                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | Overdispersed binomial regression                      |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.65                                                   |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 1.32    |
| upper limit         | 2.06    |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Odds ratio from a overdispersed binomial regression model (Williams' method) including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24 hours as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | Overdispersed binomial regression                      |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.66                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.33                                                   |
| upper limit                             | 2.07                                                   |

### **Secondary: Change from Baseline in Patient Perception of Bladder Condition Questionnaire (PPBC) at Weeks 4, 8 and 12 and EoT**

|                 |                                                                                                                   |
|-----------------|-------------------------------------------------------------------------------------------------------------------|
| End point title | Change from Baseline in Patient Perception of Bladder Condition Questionnaire (PPBC) at Weeks 4, 8 and 12 and EoT |
|-----------------|-------------------------------------------------------------------------------------------------------------------|

End point description:

The PPBC is a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems. The analysis population is FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 8, 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: units on a scale                  |                 |                  |                  |                  |
| least squares mean (standard error)      |                 |                  |                  |                  |
| Week 4 [N=397, 388, 393, 394, 791, 791]  | -0.54 (± 0.06)  | -0.72 (± 0.06)   | -0.83 (± 0.06)   | -0.81 (± 0.06)   |
| Week 8 [N=381, 372, 380, 385, 758, 761]  | -0.8 (± 0.06)   | -1.07 (± 0.06)   | -1.12 (± 0.06)   | -1.18 (± 0.06)   |
| Week 12 [N=371, 362, 366, 375, 739, 735] | -0.95 (± 0.06)  | -1.23 (± 0.06)   | -1.34 (± 0.06)   | -1.32 (± 0.06)   |
| EoT [N=400, 393, 398, 399, 801, 795]     | -0.91 (± 0.06)  | -1.18 (± 0.06)   | -1.31 (± 0.06)   | -1.27 (± 0.06)   |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: units on a scale                  |                                     |                                     |  |  |
| least squares mean (standard error)      |                                     |                                     |  |  |
| Week 4 [N=397, 388, 393, 394, 791, 791]  | -0.99 (± 0.04)                      | -1.07 (± 0.04)                      |  |  |
| Week 8 [N=381, 372, 380, 385, 758, 761]  | -1.32 (± 0.04)                      | -1.48 (± 0.04)                      |  |  |
| Week 12 [N=371, 362, 366, 375, 739, 735] | -1.57 (± 0.04)                      | -1.72 (± 0.04)                      |  |  |
| EoT [N=400, 393, 398, 399, 801, 795]     | -1.53 (± 0.04)                      | -1.66 (± 0.04)                      |  |  |

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                 | Difference vs. Solifenacin 5 mg (1) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                    | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                     | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                              | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                    | < 0.001                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                     | ANCOVA                                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                         | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                             | -0.26                                                  |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                      | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                      | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                | -0.41                                                  |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                | -0.11                                                  |

|                      |                            |
|----------------------|----------------------------|
| Variability estimate | Standard error of the mean |
| Dispersion value     | 0.07                       |

|                                   |                                           |
|-----------------------------------|-------------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Solifenacin 5 mg (2) (EoT) |
|-----------------------------------|-------------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1242                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.39                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -0.54                                                  |
| upper limit                             | -0.25                                                  |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.07                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | -0.35                                                  |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | -0.5                                                   |
| upper limit                             | -0.2                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.07                                                   |

|                                                                                                                                                                                                                                                                                                                                                                                                            |                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                          | Difference vs. Mirabegron 50 mg (EoT)                  |
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                    | 1238                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                     | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                              | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                    | < 0.001                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                     | ANCOVA                                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                         | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                             | -0.35                                                  |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                      | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                      | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                | -0.5                                                   |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                | -0.2                                                   |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                       | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                           | 0.07                                                   |

## Secondary: Change from Baseline to Weeks 4, 8 and 12 in the OAB-q Symptom Bother Score

|                                                                                                                       |                                                                             |
|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| End point title                                                                                                       | Change from Baseline to Weeks 4, 8 and 12 in the OAB-q Symptom Bother Score |
| End point description:                                                                                                |                                                                             |
| The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. |                                                                             |
| End point type                                                                                                        | Secondary                                                                   |
| End point timeframe:                                                                                                  |                                                                             |
| Baseline and Weeks 4, 8, 12                                                                                           |                                                                             |

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: units on a scale                  |                 |                  |                  |                  |
| least squares mean (standard error)      |                 |                  |                  |                  |
| Week 4 [N=397, 388, 392, 394, 790, 789]  | -13.84 (± 0.92) | -17.05 (± 0.93)  | -18.98 (± 0.93)  | -19.53 (± 0.93)  |
| Week 8 [N=381, 370, 380, 385, 757, 761]  | -17.35 (± 0.98) | -22.79 (± 0.99)  | -23.54 (± 0.98)  | -24.69 (± 0.97)  |
| Week 12 [N=371, 362, 366, 374, 738, 734] | -19.94 (± 1.01) | -24.44 (± 1.02)  | -26.8 (± 1.02)   | -26.72 (± 1.01)  |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: units on a scale                  |                                     |                                     |  |  |
| least squares mean (standard error)      |                                     |                                     |  |  |
| Week 4 [N=397, 388, 392, 394, 790, 789]  | -23.46 (± 0.65)                     | -25.19 (± 0.65)                     |  |  |
| Week 8 [N=381, 370, 380, 385, 757, 761]  | -29.1 (± 0.69)                      | -30.04 (± 0.69)                     |  |  |
| Week 12 [N=371, 362, 366, 374, 738, 734] | -31.7 (± 0.72)                      | -33.15 (± 0.72)                     |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to Weeks 4, 8, 12 and EoT in Health-Related Quality of Life Questionnaire (HRQL) Total Score

|                 |                                                                                                                   |
|-----------------|-------------------------------------------------------------------------------------------------------------------|
| End point title | Change from Baseline to Weeks 4, 8, 12 and EoT in Health-Related Quality of Life Questionnaire (HRQL) Total Score |
|-----------------|-------------------------------------------------------------------------------------------------------------------|

End point description:

The OAB-q is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion consists of 25 HRQL items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction), scored 1 -6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 8, 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: units on a scale                  |                 |                  |                  |                  |
| least squares mean (standard error)      |                 |                  |                  |                  |
| Week 4 [N=397, 388, 392, 394, 790, 789]  | 10.16 (± 0.83)  | 13.54 (± 0.83)   | 15.28 (± 0.83)   | 14.78 (± 0.83)   |
| Week 8 [N=381, 370, 380, 385, 757, 761]  | 14.51 (± 0.88)  | 17.95 (± 0.89)   | 18.54 (± 0.88)   | 18.57 (± 0.88)   |
| Week 12 [N=371, 362, 366, 374, 738, 734] | 15.76 (± 0.92)  | 19.59 (± 0.93)   | 21.48 (± 0.92)   | 20.54 (± 0.91)   |
| EoT [N=400, 392, 398, 399, 800, 795]     | 15.37 (± 0.88)  | 18.94 (± 0.89)   | 21 (± 0.89)      | 20.15 (± 0.89)   |

| <b>End point values</b>                  | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: units on a scale                  |                                     |                                     |  |  |
| least squares mean (standard error)      |                                     |                                     |  |  |
| Week 4 [N=397, 388, 392, 394, 790, 789]  | 17.46 (± 0.58)                      | 17.95 (± 0.59)                      |  |  |
| Week 8 [N=381, 370, 380, 385, 757, 761]  | 22.3 (± 0.62)                       | 22.45 (± 0.62)                      |  |  |
| Week 12 [N=371, 362, 366, 374, 738, 734] | 24.63 (± 0.65)                      | 24.93 (± 0.65)                      |  |  |
| EoT [N=400, 392, 398, 399, 800, 795]     | 23.96 (± 0.63)                      | 24.3 (± 0.63)                       |  |  |

## Statistical analyses

| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                          | Difference vs. Solifenacin 5 mg (1) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                    | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                     | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                              | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                    | < 0.001                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                     | ANCOVA                                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                         | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                             | 3.81                                                   |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                      | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                      | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                | 1.69                                                   |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                | 5.94                                                   |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                       | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                           | 1.08                                                   |

| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                                                                                                                          | Difference vs. Solifenacin 5 mg (2) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1242                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | < 0.001                       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | 4.16                          |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | 2.03                          |
| upper limit                             | 6.29                          |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 1.09                          |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | 5.02                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 2.88                                                   |
| upper limit                             | 7.15                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 1.09                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                   |                                                        |
|-------------------|--------------------------------------------------------|
| Comparison groups | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
|-------------------|--------------------------------------------------------|

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1238                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | = 0.002                       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | 3.3                           |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | 1.17                          |
| upper limit                             | 5.43                          |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 1.09                          |

### Secondary: Change from Baseline to Weeks 4, 8, 12 and EoT in HRQL Subscale Score: Coping

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Change from Baseline to Weeks 4, 8, 12 and EoT in HRQL Subscale Score: Coping |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                               |
| <p>The OAB-q is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion consists of 25 HRQL items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction), scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.</p> |                                                                               |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Secondary                                                                     |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                               |
| Baseline and Weeks 4, 8, 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                               |

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: units on a scale                  |                 |                  |                  |                  |
| least squares mean (standard error)      |                 |                  |                  |                  |
| Week 4 [N=397, 388, 392, 394, 790, 789]  | 11.74 (± 0.99)  | 14.87 (± 1)      | 17.68 (± 1)      | 16.52 (± 1)      |
| Week 8 [N=381, 370, 380, 385, 757, 761]  | 16.13 (± 1.04)  | 20.64 (± 1.05)   | 21.52 (± 1.04)   | 21.69 (± 1.03)   |
| Week 12 [N=371, 362, 366, 374, 738, 734] | 18.17 (± 1.09)  | 22.04 (± 1.1)    | 24.94 (± 1.1)    | 23.67 (± 1.09)   |
| EoT [N=400, 392, 398, 399, 800, 795]     | 17.73 (± 1.05)  | 21.28 (± 1.06)   | 24.32 (± 1.05)   | 23.25 (± 1.05)   |

| End point values | Solifenacin 5 mg + mirabegron 25 | Solifenacin 5 mg + mirabegron 50 |  |  |
|------------------|----------------------------------|----------------------------------|--|--|
|------------------|----------------------------------|----------------------------------|--|--|

|                                          | mg              | mg              |  |  |
|------------------------------------------|-----------------|-----------------|--|--|
| Subject group type                       | Reporting group | Reporting group |  |  |
| Number of subjects analysed              | 827             | 827             |  |  |
| Units: units on a scale                  |                 |                 |  |  |
| least squares mean (standard error)      |                 |                 |  |  |
| Week 4 [N=397, 388, 392, 394, 790, 789]  | 19.31 (± 0.7)   | 20.36 (± 0.7)   |  |  |
| Week 8 [N=381, 370, 380, 385, 757, 761]  | 25.49 (± 0.74)  | 25.85 (± 0.73)  |  |  |
| Week 12 [N=371, 362, 366, 374, 738, 734] | 28.32 (± 0.77)  | 29.03 (± 0.78)  |  |  |
| EoT [N=400, 392, 398, 399, 800, 795]     | 27.37 (± 0.74)  | 28.12 (± 0.75)  |  |  |

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                 | Difference vs. Solifenacin 5 mg (1) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                    | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                     | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                              | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                    | = 0.001                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                     | ANCOVA                                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                         | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                             | 4.12                                                   |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                      | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                      | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                | 1.6                                                    |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                | 6.65                                                   |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                       | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                           | 1.29                                                   |

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                 | Difference vs. Solifenacin 5 mg (2) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1242                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | < 0.001                       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | 4.87                          |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | 2.34                          |
| upper limit                             | 7.4                           |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 1.29                          |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | 6.09                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 3.55                                                   |
| upper limit                             | 8.63                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 1.3                                                    |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                   |                                                        |
|-------------------|--------------------------------------------------------|
| Comparison groups | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
|-------------------|--------------------------------------------------------|

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1238                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | = 0.003                       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | 3.8                           |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | 1.27                          |
| upper limit                             | 6.33                          |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 1.29                          |

### Secondary: Change from Baseline to Weeks 4, 8, 12 and EoT in HRQL Subscale Score: Concern

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Change from Baseline to Weeks 4, 8, 12 and EoT in HRQL Subscale Score: Concern |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                |
| <p>The OAB-q is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion consists of 25 HRQL items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction), scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.</p> |                                                                                |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Secondary                                                                      |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                |
| Baseline and Weeks 4, 8, 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                |

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: units on a scale                  |                 |                  |                  |                  |
| least squares mean (standard error)      |                 |                  |                  |                  |
| Week 4 [N=397, 388, 392, 394, 790, 789]  | 11.24 (± 0.95)  | 15.89 (± 0.96)   | 17.39 (± 0.95)   | 17.18 (± 0.95)   |
| Week 8 [N=381, 370, 380, 385, 757, 761]  | 16.1 (± 0.99)   | 20.63 (± 1.01)   | 20.55 (± 1)      | 20.96 (± 0.99)   |
| Week 12 [N=371, 362, 366, 374, 738, 734] | 17.53 (± 1.03)  | 22.37 (± 1.04)   | 23.62 (± 1.04)   | 23.19 (± 1.03)   |
| EoT [N=400, 392, 398, 399, 800, 795]     | 16.98 (± 1)     | 21.55 (± 1.01)   | 23.07 (± 1)      | 22.65 (± 1)      |

| End point values | Solifenacin 5 mg + mirabegron 25 | Solifenacin 5 mg + mirabegron 50 |  |  |
|------------------|----------------------------------|----------------------------------|--|--|
|------------------|----------------------------------|----------------------------------|--|--|

|                                          | mg              | mg              |  |  |
|------------------------------------------|-----------------|-----------------|--|--|
| Subject group type                       | Reporting group | Reporting group |  |  |
| Number of subjects analysed              | 827             | 827             |  |  |
| Units: units on a scale                  |                 |                 |  |  |
| least squares mean (standard error)      |                 |                 |  |  |
| Week 4 [N=397, 388, 392, 394, 790, 789]  | 20.48 (± 0.67)  | 21.09 (± 0.67)  |  |  |
| Week 8 [N=381, 370, 380, 385, 757, 761]  | 25.26 (± 0.71)  | 25.65 (± 0.7)   |  |  |
| Week 12 [N=371, 362, 366, 374, 738, 734] | 27.53 (± 0.73)  | 28.24 (± 0.73)  |  |  |
| EoT [N=400, 392, 398, 399, 800, 795]     | 26.89 (± 0.71)  | 27.47 (± 0.71)  |  |  |

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                 | Difference vs. Solifenacin 5 mg (1) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                    | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                     | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                              | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                    | = 0.001                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                     | ANCOVA                                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                         | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                             | 4.24                                                   |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                      | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                      | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                | 1.84                                                   |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                | 6.63                                                   |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                       | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                           | 1.22                                                   |

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                 | Difference vs. Solifenacin 5 mg (2) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1242                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | < 0.001                       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | 4.82                          |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | 2.42                          |
| upper limit                             | 7.22                          |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 1.22                          |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | 5.34                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 2.93                                                   |
| upper limit                             | 7.75                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 1.23                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                   |                                                        |
|-------------------|--------------------------------------------------------|
| Comparison groups | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
|-------------------|--------------------------------------------------------|

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1238                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | < 0.001                       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | 4.41                          |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | 2.01                          |
| upper limit                             | 6.81                          |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 1.22                          |

### Secondary: Change from Baseline to Weeks 4, 8, 12 and EoT in HRQL Subscale Score: Sleep

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Change from Baseline to Weeks 4, 8, 12 and EoT in HRQL Subscale Score: Sleep |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                              |
| <p>The OAB-q is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion consists of 25 HRQL items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction), scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.</p> |                                                                              |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Secondary                                                                    |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                              |
| Baseline and Weeks 4, 8, 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                              |

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: units on a scale                  |                 |                  |                  |                  |
| least squares mean (standard error)      |                 |                  |                  |                  |
| Week 4 [N=397, 388, 392, 394, 790, 789]  | 9.28 (± 0.95)   | 12.7 (± 0.96)    | 13.8 (± 0.96)    | 13.08 (± 0.96)   |
| Week 8 [N=381, 370, 380, 385, 757, 761]  | 13.58 (± 1.03)  | 16.39 (± 1.05)   | 17.33 (± 1.03)   | 16.43 (± 1.03)   |
| Week 12 [N=371, 362, 366, 374, 738, 734] | 14.4 (± 1.05)   | 18.04 (± 1.06)   | 19.16 (± 1.06)   | 18.35 (± 1.05)   |
| EoT [N=400, 392, 398, 399, 800, 795]     | 14.17 (± 1.01)  | 17.51 (± 1.02)   | 19.11 (± 1.02)   | 17.97 (± 1.01)   |

| End point values | Solifenacin 5 mg + mirabegron 25 | Solifenacin 5 mg + mirabegron 50 |  |  |
|------------------|----------------------------------|----------------------------------|--|--|
|------------------|----------------------------------|----------------------------------|--|--|

|                                          | mg              | mg              |  |  |
|------------------------------------------|-----------------|-----------------|--|--|
| Subject group type                       | Reporting group | Reporting group |  |  |
| Number of subjects analysed              | 827             | 827             |  |  |
| Units: units on a scale                  |                 |                 |  |  |
| least squares mean (standard error)      |                 |                 |  |  |
| Week 4 [N=397, 388, 392, 394, 790, 789]  | 15.97 (± 0.68)  | 16.66 (± 0.68)  |  |  |
| Week 8 [N=381, 370, 380, 385, 757, 761]  | 20.29 (± 0.73)  | 20.49 (± 0.73)  |  |  |
| Week 12 [N=371, 362, 366, 374, 738, 734] | 22.97 (± 0.74)  | 22.76 (± 0.75)  |  |  |
| EoT [N=400, 392, 398, 399, 800, 795]     | 22.39 (± 0.72)  | 22.39 (± 0.72)  |  |  |

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                 | Difference vs. Solifenacin 5 mg (1) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                    | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                     | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                              | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                    | < 0.001                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                     | ANCOVA                                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                         | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                             | 4.42                                                   |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                      | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                      | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                | 1.98                                                   |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                | 6.85                                                   |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                       | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                           | 1.24                                                   |

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                 | Difference vs. Solifenacin 5 mg (2) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1242                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | < 0.001                       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | 4.42                          |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | 1.98                          |
| upper limit                             | 6.86                          |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 1.24                          |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | 4.87                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 2.42                                                   |
| upper limit                             | 7.32                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 1.25                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                   |                                                        |
|-------------------|--------------------------------------------------------|
| Comparison groups | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
|-------------------|--------------------------------------------------------|

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1238                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | = 0.008                       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | 3.28                          |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | 0.84                          |
| upper limit                             | 5.72                          |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 1.24                          |

### Secondary: Change from Baseline to Weeks 4, 8, 12 and EoT in HRQL Subscale Score: Social

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Change from Baseline to Weeks 4, 8, 12 and EoT in HRQL Subscale Score: Social |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                               |
| <p>The OAB-q is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion consists of 25 HRQL items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction), scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.</p> |                                                                               |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Secondary                                                                     |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                               |
| Baseline and Weeks 4, 8, 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                               |

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: units on a scale                  |                 |                  |                  |                  |
| least squares mean (standard error)      |                 |                  |                  |                  |
| Week 4 [N=397, 388, 392, 394, 790, 789]  | 7.07 (± 0.78)   | 9.04 (± 0.79)    | 10.19 (± 0.78)   | 9.89 (± 0.78)    |
| Week 8 [N=381, 370, 380, 385, 757, 761]  | 10.65 (± 0.82)  | 11.5 (± 0.83)    | 12.34 (± 0.82)   | 12.02 (± 0.81)   |
| Week 12 [N=371, 362, 366, 374, 738, 734] | 10.84 (± 0.83)  | 13.43 (± 0.84)   | 15.35 (± 0.84)   | 13.74 (± 0.83)   |
| EoT [N=400, 392, 398, 399, 800, 795]     | 10.56 (± 0.81)  | 13.04 (± 0.81)   | 14.87 (± 0.81)   | 13.57 (± 0.81)   |

| End point values | Solifenacin 5 mg + mirabegron 25 | Solifenacin 5 mg + mirabegron 50 |  |  |
|------------------|----------------------------------|----------------------------------|--|--|
|------------------|----------------------------------|----------------------------------|--|--|

|                                          | mg              | mg              |  |  |
|------------------------------------------|-----------------|-----------------|--|--|
| Subject group type                       | Reporting group | Reporting group |  |  |
| Number of subjects analysed              | 827             | 827             |  |  |
| Units: units on a scale                  |                 |                 |  |  |
| least squares mean (standard error)      |                 |                 |  |  |
| Week 4 [N=397, 388, 392, 394, 790, 789]  | 11.55 (± 0.55)  | 11.25 (± 0.55)  |  |  |
| Week 8 [N=381, 370, 380, 385, 757, 761]  | 14.89 (± 0.58)  | 14.73 (± 0.58)  |  |  |
| Week 12 [N=371, 362, 366, 374, 738, 734] | 16.16 (± 0.59)  | 16.08 (± 0.59)  |  |  |
| EoT [N=400, 392, 398, 399, 800, 795]     | 15.84 (± 0.57)  | 15.82 (± 0.57)  |  |  |

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                 | Difference vs. Solifenacin 5 mg (1) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                                                                                                                    | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                                                                                                                     | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                                                                                                              | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                                                                                                                    | = 0.022                                                |
| Method                                                                                                                                                                                                                                                                                                                                                                                                     | ANCOVA                                                 |
| Parameter estimate                                                                                                                                                                                                                                                                                                                                                                                         | Least squares mean difference                          |
| Point estimate                                                                                                                                                                                                                                                                                                                                                                                             | 2.27                                                   |
| Confidence interval                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
| level                                                                                                                                                                                                                                                                                                                                                                                                      | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                                                                                                                      | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                                                                                                                | 0.33                                                   |
| upper limit                                                                                                                                                                                                                                                                                                                                                                                                | 4.21                                                   |
| Variability estimate                                                                                                                                                                                                                                                                                                                                                                                       | Standard error of the mean                             |
| Dispersion value                                                                                                                                                                                                                                                                                                                                                                                           | 0.99                                                   |

| Statistical analysis title                                                                                                                                                                                                                                                                                                                                                                                 | Difference vs. Solifenacin 5 mg (2) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
| Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (solifenacin 5 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                                                                          | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1242                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | = 0.023                       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | 2.25                          |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | 0.31                          |
| upper limit                             | 4.19                          |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 0.99                          |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 25 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 25 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.005                                                |
| Method                                  | ANCOVA                                                 |
| Parameter estimate                      | Least squares mean difference                          |
| Point estimate                          | 2.8                                                    |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 0.85                                                   |
| upper limit                             | 4.74                                                   |
| Variability estimate                    | Standard error of the mean                             |
| Dispersion value                        | 0.99                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Difference vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Difference of the adjusted mean calculated by subtracting the adjusted mean of the monotherapy group (mirabegron 50 mg) from the adjusted mean of the combination group (solifenacin 5 mg + mirabegron 50 mg) based on the ANCOVA model with treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as fixed factors and baseline value as a covariate.

|                   |                                                        |
|-------------------|--------------------------------------------------------|
| Comparison groups | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
|-------------------|--------------------------------------------------------|

|                                         |                               |
|-----------------------------------------|-------------------------------|
| Number of subjects included in analysis | 1238                          |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           | superiority                   |
| P-value                                 | = 0.337                       |
| Method                                  | ANCOVA                        |
| Parameter estimate                      | Least squares mean difference |
| Point estimate                          | 0.95                          |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | -0.99                         |
| upper limit                             | 2.89                          |
| Variability estimate                    | Standard error of the mean    |
| Dispersion value                        | 0.99                          |

### Secondary: Patient's Global Impression of Change (PGIC) Scale: Impression in Bladder Symptoms at Week 12 and EoT

|                                                                                                                                                                                                                                                                                                                                                               |                                                                                                          |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                               | Patient's Global Impression of Change (PGIC) Scale:<br>Impression in Bladder Symptoms at Week 12 and EoT |
| End point description:                                                                                                                                                                                                                                                                                                                                        |                                                                                                          |
| <p>The PGIC is a 2-part questionnaire, assessing both the change in the patient's overall condition and change in bladder condition since the start of the study (from very much worse to very much improved). The analysis population was the FAS. The number of participants analyzed includes participants with data available. LOCF for EoT was used.</p> |                                                                                                          |
| End point type                                                                                                                                                                                                                                                                                                                                                | Secondary                                                                                                |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                          |                                                                                                          |
| Week 12                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |

| End point values                  | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|-----------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed       | 418             | 410              | 411              | 415              |
| Units: percentage of participants |                 |                  |                  |                  |
| number (not applicable)           |                 |                  |                  |                  |
| Week 12: Very much improved       | 8.4             | 13.9             | 15.1             | 13.5             |
| Week 12: Much improved            | 29.7            | 32.9             | 34.8             | 40.5             |
| Week 12: Minimally improved       | 29.7            | 26.8             | 26.5             | 25.8             |
| Week 12: No change                | 17.5            | 12.9             | 9.7              | 8.9              |
| Week 12: Minimally worse          | 4.1             | 1.5              | 2.2              | 1.7              |
| Week 12: Much worse               | 1               | 1                | 1.2              | 0.5              |
| Week 12: Very much worse          | 0.5             | 0.5              | 0.7              | 0.5              |
| EoT: Very much improved           | 8.4             | 13.9             | 15.1             | 13.5             |
| EoT: Much improved                | 30.4            | 33.2             | 34.8             | 41               |
| EoT: Minimally improved           | 29.9            | 26.8             | 27               | 26.3             |
| EoT: No change                    | 18.2            | 13.4             | 10.2             | 9.6              |
| EoT: Minimally worse              | 4.1             | 1.5              | 2.2              | 1.7              |
| EoT: Much worse                   | 1               | 1                | 1.2              | 0.7              |
| EoT: Very much worse              | 0.5             | 0.5              | 0.7              | 0.5              |

| <b>End point values</b>           | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|-----------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed       | 827                                 | 827                                 |  |  |
| Units: percentage of participants |                                     |                                     |  |  |
| number (not applicable)           |                                     |                                     |  |  |
| Week 12: Very much improved       | 19.8                                | 27.1                                |  |  |
| Week 12: Much improved            | 39.8                                | 34                                  |  |  |
| Week 12: Minimally improved       | 22.2                                | 20.7                                |  |  |
| Week 12: No change                | 7.7                                 | 7.3                                 |  |  |
| Week 12: Minimally worse          | 0.8                                 | 0.8                                 |  |  |
| Week 12: Much worse               | 0.2                                 | 0                                   |  |  |
| Week 12: Very much worse          | 0.2                                 | 0.5                                 |  |  |
| EoT: Very much improved           | 20                                  | 27.1                                |  |  |
| EoT: Much improved                | 40                                  | 34.6                                |  |  |
| EoT: Minimally improved           | 22.6                                | 21.3                                |  |  |
| EoT: No change                    | 7.9                                 | 7.4                                 |  |  |
| EoT: Minimally worse              | 0.8                                 | 0.8                                 |  |  |
| EoT: Much worse                   | 0.4                                 | 0                                   |  |  |
| EoT: Very much worse              | 0.2                                 | 0.6                                 |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: PGIC Scale: Impression in General Health at Week 12 and EoT

|                                                                                                                                                                                                                                                                                                                                                        |                                                             |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                        | PGIC Scale: Impression in General Health at Week 12 and EoT |
| End point description:                                                                                                                                                                                                                                                                                                                                 |                                                             |
| The PGIC is a 2-part questionnaire, assessing both the change in the patient's overall condition and change in bladder condition since the start of the study (from very much worse to very much improved). The analysis population was the FAS. The number of participants analyzed includes participants with data available. LOCF for EoT was used. |                                                             |
| End point type                                                                                                                                                                                                                                                                                                                                         | Secondary                                                   |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                   |                                                             |
| Week 12                                                                                                                                                                                                                                                                                                                                                |                                                             |

| <b>End point values</b>           | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|-----------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed       | 418             | 410              | 411              | 415              |
| Units: percentage of participants |                 |                  |                  |                  |
| number (not applicable)           |                 |                  |                  |                  |
| Week 12: Very much improved       | 4.8             | 8                | 7.3              | 7.7              |

|                             |      |      |      |      |
|-----------------------------|------|------|------|------|
| Week 12: Much improved      | 23.9 | 28   | 29.2 | 31.8 |
| Week 12: Minimally improved | 23.9 | 21.5 | 22.4 | 24.1 |
| Week 12: No change          | 31.8 | 27.8 | 27.5 | 25.3 |
| Week 12: Minimally worse    | 4.3  | 2.9  | 2.2  | 1.4  |
| Week 12: Much worse         | 1.7  | 0.7  | 1.2  | 0.5  |
| Week 12: Very much worse    | 0.2  | 0.5  | 0.5  | 0.5  |
| EoT: Very much improved     | 4.8  | 8    | 7.3  | 7.7  |
| EoT: Much improved          | 24.2 | 28   | 29.2 | 31.8 |
| EoT: Minimally improved     | 24.4 | 21.5 | 22.9 | 24.1 |
| EoT: No change              | 32.3 | 28.3 | 27.7 | 26.5 |
| EoT: Minimally worse        | 4.3  | 2.9  | 2.4  | 1.9  |
| EoT: Much worse             | 1.9  | 0.7  | 1.2  | 0.5  |
| EoT: Very much worse        | 0.5  | 0.7  | 0.5  | 0.7  |

| <b>End point values</b>           | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|-----------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed       | 827                                 | 827                                 |  |  |
| Units: percentage of participants |                                     |                                     |  |  |
| number (not applicable)           |                                     |                                     |  |  |
| Week 12: Very much improved       | 10.3                                | 14.6                                |  |  |
| Week 12: Much improved            | 33.4                                | 30.2                                |  |  |
| Week 12: Minimally improved       | 20.1                                | 20.9                                |  |  |
| Week 12: No change                | 23.9                                | 21.6                                |  |  |
| Week 12: Minimally worse          | 2.5                                 | 2.2                                 |  |  |
| Week 12: Much worse               | 0.5                                 | 0.1                                 |  |  |
| Week 12: Very much worse          | 0.2                                 | 0.6                                 |  |  |
| EoT: Very much improved           | 10.3                                | 14.6                                |  |  |
| EoT: Much improved                | 33.6                                | 30.4                                |  |  |
| EoT: Minimally improved           | 20.2                                | 21.3                                |  |  |
| EoT: No change                    | 24.3                                | 21.9                                |  |  |
| EoT: Minimally worse              | 2.8                                 | 2.7                                 |  |  |
| EoT: Much worse                   | 0.5                                 | 0.2                                 |  |  |
| EoT: Very much worse              | 0.2                                 | 0.7                                 |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to EoT in European Quality of Life in 5 Dimensions (EQ-5D) Questionnaire Subscale Score: Mobility

|                 |                                                                                                                        |
|-----------------|------------------------------------------------------------------------------------------------------------------------|
| End point title | Change from Baseline to EoT in European Quality of Life in 5 Dimensions (EQ-5D) Questionnaire Subscale Score: Mobility |
|-----------------|------------------------------------------------------------------------------------------------------------------------|

End point description:

The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort,

and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity). The analysis population was the FAS. LOCF for EoT was used.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Baseline and Week 12 |           |

| End point values                             | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|----------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                           | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed                  | 418             | 410              | 411              | 415              |
| Units: participants                          |                 |                  |                  |                  |
| number (not applicable)                      |                 |                  |                  |                  |
| No problems -> no problems                   | 204             | 239              | 225              | 227              |
| No problems -> slight problems               | 16              | 20               | 25               | 22               |
| No problems -> moderate problems             | 11              | 12               | 9                | 8                |
| No problems -> severe problems               | 1               | 3                | 3                | 1                |
| No problems -> unable to walk about          | 0               | 1                | 0                | 0                |
| No problems -> no data                       | 2               | 4                | 5                | 4                |
| Slight problems -> no problems               | 33              | 35               | 35               | 30               |
| Slight problems -> slight problems           | 27              | 20               | 24               | 19               |
| Slight problems -> moderate problems         | 11              | 6                | 4                | 6                |
| Slight problems -> severe problems           | 5               | 0                | 3                | 1                |
| Slight problems -> unable to walk about      | 0               | 0                | 0                | 0                |
| Slight problems -> no data                   | 2               | 3                | 0                | 0                |
| Moderate problems -> no problems             | 17              | 7                | 25               | 18               |
| Moderate problems -> slight problems         | 18              | 10               | 10               | 22               |
| Moderate problems -> moderate problems       | 21              | 12               | 10               | 13               |
| Moderate problems -> severe problems         | 10              | 5                | 4                | 2                |
| Moderate problems -> unable to walk about    | 0               | 0                | 0                | 1                |
| Moderate problems -> no data                 | 1               | 1                | 0                | 1                |
| Severe problems -> no problems               | 3               | 5                | 9                | 7                |
| Severe problems -> slight problems           | 6               | 7                | 3                | 4                |
| Severe problems -> moderate problems         | 5               | 4                | 8                | 8                |
| Severe problems -> severe problems           | 8               | 5                | 1                | 8                |
| Severe problems -> unable to walk about      | 0               | 0                | 0                | 0                |
| Severe problems -> no data                   | 0               | 0                | 2                | 1                |
| Unable to walk about -> no problems          | 0               | 0                | 0                | 2                |
| Unable to walk about -> slight problems      | 1               | 0                | 0                | 0                |
| Unable to walk about -> moderate problems    | 1               | 0                | 0                | 0                |
| Unable to walk about -> severe problems      | 1               | 0                | 0                | 0                |
| Unable to walk about -> unable to walk about | 0               | 0                | 0                | 0                |
| Unable to walk about -> no data              | 0               | 0                | 0                | 0                |
| No data -> no problems                       | 12              | 7                | 3                | 6                |
| No data -> slight problems                   | 1               | 0                | 1                | 2                |
| No data -> moderate problems                 | 0               | 3                | 1                | 0                |

|                                 |   |   |   |   |
|---------------------------------|---|---|---|---|
| No data -> severe problems      | 0 | 1 | 0 | 2 |
| No data -> unable to walk about | 0 | 0 | 0 | 0 |
| No data -> no data              | 1 | 0 | 1 | 0 |

| <b>End point values</b>                      | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|----------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                           | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed                  | 827                                 | 827                                 |  |  |
| Units: participants                          |                                     |                                     |  |  |
| number (not applicable)                      |                                     |                                     |  |  |
| No problems -> no problems                   | 449                                 | 452                                 |  |  |
| No problems -> slight problems               | 41                                  | 38                                  |  |  |
| No problems -> moderate problems             | 20                                  | 10                                  |  |  |
| No problems -> severe problems               | 1                                   | 2                                   |  |  |
| No problems -> unable to walk about          | 0                                   | 1                                   |  |  |
| No problems -> no data                       | 6                                   | 9                                   |  |  |
| Slight problems -> no problems               | 76                                  | 60                                  |  |  |
| Slight problems -> slight problems           | 40                                  | 49                                  |  |  |
| Slight problems -> moderate problems         | 19                                  | 9                                   |  |  |
| Slight problems -> severe problems           | 2                                   | 2                                   |  |  |
| Slight problems -> unable to walk about      | 0                                   | 0                                   |  |  |
| Slight problems -> no data                   | 0                                   | 2                                   |  |  |
| Moderate problems -> no problems             | 31                                  | 46                                  |  |  |
| Moderate problems -> slight problems         | 24                                  | 25                                  |  |  |
| Moderate problems -> moderate problems       | 33                                  | 35                                  |  |  |
| Moderate problems -> severe problems         | 8                                   | 10                                  |  |  |
| Moderate problems -> unable to walk about    | 1                                   | 1                                   |  |  |
| Moderate problems -> no data                 | 0                                   | 2                                   |  |  |
| Severe problems -> no problems               | 12                                  | 17                                  |  |  |
| Severe problems -> slight problems           | 13                                  | 8                                   |  |  |
| Severe problems -> moderate problems         | 15                                  | 15                                  |  |  |
| Severe problems -> severe problems           | 11                                  | 13                                  |  |  |
| Severe problems -> unable to walk about      | 0                                   | 0                                   |  |  |
| Severe problems -> no data                   | 1                                   | 0                                   |  |  |
| Unable to walk about -> no problems          | 2                                   | 0                                   |  |  |
| Unable to walk about -> slight problems      | 0                                   | 0                                   |  |  |
| Unable to walk about -> moderate problems    | 0                                   | 1                                   |  |  |
| Unable to walk about -> severe problems      | 0                                   | 0                                   |  |  |
| Unable to walk about -> unable to walk about | 0                                   | 0                                   |  |  |
| Unable to walk about -> no data              | 0                                   | 0                                   |  |  |
| No data -> no problems                       | 15                                  | 16                                  |  |  |
| No data -> slight problems                   | 4                                   | 2                                   |  |  |
| No data -> moderate problems                 | 0                                   | 2                                   |  |  |
| No data -> severe problems                   | 2                                   | 0                                   |  |  |

|                                 |   |   |  |  |
|---------------------------------|---|---|--|--|
| No data -> unable to walk about | 0 | 0 |  |  |
| No data -> no data              | 1 | 0 |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline to EoT in EQ-5D Questionnaire Subscale Score: Self-care

|                 |                                                                              |
|-----------------|------------------------------------------------------------------------------|
| End point title | Change from Baseline to EoT in EQ-5D Questionnaire Subscale Score: Self-care |
|-----------------|------------------------------------------------------------------------------|

End point description:

The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity). The analysis population was the FAS. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 12

| End point values                                 | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|--------------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                               | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed                      | 418             | 410              | 411              | 415              |
| Units: participants                              |                 |                  |                  |                  |
| number (not applicable)                          |                 |                  |                  |                  |
| No problems -> no problems                       | 311             | 324              | 336              | 319              |
| No problems -> slight problems                   | 21              | 17               | 9                | 20               |
| No problems -> moderate problems                 | 9               | 5                | 6                | 3                |
| No problems -> severe problems                   | 0               | 0                | 1                | 1                |
| No problems -> unable to wash/dress myself       | 1               | 0                | 1                | 0                |
| No problems -> no data                           | 4               | 8                | 6                | 5                |
| Slight problems -> no problems                   | 17              | 13               | 16               | 25               |
| Slight problems -> slight problems               | 10              | 10               | 12               | 12               |
| Slight problems -> moderate problems             | 2               | 4                | 1                | 2                |
| Slight problems -> severe problems               | 2               | 0                | 0                | 0                |
| Slight problems -> unable to wash/dress myself   | 0               | 0                | 0                | 0                |
| Slight problems -> no data                       | 1               | 0                | 0                | 1                |
| Moderate problems -> no problems                 | 6               | 8                | 3                | 2                |
| Moderate problems -> slight problems             | 3               | 1                | 8                | 3                |
| Moderate problems -> moderate problems           | 9               | 1                | 2                | 6                |
| Moderate problems -> severe problems             | 0               | 0                | 0                | 0                |
| Moderate problems -> unable to wash/dress myself | 0               | 0                | 0                | 0                |
| Moderate problems -> no data                     | 0               | 0                | 0                | 0                |

|                                                     |    |   |   |   |
|-----------------------------------------------------|----|---|---|---|
| Severe problems -> no problems                      | 2  | 2 | 2 | 1 |
| Severe problems -> slight problems                  | 1  | 0 | 0 | 3 |
| Severe problems -> moderate problems                | 1  | 2 | 0 | 0 |
| Severe problems -> severe problems                  | 3  | 3 | 0 | 1 |
| Severe problems -> unable to wash/dress myself      | 0  | 0 | 0 | 0 |
| Severe problems -> no data                          | 0  | 0 | 1 | 0 |
| Unable to wash/dress myself -> no problems          | 0  | 1 | 1 | 0 |
| Unable to wash/dress myself -> slight problems      | 0  | 0 | 0 | 0 |
| Unable to wash/dress myself -> moderate problems    | 1  | 0 | 0 | 0 |
| Unable to wash/dress myself -> severe problems      | 0  | 0 | 0 | 0 |
| Unable to wash/dress myself -> unable to wash/dress | 0  | 0 | 0 | 1 |
| Unable to wash/dress myself -> no data              | 0  | 0 | 0 | 0 |
| No data -> no problems                              | 13 | 8 | 3 | 8 |
| No data -> slight problems                          | 0  | 2 | 2 | 1 |
| No data -> moderate problems                        | 0  | 1 | 0 | 1 |
| No data -> severe problems                          | 0  | 0 | 0 | 0 |
| No data -> unable to wash/dress myself              | 0  | 0 | 0 | 0 |
| No data -> no data                                  | 1  | 0 | 1 | 0 |

| <b>End point values</b>                        | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                             | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed                    | 827                                 | 827                                 |  |  |
| Units: participants                            |                                     |                                     |  |  |
| number (not applicable)                        |                                     |                                     |  |  |
| No problems -> no problems                     | 652                                 | 647                                 |  |  |
| No problems -> slight problems                 | 22                                  | 26                                  |  |  |
| No problems -> moderate problems               | 12                                  | 4                                   |  |  |
| No problems -> severe problems                 | 1                                   | 1                                   |  |  |
| No problems -> unable to wash/dress myself     | 0                                   | 0                                   |  |  |
| No problems -> no data                         | 6                                   | 12                                  |  |  |
| Slight problems -> no problems                 | 35                                  | 33                                  |  |  |
| Slight problems -> slight problems             | 22                                  | 26                                  |  |  |
| Slight problems -> moderate problems           | 3                                   | 7                                   |  |  |
| Slight problems -> severe problems             | 1                                   | 2                                   |  |  |
| Slight problems -> unable to wash/dress myself | 0                                   | 0                                   |  |  |
| Slight problems -> no data                     | 1                                   | 0                                   |  |  |
| Moderate problems -> no problems               | 17                                  | 16                                  |  |  |
| Moderate problems -> slight problems           | 9                                   | 7                                   |  |  |
| Moderate problems -> moderate problems         | 8                                   | 9                                   |  |  |
| Moderate problems -> severe problems           | 2                                   | 1                                   |  |  |

|                                                    |    |    |  |  |
|----------------------------------------------------|----|----|--|--|
| Moderate problems -> unable to wash/dress myself   | 0  | 0  |  |  |
| Moderate problems -> no data                       | 0  | 1  |  |  |
| Severe problems -> no problems                     | 3  | 4  |  |  |
| Severe problems -> slight problems                 | 3  | 3  |  |  |
| Severe problems -> moderate problems               | 7  | 3  |  |  |
| Severe problems -> severe problems                 | 1  | 0  |  |  |
| Severe problems -> unable to wash/dress myself     | 0  | 0  |  |  |
| Severe problems -> no data                         | 0  | 0  |  |  |
| Unable to wash/dress myself -> no problems         | 0  | 3  |  |  |
| Unable to wash/dress myself -> slight problems     | 0  | 0  |  |  |
| Unable to wash/dress myself -> moderate problems   | 0  | 0  |  |  |
| Unable to wash/dress myself -> severe problems     | 0  | 0  |  |  |
| Unable to wash/dress myself -> unable to wash/dres | 0  | 0  |  |  |
| Unable to wash/dress myself -> no data             | 0  | 0  |  |  |
| No data -> no problems                             | 20 | 18 |  |  |
| No data -> slight problems                         | 1  | 0  |  |  |
| No data -> moderate problems                       | 0  | 2  |  |  |
| No data -> severe problems                         | 0  | 0  |  |  |
| No data -> unable to wash/dress myself             | 0  | 0  |  |  |
| No data -> no data                                 | 1  | 0  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to EoT in EQ-5D Questionnaire Subscale Score: Usual Activities

|                 |                                                                                     |
|-----------------|-------------------------------------------------------------------------------------|
| End point title | Change from Baseline to EoT in EQ-5D Questionnaire Subscale Score: Usual Activities |
|-----------------|-------------------------------------------------------------------------------------|

End point description:

The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity). The analysis population was the FAS. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 12

| <b>End point values</b>                            | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|----------------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                                 | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed                        | 418             | 410              | 411              | 415              |
| Units: participants                                |                 |                  |                  |                  |
| number (not applicable)                            |                 |                  |                  |                  |
| No problems -> No problems                         | 196             | 228              | 219              | 223              |
| No problems -> Slight problems                     | 37              | 25               | 28               | 25               |
| No problems -> Moderate problems                   | 9               | 5                | 9                | 8                |
| No problems -> Severe problems                     | 2               | 0                | 1                | 0                |
| No problems -> unable to do usual activities       | 0               | 0                | 0                | 0                |
| No problems -> no data                             | 2               | 5                | 4                | 3                |
| Slight problems -> no problems                     | 45              | 41               | 52               | 52               |
| Slight problems -> slight problems                 | 28              | 29               | 23               | 25               |
| Slight problems -> moderate problems               | 15              | 9                | 3                | 8                |
| Slight problems -> severe problems                 | 2               | 0                | 2                | 0                |
| Slight problems -> unable to do usual activities   | 0               | 0                | 0                | 0                |
| Slight problems -> no data                         | 2               | 2                | 0                | 3                |
| Moderate problems -> no problems                   | 14              | 13               | 15               | 13               |
| Moderate problems -> slight problems               | 12              | 9                | 16               | 14               |
| Moderate problems -> moderate problems             | 15              | 11               | 9                | 12               |
| Moderate problems -> severe problems               | 1               | 3                | 0                | 1                |
| Moderate problems -> unable to do usual activities | 0               | 0                | 0                | 0                |
| Moderate problems -> no data                       | 1               | 1                | 2                | 0                |
| Severe problems -> no problems                     | 7               | 3                | 7                | 6                |
| Severe problems -> slight problems                 | 3               | 4                | 6                | 2                |
| Severe problems -> moderate problems               | 6               | 7                | 5                | 6                |
| Severe problems -> severe problems                 | 4               | 1                | 1                | 3                |
| Severe problems -> unable to do usual activities   | 0               | 1                | 0                | 0                |
| Severe problems -> no data                         | 0               | 0                | 1                | 0                |
| No data -> no problems                             | 12              | 7                | 2                | 7                |
| No data -> slight problems                         | 1               | 2                | 3                | 1                |
| No data -> moderate problems                       | 0               | 2                | 0                | 2                |
| No data -> severe problems                         | 0               | 0                | 0                | 0                |
| No data -> unable to do usual activities           | 0               | 0                | 0                | 0                |
| No data -> no data                                 | 1               | 0                | 1                | 0                |

| <b>End point values</b>        | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|--------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type             | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed    | 827                                 | 827                                 |  |  |
| Units: participants            |                                     |                                     |  |  |
| number (not applicable)        |                                     |                                     |  |  |
| No problems -> No problems     | 434                                 | 451                                 |  |  |
| No problems -> Slight problems | 37                                  | 48                                  |  |  |

|                                                   |    |    |  |  |
|---------------------------------------------------|----|----|--|--|
| No problems -> Moderate problems                  | 13 | 11 |  |  |
| No problems -> Severe problems                    | 1  | 1  |  |  |
| No problems -> unable to do usual activities      | 1  | 1  |  |  |
| No problems -> no data                            | 5  | 8  |  |  |
| Slight problems -> no problems                    | 98 | 95 |  |  |
| Slight problems -> slight problems                | 64 | 56 |  |  |
| Slight problems -> moderate problems              | 18 | 12 |  |  |
| Slight problems -> severe problems                | 2  | 3  |  |  |
| Slight problems ->unable to do usual activities   | 0  | 0  |  |  |
| Slight problems -> no data                        | 2  | 4  |  |  |
| Moderate problems -> no problems                  | 44 | 26 |  |  |
| Moderate problems -> slight problems              | 29 | 30 |  |  |
| Moderate problems -> moderate problems            | 25 | 17 |  |  |
| Moderate problems -> severe problems              | 3  | 3  |  |  |
| Moderate problems ->unable to do usual activities | 0  | 1  |  |  |
| Moderate problems -> no data                      | 0  | 1  |  |  |
| Severe problems -> no problems                    | 7  | 11 |  |  |
| Severe problems -> slight problems                | 8  | 8  |  |  |
| Severe problems -> moderate problems              | 9  | 7  |  |  |
| Severe problems -> severe problems                | 2  | 9  |  |  |
| Severe problems -> unable to do usual activities  | 0  | 0  |  |  |
| Severe problems -> no data                        | 0  | 0  |  |  |
| No data -> no problems                            | 18 | 15 |  |  |
| No data -> slight problems                        | 1  | 3  |  |  |
| No data -> moderate problems                      | 2  | 2  |  |  |
| No data -> severe problems                        | 0  | 0  |  |  |
| No data -> unable to do usual activities          | 0  | 0  |  |  |
| No data -> no data                                | 1  | 0  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to EoT in EQ-5D Questionnaire Subscale Score: Pain/Discomfort

|                 |                                                                                    |
|-----------------|------------------------------------------------------------------------------------|
| End point title | Change from Baseline to EoT in EQ-5D Questionnaire Subscale Score: Pain/Discomfort |
|-----------------|------------------------------------------------------------------------------------|

End point description:

The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity). The analysis population was the FAS. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 12

| End point values                                     | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                                   | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed                          | 418             | 410              | 411              | 415              |
| Units: participants                                  |                 |                  |                  |                  |
| number (not applicable)                              |                 |                  |                  |                  |
| No pain/discomfort -> no pain/discomfort             | 131             | 175              | 153              | 154              |
| No pain/discomfort -> slight pain/discomfort         | 38              | 29               | 37               | 33               |
| No pain/discomfort -> moderate pain/discomfort       | 10              | 9                | 17               | 13               |
| No pain/discomfort -> severe pain/discomfort         | 0               | 0                | 3                | 3                |
| No pain/discomfort -> extreme pain/discomfort        | 0               | 0                | 0                | 0                |
| No pain/discomfort -> no data                        | 2               | 3                | 4                | 2                |
| Slight pain/discomfort -> no pain/discomfort         | 53              | 51               | 44               | 46               |
| Slight pain/discomfort -> slight pain/discomfort     | 54              | 49               | 45               | 47               |
| Slight pain/discomfort -> moderate pain/discomfort   | 12              | 11               | 14               | 18               |
| Slight pain/discomfort -> severe pain/discomfort     | 3               | 0                | 2                | 0                |
| Slight pain/discomfort -> extreme pain/discomfort    | 2               | 0                | 1                | 0                |
| Slight pain/discomfort -> no data                    | 2               | 5                | 2                | 2                |
| Moderate pain/discomfort -> no pain/discomfort       | 20              | 14               | 24               | 23               |
| Moderate pain/discomfort -> slight pain/discomfort   | 23              | 15               | 20               | 22               |
| Moderate pain/discomfort -> moderate pain/discomfort | 31              | 13               | 16               | 15               |
| Moderate pain/discomfort -> severe pain/discomfort   | 4               | 5                | 3                | 1                |
| Moderate pain/discomfort -> extreme pain/discomfort  | 0               | 0                | 0                | 0                |
| Moderate pain/discomfort -> no data                  | 1               | 0                | 0                | 1                |
| Severe pain/discomfort -> no pain/discomfort         | 2               | 4                | 3                | 1                |
| Severe pain/discomfort -> slight pain/discomfort     | 3               | 4                | 6                | 4                |
| Severe pain/discomfort -> moderate pain/discomfort   | 8               | 4                | 6                | 11               |
| Severe pain/discomfort -> severe pain/discomfort     | 4               | 3                | 1                | 4                |
| Severe pain/discomfort -> extreme pain/discomfort    | 0               | 1                | 1                | 0                |
| Severe pain/discomfort -> no data                    | 0               | 0                | 1                | 0                |
| Extreme pain/discomfort -> no pain/discomfort        | 0               | 0                | 0                | 0                |
| Extreme pain/discomfort -> slight pain/discomfort    | 1               | 0                | 0                | 2                |
| Extreme pain/discomfort -> moderate pain/discomfort  | 0               | 2                | 1                | 0                |

|                                                    |    |   |   |   |
|----------------------------------------------------|----|---|---|---|
| Extreme pain/discomfort -> severe pain/discomfort  | 0  | 2 | 1 | 2 |
| Extreme pain/discomfort -> extreme pain/discomfort | 0  | 0 | 0 | 0 |
| Extreme pain/discomfort -> no data                 | 0  | 0 | 0 | 1 |
| No data -> no pain/discomfort                      | 11 | 5 | 3 | 6 |
| No data -> slight pain/discomfort                  | 2  | 2 | 2 | 2 |
| No data -> moderate pain/discomfort                | 0  | 4 | 0 | 2 |
| No data -> severe pain/discomfort                  | 0  | 0 | 0 | 0 |
| No data -> extreme pain/discomfort                 | 0  | 0 | 0 | 0 |
| No data -> no data                                 | 1  | 0 | 1 | 0 |

| <b>End point values</b>                            | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|----------------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                                 | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed                        | 827                                 | 827                                 |  |  |
| Units: participants                                |                                     |                                     |  |  |
| number (not applicable)                            |                                     |                                     |  |  |
| No pain/discomfort -> no pain/discomfort           | 290                                 | 317                                 |  |  |
| No pain/discomfort -> slight pain/discomfort       | 74                                  | 51                                  |  |  |
| No pain/discomfort -> moderate pain/discomfort     | 19                                  | 20                                  |  |  |
| No pain/discomfort -> severe pain/discomfort       | 3                                   | 1                                   |  |  |
| No pain/discomfort -> extreme pain/discomfort      | 1                                   | 0                                   |  |  |
| No pain/discomfort -> no data                      | 3                                   | 8                                   |  |  |
| Slight pain/discomfort -> no pain/discomfort       | 117                                 | 105                                 |  |  |
| Slight pain/discomfort -> slight pain/discomfort   | 94                                  | 101                                 |  |  |
| Slight pain/discomfort -> moderate pain/discomfort | 15                                  | 19                                  |  |  |
| Slight pain/discomfort -> severe pain/discomfort   | 6                                   | 3                                   |  |  |
| Slight pain/discomfort -> exteme pain/discomfort   | 0                                   | 0                                   |  |  |
| Slight pain/discomfort -> no data                  | 2                                   | 4                                   |  |  |
| Moderate pain/discomfort -> no pain/discomfort     | 45                                  | 46                                  |  |  |
| Moderate pain/discomfort -> slight pain/discomfort | 46                                  | 45                                  |  |  |
| Moderate pain/discomfort -> moderate pain/discomf  | 34                                  | 40                                  |  |  |
| Moderate pain/discomfort -> severe pain/discomfort | 4                                   | 6                                   |  |  |
| Moderate pain/discomfort -> extreme pain/discomf   | 1                                   | 0                                   |  |  |
| Moderate pain/discomfort -> no data                | 1                                   | 1                                   |  |  |
| Severe pain/discomfort -> no pain/discomfort       | 8                                   | 12                                  |  |  |

|                                                     |    |    |  |  |
|-----------------------------------------------------|----|----|--|--|
| Severe pain/discomfort -> slight pain/discomfort    | 11 | 7  |  |  |
| Severe pain/discomfort -> moderate pain/discomfort  | 15 | 11 |  |  |
| Severe pain/discomfort -> severe pain/discomfort    | 7  | 8  |  |  |
| Severe pain/discomfort -> extreme pain/discomfort   | 1  | 0  |  |  |
| Severe pain/discomfort -> no data                   | 1  | 0  |  |  |
| Extreme pain/discomfort -> no pain/discomfort       | 1  | 0  |  |  |
| Extreme pain/discomfort -> slight pain/discomfort   | 1  | 1  |  |  |
| Extreme pain/discomfort -> moderate pain/discomfort | 1  | 1  |  |  |
| Extreme pain/discomfort -> severe pain/discomfort   | 3  | 0  |  |  |
| Extreme pain/discomfort -> extreme pain/discomfort  | 1  | 0  |  |  |
| Extreme pain/discomfort -> no data                  | 0  | 0  |  |  |
| No data -> no pain/discomfort                       | 14 | 14 |  |  |
| No data -> slight pain/discomfort                   | 6  | 3  |  |  |
| No data -> moderate pain/discomfort                 | 1  | 3  |  |  |
| No data -> severe pain/discomfort                   | 0  | 0  |  |  |
| No data -> extreme pain/discomfort                  | 0  | 0  |  |  |
| No data -> no data                                  | 1  | 0  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to EoT in EQ-5D Questionnaire Subscale Score: Anxiety/Depression

|                 |                                                                                       |
|-----------------|---------------------------------------------------------------------------------------|
| End point title | Change from Baseline to EoT in EQ-5D Questionnaire Subscale Score: Anxiety/Depression |
|-----------------|---------------------------------------------------------------------------------------|

End point description:

The EQ-5D questionnaire is an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity). The analysis population was the FAS. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: participants                      |                 |                  |                  |                  |
| number (not applicable)                  |                 |                  |                  |                  |
| Not anxious -> not anxious               | 137             | 176              | 187              | 166              |
| Not anxious -> slightly anxious          | 42              | 27               | 25               | 29               |
| Not anxious -> moderately anxious        | 7               | 6                | 6                | 8                |
| Not anxious -> severely anxious          | 0               | 2                | 5                | 1                |
| Not anxious -> extremely anxious         | 0               | 0                | 1                | 0                |
| Not anxious -> no data                   | 2               | 3                | 2                | 1                |
| Slightly anxious -> not anxious          | 42              | 60               | 54               | 59               |
| Slightly anxious -> slightly anxious     | 49              | 40               | 45               | 40               |
| Slightly anxious -> moderately anxious   | 17              | 16               | 12               | 17               |
| Slightly anxious -> severely anxious     | 4               | 2                | 2                | 2                |
| Slightly anxious -> extremely anxious    | 0               | 0                | 0                | 0                |
| Slightly anxious -> no data              | 2               | 3                | 2                | 5                |
| Moderately anxious -> not anxious        | 12              | 13               | 12               | 22               |
| Moderately anxious -> slightly anxious   | 19              | 17               | 19               | 14               |
| Moderately anxious -> moderately anxious | 17              | 7                | 11               | 10               |
| Moderately anxious -> severely anxious   | 2               | 3                | 0                | 1                |
| Moderately anxious -> extremely anxious  | 0               | 1                | 0                | 0                |
| Moderately anxious -> no data            | 1               | 1                | 2                | 0                |
| Severely anxious -> not anxious          | 7               | 5                | 6                | 6                |
| Severely anxious -> slightly anxious     | 3               | 3                | 4                | 5                |
| Severely anxious -> moderately anxious   | 5               | 7                | 2                | 6                |
| Severely anxious -> severely anxious     | 10              | 1                | 2                | 5                |
| Severely anxious -> extremely anxious    | 1               | 0                | 0                | 1                |
| Severely anxious -> no data              | 0               | 1                | 1                | 0                |
| Extremely anxious -> not anxious         | 2               | 1                | 0                | 0                |
| Extremely anxious -> slightly anxious    | 2               | 2                | 1                | 2                |
| Extremely anxious -> moderately anxious  | 1               | 1                | 1                | 1                |
| Extremely anxious -> severely anxious    | 0               | 1                | 1                | 3                |
| Extremely anxious -> extremely anxious   | 0               | 0                | 2                | 1                |
| Extremely anxious -> no data             | 0               | 0                | 0                | 0                |
| No data -> not anxious                   | 9               | 8                | 3                | 6                |
| No data -> slightly anxious              | 4               | 1                | 2                | 2                |
| No data -> moderately anxious            | 0               | 2                | 0                | 2                |
| No data -> severely anxious              | 0               | 0                | 0                | 0                |
| No data -> extremely anxious             | 0               | 0                | 0                | 0                |
| No data -> no data                       | 1               | 0                | 1                | 0                |

|                  |                                     |                                     |  |  |
|------------------|-------------------------------------|-------------------------------------|--|--|
| End point values | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------|-------------------------------------|-------------------------------------|--|--|

| Subject group type                       | Reporting group | Reporting group |  |  |
|------------------------------------------|-----------------|-----------------|--|--|
| Number of subjects analysed              | 827             | 827             |  |  |
| Units: participants                      |                 |                 |  |  |
| number (not applicable)                  |                 |                 |  |  |
| Not anxious -> not anxious               | 360             | 370             |  |  |
| Not anxious -> slightly anxious          | 45              | 50              |  |  |
| Not anxious -> moderately anxious        | 13              | 11              |  |  |
| Not anxious -> severely anxious          | 2               | 1               |  |  |
| Not anxious -> extremely anxious         | 0               | 1               |  |  |
| Not anxious -> no data                   | 3               | 6               |  |  |
| Slightly anxious -> not anxious          | 122             | 134             |  |  |
| Slightly anxious -> slightly anxious     | 79              | 65              |  |  |
| Slightly anxious -> moderately anxious   | 18              | 16              |  |  |
| Slightly anxious -> severely anxious     | 5               | 5               |  |  |
| Slightly anxious -> extremely anxious    | 1               | 0               |  |  |
| Slightly anxious -> no data              | 3               | 4               |  |  |
| Moderately anxious -> not anxious        | 42              | 35              |  |  |
| Moderately anxious -> slightly anxious   | 43              | 41              |  |  |
| Moderately anxious -> moderately anxious | 18              | 23              |  |  |
| Moderately anxious -> severely anxious   | 8               | 7               |  |  |
| Moderately anxious -> extremely anxious  | 1               | 1               |  |  |
| Moderately anxious -> no data            | 1               | 3               |  |  |
| Severely anxious -> not anxious          | 12              | 8               |  |  |
| Severely anxious -> slightly anxious     | 11              | 6               |  |  |
| Severely anxious -> moderately anxious   | 6               | 7               |  |  |
| Severely anxious -> severely anxious     | 5               | 2               |  |  |
| Severely anxious -> extremely anxious    | 0               | 3               |  |  |
| Severely anxious -> no data              | 0               | 0               |  |  |
| Extremely anxious -> not anxious         | 2               | 1               |  |  |
| Extremely anxious -> slightly anxious    | 2               | 3               |  |  |
| Extremely anxious -> moderately anxious  | 2               | 1               |  |  |
| Extremely anxious -> severely anxious    | 0               | 1               |  |  |
| Extremely anxious -> extremely anxious   | 1               | 2               |  |  |
| Extremely anxious -> no data             | 0               | 0               |  |  |
| No data -> not anxious                   | 13              | 14              |  |  |
| No data -> slightly anxious              | 6               | 3               |  |  |
| No data -> moderately anxious            | 1               | 2               |  |  |
| No data -> severely anxious              | 0               | 1               |  |  |
| No data -> extremely anxious             | 1               | 0               |  |  |
| No data -> no data                       | 1               | 0               |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to Week 12 and EoT in Work Productivity and Activity Impairment: Specific Health Problem Questionnaire (WPAI:SHP) Score:

## Percent Time Work Missed

|                 |                                                                                                                                                                        |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Change from Baseline to Week 12 and EoT in Work Productivity and Activity Impairment: Specific Health Problem Questionnaire (WPAI:SHP) Score: Percent Time Work Missed |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

### End point description:

The WPAI:SHP is a self-administered questionnaire with 6 questions (Q1=Employment status; Q2=Hours absent from work due to the bladder condition; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the bladder condition on productivity while working; Q6=Impact of the bladder condition on productivity while doing regular daily activities other than work) and a 1-week recall period. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicates improvement. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. Only participants with both baseline and post-baseline values are included in the analysis. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

### End point timeframe:

Baseline and Week 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: percentage of work time missed    |                 |                  |                  |                  |
| arithmetic mean (standard deviation)     |                 |                  |                  |                  |
| Week 12 [N=128, 127, 139, 130, 274, 244] | -2.98 (± 21.7)  | -0.33 (± 22.03)  | -1.72 (± 18.7)   | -2.47 (± 14.13)  |
| EoT [N=129, 127, 140, 132, 277, 247]     | -2.96 (± 21.61) | -0.33 (± 22.03)  | -1.71 (± 18.64)  | -2.44 (± 14.03)  |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: percentage of work time missed    |                                     |                                     |  |  |
| arithmetic mean (standard deviation)     |                                     |                                     |  |  |
| Week 12 [N=128, 127, 139, 130, 274, 244] | -2.06 (± 20.93)                     | -2.59 (± 19.65)                     |  |  |
| EoT [N=129, 127, 140, 132, 277, 247]     | -1.48 (± 21.95)                     | -2.55 (± 19.54)                     |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Impairment While Working

|                 |                                                            |
|-----------------|------------------------------------------------------------|
| End point title | Change from Baseline to Week 12 and EoT in WPAI:SHP Score: |
|-----------------|------------------------------------------------------------|

## End point description:

The WPAI:SHP is a self-administered questionnaire with 6 questions (Q1=Employment status; Q2=Hours absent from work due to the bladder condition; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the bladder condition on productivity while working; Q6=Impact of the bladder condition on productivity while doing regular daily activities other than work) and a 1-week recall period. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicates improvement. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. Only participants with both baseline and post-baseline values are included in the analysis. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 12

| End point values                              | Placebo          | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|-----------------------------------------------|------------------|------------------|------------------|------------------|
| Subject group type                            | Reporting group  | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed                   | 418              | 410              | 411              | 415              |
| Units: percentage of impairment while working |                  |                  |                  |                  |
| arithmetic mean (standard deviation)          |                  |                  |                  |                  |
| Week 12 [N=126,122, 138, 130, 271, 241]       | -11.27 (± 25.36) | -14.96 (± 26.21) | -12.25 (± 25.06) | -10.85 (± 25.58) |
| EoT [N=127, 122, 139, 132, 273, 244]          | -11.18 (± 25.28) | -14.96 (± 26.21) | -12.37 (± 25.01) | -10.98 (± 25.68) |

| End point values                              | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|-----------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                            | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed                   | 827                                 | 827                                 |  |  |
| Units: percentage of impairment while working |                                     |                                     |  |  |
| arithmetic mean (standard deviation)          |                                     |                                     |  |  |
| Week 12 [N=126,122, 138, 130, 271, 241]       | -14.69 (± 26.99)                    | -13.07 (± 27.35)                    |  |  |
| EoT [N=127, 122, 139, 132, 273, 244]          | -14.58 (± 26.92)                    | -12.87 (± 27.31)                    |  |  |

## Statistical analyses

No statistical analyses for this end point

**Secondary: Change from Baseline to Weeks 4, 8 and 12 in the Patient's Assessment of TS-VAS**

|                 |                                                                                 |
|-----------------|---------------------------------------------------------------------------------|
| End point title | Change from Baseline to Weeks 4, 8 and 12 in the Patient's Assessment of TS-VAS |
|-----------------|---------------------------------------------------------------------------------|

End point description:

The analysis population was the FAS. N is the number of participants analyzed with data available at each time point.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 8, 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: units on a scale                  |                 |                  |                  |                  |
| least squares mean (standard error)      |                 |                  |                  |                  |
| Week 4 [N=395, 386, 391, 394, 788, 788]  | 1.14 (± 0.12)   | 1.68 (± 0.12)    | 1.77 (± 0.12)    | 1.82 (± 0.12)    |
| Week 8 [N=380, 369, 380, 385, 754, 756]  | 1.5 (± 0.11)    | 2.16 (± 0.12)    | 2.09 (± 0.11)    | 2.2 (± 0.11)     |
| Week 12 [N=370, 361, 366, 373, 736, 732] | 1.47 (± 0.12)   | 2.24 (± 0.12)    | 2.23 (± 0.12)    | 2.32 (± 0.12)    |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: units on a scale                  |                                     |                                     |  |  |
| least squares mean (standard error)      |                                     |                                     |  |  |
| Week 4 [N=395, 386, 391, 394, 788, 788]  | 2.06 (± 0.08)                       | 2.13 (± 0.08)                       |  |  |
| Week 8 [N=380, 369, 380, 385, 754, 756]  | 2.48 (± 0.08)                       | 2.48 (± 0.08)                       |  |  |
| Week 12 [N=370, 361, 366, 373, 736, 732] | 2.58 (± 0.08)                       | 2.63 (± 0.08)                       |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants with Zero Incontinence Episodes per 24 Hours Using the Last 3 Diary Days at Weeks 4, 8, 12 and EoT

|                 |                                                                                                                               |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with Zero Incontinence Episodes per 24 Hours Using the Last 3 Diary Days at Weeks 4, 8, 12 and EoT |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------|

End point description:

The percentage of participants with zero incontinence episodes per 24 hours postbaseline in the last 3 days prior to weeks 4, 8, 12 and EoT. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Weeks 4, 8 and 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 410              |
| Units: percentage of participants        |                 |                  |                  |                  |
| number (not applicable)                  |                 |                  |                  |                  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | 23.2            | 24.9             | 27.6             | 28.9             |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | 28.7            | 35.3             | 40.7             | 38.3             |
| Week 12 [N=374, 369, 369, 379, 754, 750] | 38              | 42.5             | 47.4             | 42.7             |
| EoT [N=412, 409, 406, 413, 823, 816]     | 37.6            | 40.6             | 46.3             | 42.9             |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: percentage of participants        |                                     |                                     |  |  |
| number (not applicable)                  |                                     |                                     |  |  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | 35.1                                | 37.3                                |  |  |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | 45.3                                | 48.2                                |  |  |
| Week 12 [N=374, 369, 369, 379, 754, 750] | 52.3                                | 52.7                                |  |  |
| EoT [N=412, 409, 406, 413, 823, 816]     | 50.7                                | 52.2                                |  |  |

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                                        | Odds ratio vs. Solifenacin 5 mg (1) (EoT)              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                 |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                 | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                           | 1237                                                   |
| Analysis specification                                                                                                                                                                                                                                                            | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                     | superiority                                            |
| P-value                                                                                                                                                                                                                                                                           | = 0.035                                                |
| Method                                                                                                                                                                                                                                                                            | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                                                                                | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                    | 1.31                                                   |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 1.02    |
| upper limit         | 1.69    |

|                                   |                                           |
|-----------------------------------|-------------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Solifenacin 5 mg (2) (EoT) |
|-----------------------------------|-------------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.009                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.4                                                    |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.09                                                   |
| upper limit                             | 1.81                                                   |

|                                   |                                           |
|-----------------------------------|-------------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 25 mg (1) (EoT) |
|-----------------------------------|-------------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.002                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.5                                                    |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.16                                                   |
| upper limit                             | 1.93                                                   |

|                                   |                                           |
|-----------------------------------|-------------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 50 mg (1) (EoT) |
|-----------------------------------|-------------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.023                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.34                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.04                                                   |
| upper limit                             | 1.73                                                   |

**Secondary: Percentage of Participants with ≥ 10 Points Improvement from Baseline in the OAB-q Symptom Bother Score at Weeks 4, 8, 12 and EoT**

|                 |                                                                                                                                   |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with ≥ 10 Points Improvement from Baseline in the OAB-q Symptom Bother Score at Weeks 4, 8, 12 and EoT |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------|

End point description:

The percentage of participants with ≥ 10 points improvement from baseline to each visit (weeks 4, 8, 12 and EoT). The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 8, 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: percentage of participants        |                 |                  |                  |                  |
| number (not applicable)                  |                 |                  |                  |                  |
| Week 4 [N=397, 388, 392, 394, 790, 789]  | 56.4            | 62.6             | 69.9             | 73.9             |
| Week 8 [N=381, 370, 380, 385, 757, 761]  | 62.2            | 71.6             | 73.4             | 79.2             |
| Week 12 [N=371, 362, 366, 374, 738, 734] | 66              | 72.1             | 78.4             | 82.4             |
| EoT [N=400, 392, 398, 399, 800, 795]     | 65.3            | 71.2             | 77.1             | 81.2             |

| End point values | Solifenacin 5 mg + | Solifenacin 5 mg + |  |  |
|------------------|--------------------|--------------------|--|--|
|------------------|--------------------|--------------------|--|--|

|                                          | mirabegron 25 mg | mirabegron 50 mg |  |  |
|------------------------------------------|------------------|------------------|--|--|
| Subject group type                       | Reporting group  | Reporting group  |  |  |
| Number of subjects analysed              | 827              | 827              |  |  |
| Units: percentage of participants        |                  |                  |  |  |
| number (not applicable)                  |                  |                  |  |  |
| Week 4 [N=397, 388, 392, 394, 790, 789]  | 73.9             | 75.8             |  |  |
| Week 8 [N=381, 370, 380, 385, 757, 761]  | 83.9             | 82.8             |  |  |
| Week 12 [N=371, 362, 366, 374, 738, 734] | 83.5             | 85.1             |  |  |
| EoT [N=400, 392, 398, 399, 800, 795]     | 82.8             | 84.3             |  |  |

## Statistical analyses

|                                                                                                                                                                                                                         |                                                        |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                       | Odds ratio vs. Solifenacin 5 mg (1) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                       |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline OAB-q subscale as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                 | 1242                                                   |
| Analysis specification                                                                                                                                                                                                  | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                           | superiority                                            |
| P-value                                                                                                                                                                                                                 | = 0.224                                                |
| Method                                                                                                                                                                                                                  | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                      | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                          | 1.22                                                   |
| Confidence interval                                                                                                                                                                                                     |                                                        |
| level                                                                                                                                                                                                                   | 95 %                                                   |
| sides                                                                                                                                                                                                                   | 2-sided                                                |
| lower limit                                                                                                                                                                                                             | 0.88                                                   |
| upper limit                                                                                                                                                                                                             | 1.69                                                   |

|                                                                                                                                                                                                                         |                                                        |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                       | Odds ratio vs. Solifenacin 5 mg (2) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                       |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline OAB-q subscale as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                 | 1242                                                   |
| Analysis specification                                                                                                                                                                                                  | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                           | superiority                                            |
| P-value                                                                                                                                                                                                                 | = 0.037                                                |
| Method                                                                                                                                                                                                                  | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                      | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                          | 1.42                                                   |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 1.02    |
| upper limit         | 1.96    |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline OAB-q subscale as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.98                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.47                                                   |
| upper limit                             | 2.67                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline OAB-q subscale as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.002                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.65                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.21                                                   |
| upper limit                             | 2.26                                                   |

## Secondary: Percentage of Participants with ≥ 10 Points Improvement from Baseline

**in HRQL Total Score at Weeks 4, 8, 12 and EoT**

|                 |                                                                                                                          |
|-----------------|--------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with $\geq 10$ Points Improvement from Baseline in HRQL Total Score at Weeks 4, 8, 12 and EoT |
|-----------------|--------------------------------------------------------------------------------------------------------------------------|

End point description:

The percentage of participants with  $\geq 10$  points improvement from baseline to each visit (weeks 4, 8, 12 and EoT). The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 8, 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: percentage of participants        |                 |                  |                  |                  |
| number (not applicable)                  |                 |                  |                  |                  |
| Week 4 [N=397, 388, 392, 394, 790, 789]  | 45.3            | 52.8             | 59.7             | 61.7             |
| Week 8 [N=381, 370, 380, 385, 757, 761]  | 51.2            | 62.2             | 65.3             | 66.2             |
| Week 12 [N=371, 362, 366, 374, 738, 734] | 57.7            | 62.4             | 69.1             | 71.7             |
| EoT [N=400, 392, 398, 399, 800, 795]     | 56.8            | 61               | 68.3             | 71.2             |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: percentage of participants        |                                     |                                     |  |  |
| number (not applicable)                  |                                     |                                     |  |  |
| Week 4 [N=397, 388, 392, 394, 790, 789]  | 62.9                                | 61.3                                |  |  |
| Week 8 [N=381, 370, 380, 385, 757, 761]  | 71.5                                | 69.3                                |  |  |
| Week 12 [N=371, 362, 366, 374, 738, 734] | 76.3                                | 71.8                                |  |  |
| EoT [N=400, 392, 398, 399, 800, 795]     | 74.5                                | 71.1                                |  |  |

**Statistical analyses**

|                            |                                           |
|----------------------------|-------------------------------------------|
| Statistical analysis title | Odds ratio vs. Solifenacin 5 mg (1) (EoT) |
|----------------------------|-------------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65,  $\geq 65$  years), previous OAB medication (yes, no) and geographic region as factors and baseline OAB-q subscale as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1242                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.077                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.29                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 0.97                                                   |
| upper limit                             | 1.72                                                   |

|                                   |                                           |
|-----------------------------------|-------------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Solifenacin 5 mg (2) (EoT) |
|-----------------------------------|-------------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline OAB-q subscale as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1242                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.321                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.15                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 0.87                                                   |
| upper limit                             | 1.53                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline OAB-q subscale as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.92                                                   |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 1.46    |
| upper limit         | 2.53    |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline OAB-q subscale as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.294                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.16                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 0.88                                                   |
| upper limit                             | 1.53                                                   |

### **Secondary: Percentage of Participants with 50% Reduction in Mean Number of Incontinence Episodes per 24 Hours at Weeks 4, 8, 12 and EoT**

|                 |                                                                                                                              |
|-----------------|------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with 50% Reduction in Mean Number of Incontinence Episodes per 24 Hours at Weeks 4, 8, 12 and EoT |
|-----------------|------------------------------------------------------------------------------------------------------------------------------|

End point description:

The percentage of participants with ≥ 50% decrease from baseline in mean number of incontinence episodes per 24 hours at each time point (weeks 4, 8, 12 and EoT). The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 8, 12

| <b>End point values</b>           | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|-----------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed       | 418             | 410              | 411              | 415              |
| Units: percentage of participants |                 |                  |                  |                  |
| number (not applicable)           |                 |                  |                  |                  |

|                                          |      |      |      |      |
|------------------------------------------|------|------|------|------|
| Week 4 [N=406, 406, 402, 402, 817, 810]  | 41.1 | 45.3 | 56.7 | 53.2 |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | 54.9 | 61.8 | 63.7 | 65.3 |
| Week 12 [N=374, 369, 369, 379, 754, 750] | 58.6 | 66.4 | 70.2 | 71   |
| EoT [N=412, 409, 406, 413, 823, 816]     | 59.5 | 64.5 | 69   | 70.5 |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: percentage of participants        |                                     |                                     |  |  |
| number (not applicable)                  |                                     |                                     |  |  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | 57.2                                | 60.6                                |  |  |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | 69.8                                | 70.6                                |  |  |
| Week 12 [N=374, 369, 369, 379, 754, 750] | 75.9                                | 76.1                                |  |  |
| EoT [N=412, 409, 406, 413, 823, 816]     | 74.5                                | 75.7                                |  |  |

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                                        | Odds ratio vs. Solifenacin 5 mg (1) (EoT)              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                 |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                 | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                           | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                            | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                     | superiority                                            |
| P-value                                                                                                                                                                                                                                                                           | = 0.251                                                |
| Method                                                                                                                                                                                                                                                                            | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                                                                                | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                    | 1.17                                                   |
| Confidence interval                                                                                                                                                                                                                                                               |                                                        |
| level                                                                                                                                                                                                                                                                             | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                             | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                       | 0.89                                                   |
| upper limit                                                                                                                                                                                                                                                                       | 1.53                                                   |

| Statistical analysis title | Odds ratio vs. Solifenacin 5 mg (2) (EoT) |
|----------------------------|-------------------------------------------|
|----------------------------|-------------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, >=65

years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1242                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.107                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.25                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 0.95                                                   |
| upper limit                             | 1.64                                                   |

|                                                                                                                                                                                                                                                                                  |                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                | Odds ratio vs. Mirabegron 25 mg (EoT)                  |
| Statistical analysis description:                                                                                                                                                                                                                                                |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                          | 1237                                                   |
| Analysis specification                                                                                                                                                                                                                                                           | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                    | superiority                                            |
| P-value                                                                                                                                                                                                                                                                          | < 0.001                                                |
| Method                                                                                                                                                                                                                                                                           | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                                                                               | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                   | 1.59                                                   |
| Confidence interval                                                                                                                                                                                                                                                              |                                                        |
| level                                                                                                                                                                                                                                                                            | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                            | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                      | 1.23                                                   |
| upper limit                                                                                                                                                                                                                                                                      | 2.07                                                   |

|                                                                                                                                                                                                                                                                                  |                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                | Odds ratio vs. Mirabegron 50 mg (EoT)                  |
| Statistical analysis description:                                                                                                                                                                                                                                                |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                          | 1238                                                   |
| Analysis specification                                                                                                                                                                                                                                                           | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                    | superiority                                            |
| P-value                                                                                                                                                                                                                                                                          | = 0.012                                                |
| Method                                                                                                                                                                                                                                                                           | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                                                                               | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                   | 1.41                                                   |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 1.08    |
| upper limit         | 1.85    |

### Secondary: Percentage of Participants with Micturition Frequency Normalization at Weeks 4, 8, 12 and EoT

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Percentage of Participants with Micturition Frequency Normalization at Weeks 4, 8, 12 and EoT |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                               |
| The percentage of participants with micturition frequency normalization is defined as any participant who had $\geq 8$ micturitions/24 hours at baseline and $< 8$ micturitions/24 h postbaseline at weeks 4, 8, 12 and EoT. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. Participants with less $< 8$ micturitions per 24 hours at baseline was not included in the analysis. LOCF for EoT was used. |                                                                                               |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Secondary                                                                                     |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                               |
| Baseline and Weeks 4, 8, 12                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                               |

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: percentage of participants        |                 |                  |                  |                  |
| number (not applicable)                  |                 |                  |                  |                  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | 24.1            | 30.8             | 25.4             | 31.1             |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | 28.7            | 37.9             | 34.5             | 37               |
| Week 12 [N=374, 369, 369, 379, 754, 750] | 29.7            | 42.3             | 40.7             | 44.9             |
| EoT [N=412, 409, 406, 413, 823, 816]     | 31.1            | 42.1             | 40.1             | 45               |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: percentage of participants        |                                     |                                     |  |  |
| number (not applicable)                  |                                     |                                     |  |  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | 36                                  | 37.7                                |  |  |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | 45.3                                | 49                                  |  |  |
| Week 12 [N=374, 369, 369, 379, 754, 750] | 50.8                                | 53.1                                |  |  |

|                                      |      |      |  |  |
|--------------------------------------|------|------|--|--|
| EoT [N=412, 409, 406, 413, 823, 816] | 51.3 | 52.6 |  |  |
|--------------------------------------|------|------|--|--|

## Statistical analyses

|                                                                                                                                                                                                                                                                                   |                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                 | Odds ratio vs. Solifenacin 5 mg (1) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                 |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                 | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                           | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                            | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                     | superiority                                            |
| P-value                                                                                                                                                                                                                                                                           | = 0.044                                                |
| Method                                                                                                                                                                                                                                                                            | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                                                                                | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                    | 1.3                                                    |
| Confidence interval                                                                                                                                                                                                                                                               |                                                        |
| level                                                                                                                                                                                                                                                                             | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                             | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                       | 1.01                                                   |
| upper limit                                                                                                                                                                                                                                                                       | 1.67                                                   |

|                                                                                                                                                                                                                                                                                   |                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                 | Odds ratio vs. Solifenacin 5 mg (2) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                 |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                 | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                           | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                            | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                     | superiority                                            |
| P-value                                                                                                                                                                                                                                                                           | = 0.006                                                |
| Method                                                                                                                                                                                                                                                                            | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                                                                                | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                    | 1.43                                                   |
| Confidence interval                                                                                                                                                                                                                                                               |                                                        |
| level                                                                                                                                                                                                                                                                             | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                             | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                       | 1.11                                                   |
| upper limit                                                                                                                                                                                                                                                                       | 1.84                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

---

**Statistical analysis description:**

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours during the last 3 days as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.004                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.47                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.13                                                   |
| upper limit                             | 1.9                                                    |

---

**Statistical analysis title**

Odds ratio vs. Mirabegron 50 mg (EoT)

---

**Statistical analysis description:**

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of micturitions as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.6                                                    |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.23                                                   |
| upper limit                             | 2.08                                                   |

---

**Secondary: Percentage of Participants with Zero Incontinence Episodes per 24 Hours Using the Last 7 Diary Days at Weeks 4, 8, 12 and EoT**

|                 |                                                                                                                               |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with Zero Incontinence Episodes per 24 Hours Using the Last 7 Diary Days at Weeks 4, 8, 12 and EoT |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------|

---

**End point description:**

The percentage of participants with zero incontinence episodes per 24 hours postbaseline in the last 7 days prior to weeks 4, 8, 12 and EoT. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Weeks 4, 8 and 12    |           |

| <b>End point values</b>                  | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: percentage of participants        |                 |                  |                  |                  |
| number (not applicable)                  |                 |                  |                  |                  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | 12.8            | 13.1             | 16.7             | 17.7             |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | 19.1            | 24.4             | 29.8             | 28.2             |
| Week 12 [N=374, 369, 369, 379, 754, 750] | 29.1            | 32.2             | 35               | 31.9             |
| EoT [N=412, 409, 406, 413, 823, 816]     | 28.6            | 30.6             | 34               | 31.5             |

| <b>End point values</b>                  | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: percentage of participants        |                                     |                                     |  |  |
| number (not applicable)                  |                                     |                                     |  |  |
| Week 4 [N=406, 406, 402, 402, 817, 810]  | 23.9                                | 26                                  |  |  |
| Week 8 [N=397, 385, 386, 386, 784, 769]  | 36.6                                | 38.4                                |  |  |
| Week 12 [N=374, 369, 369, 379, 754, 750] | 42.4                                | 43.7                                |  |  |
| EoT [N=412, 409, 406, 413, 823, 816]     | 40.9                                | 43.1                                |  |  |

## Statistical analyses

| <b>Statistical analysis title</b>                                                                                                                                                                                                                         | Odds ratio vs. Solifenacin 5 mg (1) (EoT)              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                         |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                                                                         | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                   | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                    | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                             | superiority                                            |
| P-value                                                                                                                                                                                                                                                   | = 0.004                                                |
| Method                                                                                                                                                                                                                                                    | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                                                        | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                            | 1.47                                                   |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 1.13    |
| upper limit         | 1.92    |

|                                   |                                           |
|-----------------------------------|-------------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Solifenacin 5 mg (2) (EoT) |
|-----------------------------------|-------------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1242                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.62                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.24                                                   |
| upper limit                             | 2.11                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.001                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.59                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.22                                                   |
| upper limit                             | 2.07                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

# Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24 hours as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.001                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.57                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.21                                                   |
| upper limit                             | 2.04                                                   |

## Secondary: Percentage of Participants with ≥ 1 Point Improvement from Baseline in PPBC at Weeks 4, 8, 12 and EoT

|                 |                                                                                                       |
|-----------------|-------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with ≥ 1 Point Improvement from Baseline in PPBC at Weeks 4, 8, 12 and EoT |
|-----------------|-------------------------------------------------------------------------------------------------------|

### End point description:

The percentage of participants with ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

### End point timeframe:

Baseline and Weeks 4, 8, 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: percentage of participants        |                 |                  |                  |                  |
| number (not applicable)                  |                 |                  |                  |                  |
| Week 4 [N=397, 388, 393, 394, 791, 791]  | 48.9            | 52.8             | 60.3             | 58.1             |
| Week 8 [N=381, 372, 380, 385, 758, 761]  | 56.4            | 65.3             | 69.7             | 72.7             |
| Week 12 [N=371, 362, 366, 375, 739, 735] | 59.8            | 66.9             | 73.8             | 74.1             |
| EoT [N=400, 393, 398, 399, 801, 795]     | 59.8            | 65.4             | 72.4             | 71.9             |

| End point values | Solifenacin 5 mg + mirabegron 25 | Solifenacin 5 mg + mirabegron 50 |  |  |
|------------------|----------------------------------|----------------------------------|--|--|
|------------------|----------------------------------|----------------------------------|--|--|

|                                          | mg              | mg              |  |  |
|------------------------------------------|-----------------|-----------------|--|--|
| Subject group type                       | Reporting group | Reporting group |  |  |
| Number of subjects analysed              | 827             | 827             |  |  |
| Units: percentage of participants        |                 |                 |  |  |
| number (not applicable)                  |                 |                 |  |  |
| Week 4 [N=397, 388, 393, 394, 791, 791]  | 63.1            | 62.7            |  |  |
| Week 8 [N=381, 372, 380, 385, 758, 761]  | 71.6            | 75.4            |  |  |
| Week 12 [N=371, 362, 366, 375, 739, 735] | 76.6            | 80              |  |  |
| EoT [N=400, 393, 398, 399, 801, 795]     | 75.7            | 78.4            |  |  |

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                   | Odds ratio vs. Solifenacin 5 mg (1) (EoT)              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                            |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline PPBC as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                            | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                      | 1242                                                   |
| Analysis specification                                                                                                                                                                                       | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                | superiority                                            |
| P-value                                                                                                                                                                                                      | = 0.065                                                |
| Method                                                                                                                                                                                                       | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                           | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                               | 1.32                                                   |
| Confidence interval                                                                                                                                                                                          |                                                        |
| level                                                                                                                                                                                                        | 95 %                                                   |
| sides                                                                                                                                                                                                        | 2-sided                                                |
| lower limit                                                                                                                                                                                                  | 0.98                                                   |
| upper limit                                                                                                                                                                                                  | 1.78                                                   |

| Statistical analysis title                                                                                                                                                                                   | Odds ratio vs. Solifenacin 5 mg (2) (EoT)              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                            |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline PPBC as a covariate. |                                                        |
| Comparison groups                                                                                                                                                                                            | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                      | 1242                                                   |
| Analysis specification                                                                                                                                                                                       | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                | superiority                                            |
| P-value                                                                                                                                                                                                      | = 0.001                                                |
| Method                                                                                                                                                                                                       | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                           | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                               | 1.68                                                   |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 1.24    |
| upper limit         | 2.27    |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline PPBC as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.76                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.32                                                   |
| upper limit                             | 2.36                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline PPBC as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.007                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.51                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.12                                                   |
| upper limit                             | 2.04                                                   |

## Secondary: Percentage of Participants with Major (≥ 2 points) Improvement from

**Baseline in PPBC at Weeks 4, 8, 12 and EoT**

|                 |                                                                                                                         |
|-----------------|-------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with Major ( $\geq 2$ points)<br>Improvement from Baseline in PPBC at Weeks 4, 8, 12 and EoT |
|-----------------|-------------------------------------------------------------------------------------------------------------------------|

End point description:

The percentage of participants with a major ( $\geq 2$  points) improvement from baseline in PPBC at weeks 4, 8, 12 and EoT. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 8, 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: percentage of participants        |                 |                  |                  |                  |
| number (not applicable)                  |                 |                  |                  |                  |
| Week 4 [N=397, 388, 393, 394, 791, 791]  | 15.9            | 20.6             | 22.4             | 27.4             |
| Week 8 [N=381, 372, 380, 385, 758, 761]  | 27              | 33.3             | 35               | 40.5             |
| Week 12 [N=371, 362, 366, 375, 739, 735] | 29.6            | 39               | 42.3             | 44.5             |
| EoT [N=400, 393, 398, 399, 801, 795]     | 29.5            | 37.2             | 40.7             | 42.6             |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: percentage of participants        |                                     |                                     |  |  |
| number (not applicable)                  |                                     |                                     |  |  |
| Week 4 [N=397, 388, 393, 394, 791, 791]  | 31.1                                | 31.1                                |  |  |
| Week 8 [N=381, 372, 380, 385, 758, 761]  | 42.7                                | 46.4                                |  |  |
| Week 12 [N=371, 362, 366, 375, 739, 735] | 50.7                                | 52.9                                |  |  |
| EoT [N=400, 393, 398, 399, 801, 795]     | 49.7                                | 51.2                                |  |  |

**Statistical analyses**

|                            |                                           |
|----------------------------|-------------------------------------------|
| Statistical analysis title | Odds ratio vs. Solifenacin 5 mg (1) (EoT) |
|----------------------------|-------------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group ( $<65$ ,  $\geq 65$  years), previous OAB medication (yes, no) and geographic region as factors and baseline PPBC as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1242                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.007                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.44                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.11                                                   |
| upper limit                             | 1.87                                                   |

|                                   |                                           |
|-----------------------------------|-------------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Solifenacin 5 mg (2) (EoT) |
|-----------------------------------|-------------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline PPBC as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1242                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.67                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.28                                                   |
| upper limit                             | 2.17                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline PPBC as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.76                                                   |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 1.34    |
| upper limit         | 2.3     |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors and baseline PPBC as a covariate.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.68                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.29                                                   |
| upper limit                             | 2.19                                                   |

**Secondary: Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes per 24 Hours and at least 10 Points Improvement on OAB-q Symptom Bother Scale) at Weeks 4, 8, 12 and EoT**

|                 |                                                                                                                                                                                                                       |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes per 24 Hours and at least 10 Points Improvement on OAB-q Symptom Bother Scale) at Weeks 4, 8, 12 and EoT |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and minimal important difference reached (improvement by ≥ 10 points) on the OAB-q Symptom Bother score at weeks 4, 8, 12 and EoT. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 8, 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: percentage of participants        |                 |                  |                  |                  |
| number (not applicable)                  |                 |                  |                  |                  |
| Week 4 [N=388, 385, 387, 385, 784, 778]  | 28.6            | 34.8             | 45.7             | 44.9             |
| Week 8 [N=374, 366, 375, 372, 750, 742]  | 39.8            | 50               | 51.5             | 56.5             |
| Week 12 [N=360, 350, 355, 363, 727, 721] | 45              | 55.7             | 59.4             | 63.1             |
| EoT [N=396, 391, 395, 398, 798, 790]     | 45.2            | 54               | 58.2             | 62.6             |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: percentage of participants        |                                     |                                     |  |  |
| number (not applicable)                  |                                     |                                     |  |  |
| Week 4 [N=388, 385, 387, 385, 784, 778]  | 47.8                                | 52.3                                |  |  |
| Week 8 [N=374, 366, 375, 372, 750, 742]  | 63.1                                | 63.5                                |  |  |
| Week 12 [N=360, 350, 355, 363, 727, 721] | 66.7                                | 69.5                                |  |  |
| EoT [N=396, 391, 395, 398, 798, 790]     | 65.2                                | 68.2                                |  |  |

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                                                         | Odds ratio vs. Solifenacin 5 mg (1) (EoT)              |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                                  |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours and baseline OAB-q symptom bother scale as covariates. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                  | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                            | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                             | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                      | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                            | = 0.381                                                |
| Method                                                                                                                                                                                                                                                                                             | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                                                                                                 | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                                     | 1.12                                                   |
| Confidence interval                                                                                                                                                                                                                                                                                |                                                        |
| level                                                                                                                                                                                                                                                                                              | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                              | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                        | 0.87                                                   |
| upper limit                                                                                                                                                                                                                                                                                        | 1.45                                                   |

|                                                                                                                                                                                                                                                                                                   |                                                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                 | Odds ratio vs. Solifenacin 5 mg (2) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                                 |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours and baseline OAB-q symptom bother scale as covariates. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                 | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                           | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                            | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                     | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                           | = 0.04                                                 |
| Method                                                                                                                                                                                                                                                                                            | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                                                                                                | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                                    | 1.31                                                   |
| Confidence interval                                                                                                                                                                                                                                                                               |                                                        |
| level                                                                                                                                                                                                                                                                                             | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                             | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                       | 1.01                                                   |
| upper limit                                                                                                                                                                                                                                                                                       | 1.7                                                    |

|                                                                                                                                                                                                                                                                                                   |                                                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                 | Odds ratio vs. Mirabegron 25 mg (EoT)                  |
| Statistical analysis description:                                                                                                                                                                                                                                                                 |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours and baseline OAB-q symptom bother scale as covariates. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                 | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                           | 1237                                                   |
| Analysis specification                                                                                                                                                                                                                                                                            | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                     | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                           | = 0.001                                                |
| Method                                                                                                                                                                                                                                                                                            | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                                                                                                | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                                    | 1.56                                                   |
| Confidence interval                                                                                                                                                                                                                                                                               |                                                        |
| level                                                                                                                                                                                                                                                                                             | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                             | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                       | 1.21                                                   |
| upper limit                                                                                                                                                                                                                                                                                       | 2                                                      |

|                                                                                                                                                                                                                                                                                                   |                                                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                 | Odds ratio vs. Mirabegron 50 mg (EoT)                  |
| Statistical analysis description:                                                                                                                                                                                                                                                                 |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours and baseline OAB-q symptom bother scale as covariates. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                 | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |

|                                         |                     |
|-----------------------------------------|---------------------|
| Number of subjects included in analysis | 1238                |
| Analysis specification                  | Pre-specified       |
| Analysis type                           | superiority         |
| P-value                                 | = 0.001             |
| Method                                  | Logistic regression |
| Parameter estimate                      | Odds ratio (OR)     |
| Point estimate                          | 1.57                |
| Confidence interval                     |                     |
| level                                   | 95 %                |
| sides                                   | 2-sided             |
| lower limit                             | 1.21                |
| upper limit                             | 2.03                |

**Secondary: Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes per 24 Hours and at least 10 Points Improvement on OAB-q HRQL Total Score) at Weeks 4, 8, 12 and EoT**

|                 |                                                                                                                                                                                                                   |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes per 24 Hours and at least 10 Points Improvement on OAB-q HRQL Total Score) at Weeks 4, 8, 12 and EoT |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and minimal important difference reached (improvement by  $\geq 10$  points) on the OAB-q HRQL total score at weeks 4, 8, 12 and EoT. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 8, 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: percentage of participants        |                 |                  |                  |                  |
| number (not applicable)                  |                 |                  |                  |                  |
| Week 4 [N=388, 385, 387, 385, 784, 778]  | 23.2            | 28.3             | 39.8             | 37.7             |
| Week 8 [N=374, 366, 375, 372, 750, 742]  | 32.9            | 43.2             | 46.1             | 48.4             |
| Week 12 [N=360, 350, 355, 363, 727, 721] | 39.2            | 48.3             | 53.5             | 54.8             |
| EoT [N=396, 391, 395, 398, 798, 790]     | 39.1            | 46               | 52.9             | 54               |

|                  |                                  |                                  |  |  |
|------------------|----------------------------------|----------------------------------|--|--|
| End point values | Solifenacin 5 mg + mirabegron 25 | Solifenacin 5 mg + mirabegron 50 |  |  |
|------------------|----------------------------------|----------------------------------|--|--|

|                                          | mg              | mg              |  |  |
|------------------------------------------|-----------------|-----------------|--|--|
| Subject group type                       | Reporting group | Reporting group |  |  |
| Number of subjects analysed              | 827             | 827             |  |  |
| Units: percentage of participants        |                 |                 |  |  |
| number (not applicable)                  |                 |                 |  |  |
| Week 4 [N=388, 385, 387, 385, 784, 778]  | 40.4            | 40.5            |  |  |
| Week 8 [N=374, 366, 375, 372, 750, 742]  | 54.1            | 53              |  |  |
| Week 12 [N=360, 350, 355, 363, 727, 721] | 61.6            | 59.2            |  |  |
| EoT [N=396, 391, 395, 398, 798, 790]     | 59              | 58.2            |  |  |

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                                                     | Odds ratio vs. Solifenacin 5 mg (1) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                              |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours and baseline OAB-q HRQL total score as covariates. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                              | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                        | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                         | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                  | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                        | = 0.095                                                |
| Method                                                                                                                                                                                                                                                                                         | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                                                                                             | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                                 | 1.24                                                   |
| Confidence interval                                                                                                                                                                                                                                                                            |                                                        |
| level                                                                                                                                                                                                                                                                                          | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                          | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                    | 0.96                                                   |
| upper limit                                                                                                                                                                                                                                                                                    | 1.59                                                   |

| Statistical analysis title                                                                                                                                                                                                                                                                     | Odds ratio vs. Solifenacin 5 mg (2) (EoT)              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                                                                                              |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours and baseline OAB-q HRQL total score as covariates. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                              | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                        | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                         | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                  | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                        | = 0.073                                                |
| Method                                                                                                                                                                                                                                                                                         | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                                                                                             | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                                 | 1.26                                                   |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 0.98    |
| upper limit         | 1.62    |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours and baseline OAB-q HRQL total score as covariates.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.66                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.29                                                   |
| upper limit                             | 2.13                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours and baseline OAB-q HRQL total score as covariates.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.067                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.27                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 0.98                                                   |
| upper limit                             | 1.63                                                   |

## Secondary: Percentage of Participants Who Were Double Responders (50%)

## Reduction in Mean Number of Incontinence Episodes per 24 Hours and at least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT

|                 |                                                                                                                                                                                               |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes per 24 Hours and at least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and  $\geq 1$  point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.

|                      |                             |
|----------------------|-----------------------------|
| End point type       | Secondary                   |
| End point timeframe: | Baseline and Weeks 4, 8, 12 |

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: percentage of participants        |                 |                  |                  |                  |
| number (not applicable)                  |                 |                  |                  |                  |
| Week 4 [N=388, 384, 387, 385, 785, 780]  | 23.2            | 27.9             | 37.7             | 34.5             |
| Week 8 [N=374, 367, 375, 372, 751, 742]  | 35.6            | 44.7             | 50.1             | 51.3             |
| Week 12 [N=360, 350, 355, 364, 728, 722] | 40.6            | 51.7             | 54.9             | 56.9             |
| EoT [N=396, 392, 395, 398, 799, 790]     | 40.9            | 48.5             | 53.9             | 56               |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: percentage of participants        |                                     |                                     |  |  |
| number (not applicable)                  |                                     |                                     |  |  |
| Week 4 [N=388, 384, 387, 385, 785, 780]  | 39.9                                | 42.9                                |  |  |
| Week 8 [N=374, 367, 375, 372, 751, 742]  | 53.8                                | 57.7                                |  |  |
| Week 12 [N=360, 350, 355, 364, 728, 722] | 62                                  | 65.4                                |  |  |
| EoT [N=396, 392, 395, 398, 799, 790]     | 59.9                                | 63.8                                |  |  |

## Statistical analyses

|                                                                                                                                                                                                                                                                              |                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                            | Odds ratio vs. Solifenacin 5 mg (1) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                            |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of Incontinence episodes per 24 hours and baseline PPBC as covariates. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                            | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                      | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                       | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                | superiority                                            |
| P-value                                                                                                                                                                                                                                                                      | = 0.21                                                 |
| Method                                                                                                                                                                                                                                                                       | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                                                                           | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                               | 1.18                                                   |
| Confidence interval                                                                                                                                                                                                                                                          |                                                        |
| level                                                                                                                                                                                                                                                                        | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                        | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                  | 0.91                                                   |
| upper limit                                                                                                                                                                                                                                                                  | 1.52                                                   |

|                                                                                                                                                                                                                                                                              |                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                            | Odds ratio vs. Solifenacin 5 mg (2) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                            |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of Incontinence episodes per 24 hours and baseline PPBC as covariates. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                            | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                      | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                       | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                | superiority                                            |
| P-value                                                                                                                                                                                                                                                                      | = 0.004                                                |
| Method                                                                                                                                                                                                                                                                       | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                                                                           | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                               | 1.46                                                   |
| Confidence interval                                                                                                                                                                                                                                                          |                                                        |
| level                                                                                                                                                                                                                                                                        | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                        | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                  | 1.13                                                   |
| upper limit                                                                                                                                                                                                                                                                  | 1.89                                                   |

|                                                                                                                                                                                                                                                                              |                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                            | Odds ratio vs. Mirabegron 25 mg (EoT)                  |
| Statistical analysis description:                                                                                                                                                                                                                                            |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of Incontinence episodes per 24 hours and baseline PPBC as covariates. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                            | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |

|                                         |                     |
|-----------------------------------------|---------------------|
| Number of subjects included in analysis | 1237                |
| Analysis specification                  | Pre-specified       |
| Analysis type                           | superiority         |
| P-value                                 | < 0.001             |
| Method                                  | Logistic regression |
| Parameter estimate                      | Odds ratio (OR)     |
| Point estimate                          | 1.59                |
| Confidence interval                     |                     |
| level                                   | 95 %                |
| sides                                   | 2-sided             |
| lower limit                             | 1.23                |
| upper limit                             | 2.06                |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of Incontinence episodes per 24 hours and baseline PPBC as covariates.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.59                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.23                                                   |
| upper limit                             | 2.05                                                   |

**Secondary: Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes per 24 Hours, at least 10 Points Improvement on OAB-q Symptom Bother Scale and at least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT**

|                 |                                                                                                                                                                                                                                                             |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes per 24 Hours, at least 10 Points Improvement on OAB-q Symptom Bother Scale and at least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

The percentage of participants considered as triple responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline, minimal important difference reached (improvement by ≥ 10 points) on the OAB-q Symptom Bother score, and ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 8, 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: percentage of participants        |                 |                  |                  |                  |
| number (not applicable)                  |                 |                  |                  |                  |
| Week 4 [N=388, 384, 387, 385, 784, 778]  | 17.8            | 24               | 33.6             | 31.4             |
| Week 8 [N=374, 366, 375, 372, 750, 742]  | 29.7            | 41.3             | 43.2             | 47.8             |
| Week 12 [N=360, 350, 355, 363, 727, 721] | 35.8            | 47.7             | 49.6             | 54.5             |
| EoT [N=396, 391, 395, 398, 798, 790]     | 36.1            | 45               | 48.4             | 53.3             |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: percentage of participants        |                                     |                                     |  |  |
| number (not applicable)                  |                                     |                                     |  |  |
| Week 4 [N=388, 384, 387, 385, 784, 778]  | 37.5                                | 40.2                                |  |  |
| Week 8 [N=374, 366, 375, 372, 750, 742]  | 51.6                                | 54.7                                |  |  |
| Week 12 [N=360, 350, 355, 363, 727, 721] | 58.2                                | 62                                  |  |  |
| EoT [N=396, 391, 395, 398, 798, 790]     | 56.3                                | 60.3                                |  |  |

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                                                                                                                                             | Odds ratio vs. Solifenacin 5 mg (1) (EoT)              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Statistical analysis description:<br>Odds ratio from a logistic regression model including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q symptom bother scale and baseline PPBC as covariates. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                                                                      | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |

|                                         |                     |
|-----------------------------------------|---------------------|
| Number of subjects included in analysis | 1242                |
| Analysis specification                  | Pre-specified       |
| Analysis type                           | superiority         |
| P-value                                 | = 0.335             |
| Method                                  | Logistic regression |
| Parameter estimate                      | Odds ratio (OR)     |
| Point estimate                          | 1.13                |
| Confidence interval                     |                     |
| level                                   | 95 %                |
| sides                                   | 2-sided             |
| lower limit                             | 0.88                |
| upper limit                             | 1.46                |

|                                   |                                           |
|-----------------------------------|-------------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Solifenacin 5 mg (2) (EoT) |
|-----------------------------------|-------------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q symptom bother scale and baseline PPBC as covariates.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1242                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.009                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.4                                                    |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.09                                                   |
| upper limit                             | 1.81                                                   |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 25 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q symptom bother scale and baseline PPBC as covariates.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis | 1237                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.001                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.56                                                   |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 1.21    |
| upper limit         | 2.02    |

|                                   |                                       |
|-----------------------------------|---------------------------------------|
| <b>Statistical analysis title</b> | Odds ratio vs. Mirabegron 50 mg (EoT) |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q symptom bother scale and baseline PPBC as covariates.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | < 0.001                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.71                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.33                                                   |
| upper limit                             | 2.21                                                   |

**Secondary: Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes per 24 Hours, at least 10 Points Improvement on OAB-q HRQL Total Score and at least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT**

|                 |                                                                                                                                                                                                                                                         |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes per 24 Hours, at least 10 Points Improvement on OAB-q HRQL Total Score and at least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

The percentage of participants considered as triple responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline, minimal important difference reached (improvement by ≥ 10 points) on the HRQL total score, and ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT. The analysis population was the FAS. N is the number of participants analyzed with data available at each time point. LOCF for EOT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 8, 12

| End point values                         | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 418             | 410              | 411              | 415              |
| Units: percentage of participants        |                 |                  |                  |                  |
| number (not applicable)                  |                 |                  |                  |                  |
| Week 4 [N=388, 384, 387, 385, 784, 778]  | 15.2            | 20.6             | 30               | 28.6             |
| Week 8 [N=374, 366, 375, 372, 750, 742]  | 24.9            | 36.9             | 38.9             | 43               |
| Week 12 [N=360, 350, 355, 362, 727, 721] | 33.3            | 42               | 45.6             | 49.9             |
| EoT [N=396, 391, 395, 398, 798, 790]     | 33.3            | 39.1             | 44.8             | 49.2             |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 827                                 | 827                                 |  |  |
| Units: percentage of participants        |                                     |                                     |  |  |
| number (not applicable)                  |                                     |                                     |  |  |
| Week 4 [N=388, 384, 387, 385, 784, 778]  | 32.7                                | 33.4                                |  |  |
| Week 8 [N=374, 366, 375, 372, 750, 742]  | 46.3                                | 46.8                                |  |  |
| Week 12 [N=360, 350, 355, 362, 727, 721] | 54.5                                | 54.2                                |  |  |
| EoT [N=396, 391, 395, 398, 798, 790]     | 51.6                                | 52.8                                |  |  |

## Statistical analyses

|                                                                                                                                                                                                                                                                                                               |                                                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                             | Odds ratio vs. Solifenacin 5 mg (1) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                                             |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, >=65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q HRQL total score and baseline PPBC as covariates. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                             | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                       | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                        | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                 | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                       | = 0.416                                                |
| Method                                                                                                                                                                                                                                                                                                        | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                                                                                                            | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                                                | 1.11                                                   |
| Confidence interval                                                                                                                                                                                                                                                                                           |                                                        |
| level                                                                                                                                                                                                                                                                                                         | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                         | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                   | 0.86                                                   |
| upper limit                                                                                                                                                                                                                                                                                                   | 1.43                                                   |

|                                                                                                                                                                                                                                                                                                              |                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                            | Odds ratio vs. Solifenacin 5 mg (2) (EoT)              |
| Statistical analysis description:                                                                                                                                                                                                                                                                            |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q HRQL total score and baseline PPBC as covariates. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                            | Solifenacin 5 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                      | 1242                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                       | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                      | = 0.105                                                |
| Method                                                                                                                                                                                                                                                                                                       | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                                                                                                           | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                                               | 1.23                                                   |
| Confidence interval                                                                                                                                                                                                                                                                                          |                                                        |
| level                                                                                                                                                                                                                                                                                                        | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                        | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                  | 0.96                                                   |
| upper limit                                                                                                                                                                                                                                                                                                  | 1.59                                                   |

|                                                                                                                                                                                                                                                                                                              |                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                            | Odds ratio vs. Mirabegron 25 mg (EoT)                  |
| Statistical analysis description:                                                                                                                                                                                                                                                                            |                                                        |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q HRQL total score and baseline PPBC as covariates. |                                                        |
| Comparison groups                                                                                                                                                                                                                                                                                            | Mirabegron 25 mg v Solifenacin 5 mg + mirabegron 25 mg |
| Number of subjects included in analysis                                                                                                                                                                                                                                                                      | 1237                                                   |
| Analysis specification                                                                                                                                                                                                                                                                                       | Pre-specified                                          |
| Analysis type                                                                                                                                                                                                                                                                                                | superiority                                            |
| P-value                                                                                                                                                                                                                                                                                                      | < 0.001                                                |
| Method                                                                                                                                                                                                                                                                                                       | Logistic regression                                    |
| Parameter estimate                                                                                                                                                                                                                                                                                           | Odds ratio (OR)                                        |
| Point estimate                                                                                                                                                                                                                                                                                               | 1.66                                                   |
| Confidence interval                                                                                                                                                                                                                                                                                          |                                                        |
| level                                                                                                                                                                                                                                                                                                        | 95 %                                                   |
| sides                                                                                                                                                                                                                                                                                                        | 2-sided                                                |
| lower limit                                                                                                                                                                                                                                                                                                  | 1.28                                                   |
| upper limit                                                                                                                                                                                                                                                                                                  | 2.16                                                   |

|                                                                                                                                                                                                                                                                                                  |                                       |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                                                                                                                | Odds ratio vs. Mirabegron 50 mg (EoT) |
| Statistical analysis description:                                                                                                                                                                                                                                                                |                                       |
| Odds ratio from a logistic regression model including treatment group, sex, age group (<65, ≥65 years), previous OAB medication (yes, no) and geographic region as factors, and baseline mean number of incontinence episodes per 24 hours, baseline OAB-q HRQL total score and baseline PPBC as |                                       |

covariates.

|                                         |                                                        |
|-----------------------------------------|--------------------------------------------------------|
| Comparison groups                       | Mirabegron 50 mg v Solifenacin 5 mg + mirabegron 50 mg |
| Number of subjects included in analysis | 1238                                                   |
| Analysis specification                  | Pre-specified                                          |
| Analysis type                           | superiority                                            |
| P-value                                 | = 0.005                                                |
| Method                                  | Logistic regression                                    |
| Parameter estimate                      | Odds ratio (OR)                                        |
| Point estimate                          | 1.45                                                   |
| Confidence interval                     |                                                        |
| level                                   | 95 %                                                   |
| sides                                   | 2-sided                                                |
| lower limit                             | 1.12                                                   |
| upper limit                             | 1.87                                                   |

## Secondary: Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

|                 |                                                                       |
|-----------------|-----------------------------------------------------------------------|
| End point title | Number of Participants with Treatment-Emergent Adverse Events (TEAEs) |
|-----------------|-----------------------------------------------------------------------|

End point description:

A TEAE refers to an adverse event (AE; defined as any untoward medical occurrence in a participant administered a study drug or who had undergone study procedures and did not necessarily have a causal relationship with this treatment) which started or worsened in the period from first double-blind medication intake until 14 days after the last double-blind medication intake. Serious TEAEs with a start date reported until 30 days after the last double-blind medication intake were also summarized as TEAEs, and also included serious TEAEs upgraded by the sponsor based on review of the sponsor's list of Always Serious terms if any upgrade was done. Drug-related TEAEs may be possible or probable, as assessed by the investigator, or records where relationship is missing. The analysis population was the Safety Analysis Set (SAF), which comprised all randomized participants who received  $\geq 1$  dose of double-blind treatment and excluded participants from site 10153.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From first dose of double-blind study drug up to 30 days after last dose of double-blind study drug (up to 16 weeks)

| End point values                              | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|-----------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                            | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed                   | 429             | 423              | 422              | 423              |
| Units: participants                           |                 |                  |                  |                  |
| Any TEAE                                      | 145             | 135              | 147              | 149              |
| Drug-related TEAEs                            | 45              | 37               | 52               | 63               |
| Deaths                                        | 0               | 0                | 0                | 0                |
| Serious TEAEs                                 | 8               | 6                | 5                | 3                |
| Drug-related serious TEAEs                    | 0               | 1                | 1                | 0                |
| TEAEs leading to discontinuation              | 9               | 7                | 10               | 7                |
| Drug-related TEAEs leading to discontinuation | 7               | 4                | 6                | 5                |

| <b>End point values</b>                       | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|-----------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                            | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed                   | 853                                 | 848                                 |  |  |
| Units: participants                           |                                     |                                     |  |  |
| Any TEAE                                      | 345                                 | 314                                 |  |  |
| Drug-related TEAEs                            | 157                                 | 150                                 |  |  |
| Deaths                                        | 0                                   | 0                                   |  |  |
| Serious TEAEs                                 | 12                                  | 19                                  |  |  |
| Drug-related serious TEAEs                    | 2                                   | 3                                   |  |  |
| TEAEs leading to discontinuation              | 20                                  | 22                                  |  |  |
| Drug-related TEAEs leading to discontinuation | 17                                  | 19                                  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to Weeks 4, 8, 12 and EoT in Postvoid Residual (PVR) Volume

|                                                                                                                                                                                                               |                                                                                  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                               | Change from Baseline to Weeks 4, 8, 12 and EoT in Postvoid Residual (PVR) Volume |
| End point description:                                                                                                                                                                                        |                                                                                  |
| PVR volume was assessed by ultrasonography or a bladder scanner. The analysis population was the SAF. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used. |                                                                                  |
| End point type                                                                                                                                                                                                | Secondary                                                                        |
| End point timeframe:                                                                                                                                                                                          |                                                                                  |
| Baseline and Weeks 4, 8, 12                                                                                                                                                                                   |                                                                                  |

| <b>End point values</b>                  | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                       | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed              | 429             | 423              | 422              | 423              |
| Units: mL                                |                 |                  |                  |                  |
| arithmetic mean (standard deviation)     |                 |                  |                  |                  |
| Week 4 [N=408, 397, 398, 412, 815, 812]  | -0.8 (± 29.9)   | 1.6 (± 28)       | -2.1 (± 29.7)    | 5.8 (± 35.6)     |
| Week 8 [N=393, 378, 383, 393, 779, 784]  | -1.9 (± 28.6)   | -0.4 (± 29.8)    | -0.6 (± 34.4)    | 5.4 (± 35.2)     |
| Week 12 [N=382, 376, 370, 383, 766, 763] | -1 (± 29.9)     | 1 (± 29.8)       | 0 (± 30.1)       | 4.7 (± 33.1)     |
| EoT [N=410, 401, 404, 414, 821, 815]     | -1 (± 29.4)     | 0.7 (± 29.1)     | -0.8 (± 30)      | 4.8 (± 33.3)     |

| End point values                         | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                       | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed              | 853                                 | 848                                 |  |  |
| Units: mL                                |                                     |                                     |  |  |
| arithmetic mean (standard deviation)     |                                     |                                     |  |  |
| Week 4 [N=408, 397, 398, 412, 815, 812]  | 7.2 (± 47.7)                        | 10.6 (± 51.1)                       |  |  |
| Week 8 [N=393, 378, 383, 393, 779, 784]  | 7 (± 37.4)                          | 9.9 (± 46)                          |  |  |
| Week 12 [N=382, 376, 370, 383, 766, 763] | 7.9 (± 44.4)                        | 9.6 (± 50.1)                        |  |  |
| EoT [N=410, 401, 404, 414, 821, 815]     | 9 (± 55)                            | 1.5 (± 32.5)                        |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline to Weeks 4, 12 and EoT in Mean 24 hours (h), Mean Daytime and Mean Nighttime Systolic Blood Pressure (SBP)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Change from Baseline to Weeks 4, 12 and EoT in Mean 24 hours (h), Mean Daytime and Mean Nighttime Systolic Blood Pressure (SBP) |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                 |
| Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. The analysis population was the ABPM analysis set (ABPMAS) which consisted of all participants in the SAF for whom at least 1 ABPM variable (mean value at tmax (4-6h), mean 24-h value, maximum 1-h change from time-matched baseline value, mean daytime value, mean nighttime value or peak/trough difference) could be calculated at baseline and postbaseline visit. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used. |                                                                                                                                 |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Secondary                                                                                                                       |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                 |
| Baseline and Weeks 4, 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                 |

| End point values                                 | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|--------------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                               | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed                      | 92              | 85               | 87               | 86               |
| Units: mmHg                                      |                 |                  |                  |                  |
| least squares mean (standard error)              |                 |                  |                  |                  |
| Week 4 24-hour mean [N=76, 66, 67, 72, 141, 157] | -1 (± 1.22)     | -2.04 (± 1.31)   | 0.96 (± 1.3)     | 1.03 (± 1.26)    |
| Week 4 mean daytime [N=72, 60, 62, 60, 129, 147] | -1.55 (± 1.22)  | -1.19 (± 1.33)   | -0.67 (± 1.31)   | -1.13 (± 1.34)   |

|                                                    |                |                |                |               |
|----------------------------------------------------|----------------|----------------|----------------|---------------|
| Week 4 mean nighttime [N=82, 74, 75, 72, 147, 161] | -0.51 (± 1.38) | -1.14 (± 1.46) | 1.42 (± 1.44)  | 0.41 (± 1.47) |
| Week 12 24-hour mean [N=67, 62, 63, 60, 121, 139]  | -1.97 (± 1.37) | -2.7 (± 1.42)  | -1.75 (± 1.41) | 0.4 (± 1.45)  |
| Week 12 mean daytime [N=65, 56, 55, 53, 106, 116]  | -2.22 (± 1.37) | -2.53 (± 1.46) | -2.14 (± 1.48) | -2.09 (± 1.5) |
| Week 12 mean nighttime [N=75, 64, 71, 65, 132,146] | -1.03 (± 1.64) | -2.81 (± 1.77) | -0.77 (± 1.68) | 1.31 (± 1.76) |
| EoT 24-hour mean [N=80, 73, 76, 78, 150, 168]      | -1.73 (± 1.24) | -3.44 (± 1.29) | -1.14 (± 1.27) | 0.37 (± 1.25) |
| EoT mean daytime [N=78, 67, 69, 69, 137, 153]      | -2.01 (± 1.22) | -3.29 (± 1.31) | -1.92 (± 1.3)  | -2.17 (± 1.3) |
| EoT mean nighttime [N=88, 80, 82, 82, 160, 175]    | -1 (± 1.47)    | -3.48 (± 1.54) | -0.6 (± 1.52)  | 1.42 (± 1.52) |

| End point values                                   | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|----------------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                                 | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed                        | 176                                 | 189                                 |  |  |
| Units: mmHg                                        |                                     |                                     |  |  |
| least squares mean (standard error)                |                                     |                                     |  |  |
| Week 4 24-hour mean [N=76, 66, 67, 72, 141, 157]   | -0.85 (± 0.9)                       | 0.31 (± 0.85)                       |  |  |
| Week 4 mean daytime [N=72, 60, 62, 60, 129, 147]   | -1.63 (± 0.91)                      | -0.53 (± 0.85)                      |  |  |
| Week 4 mean nighttime [N=82, 74, 75, 72, 147, 161] | 1.14 (± 1.03)                       | 0.54 (± 0.98)                       |  |  |
| Week 12 24-hour mean [N=67, 62, 63, 60, 121, 139]  | -0.71 (± 1.02)                      | 0.4 (± 0.95)                        |  |  |
| Week 12 mean daytime [N=65, 56, 55, 53, 106, 116]  | -0.39 (± 1.06)                      | -0.71 (± 1.02)                      |  |  |
| Week 12 mean nighttime [N=75, 64, 71, 65, 132,146] | 0.11 (± 1.23)                       | 0.79 (± 1.17)                       |  |  |
| EoT 24-hour mean [N=80, 73, 76, 78, 150, 168]      | -0.52 (± 0.9)                       | -0.08 (± 0.85)                      |  |  |
| EoT mean daytime [N=78, 67, 69, 69, 137, 153]      | -0.68 (± 0.92)                      | -1.28 (± 0.87)                      |  |  |
| EoT mean nighttime [N=88, 80, 82, 82, 160, 175]    | 0.41 (± 1.09)                       | 0.91 (± 1.04)                       |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Diastolic Blood Pressure (DBP)

|                 |                                                                                                                          |
|-----------------|--------------------------------------------------------------------------------------------------------------------------|
| End point title | Change from Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Diastolic Blood Pressure (DBP) |
|-----------------|--------------------------------------------------------------------------------------------------------------------------|

End point description:

Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study

medication and worn for at least 24 hours. The analysis population was the ABPMAS. N is the number of participants analyzed with data available at each time point. LOCF for EOT was used.

|                          |           |
|--------------------------|-----------|
| End point type           | Secondary |
| End point timeframe:     |           |
| Baseline and Weeks 4, 12 |           |

| End point values                                    | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|-----------------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                                  | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed                         | 92              | 85               | 87               | 86               |
| Units: mmHg                                         |                 |                  |                  |                  |
| least squares mean (standard error)                 |                 |                  |                  |                  |
| Week 4 24-hour mean [N=76, 66, 67, 72, 141, 157]    | -0.7 (± 0.5)    | -0.86 (± 0.54)   | 0.22 (± 0.54)    | 0.25 (± 0.52)    |
| Week 4 mean daytime [N=72, 60, 62, 60, 129, 147]    | -1.25 (± 0.53)  | -0.36 (± 0.58)   | -0.33 (± 0.57)   | -0.77 (± 0.58)   |
| Week 4 mean nighttime [N=82, 74, 75, 72, 147, 161]  | -0.12 (± 0.59)  | -0.97 (± 0.62)   | 0.4 (± 0.62)     | 0.48 (± 0.63)    |
| Week 12 24-hour mean [N=67, 62, 63, 60, 121, 139]   | -0.8 (± 0.56)   | -0.93 (± 0.58)   | -0.19 (± 0.57)   | 0.43 (± 0.59)    |
| Week 12 mean daytime [N=65, 56, 55, 53, 106, 116]   | -0.85 (± 0.6)   | -0.54 (± 0.64)   | -0.4 (± 0.65)    | -0.33 (± 0.66)   |
| Week 12 mean nighttime [N=75, 64, 71, 65, 132, 146] | -0.49 (± 0.66)  | -1.39 (± 0.71)   | -0.03 (± 0.68)   | 0.92 (± 0.71)    |
| EoT 24-hour mean [N=80, 73, 76, 78, 150, 168]       | -0.96 (± 0.51)  | -1.41 (± 0.53)   | -0.11 (± 0.52)   | 0.05 (± 0.52)    |
| EoT mean daytime [N=78, 67, 69, 69, 137, 153]       | -1.17 (± 0.53)  | -0.98 (± 0.58)   | -0.69 (± 0.57)   | -0.79 (± 0.57)   |
| EoT mean nighttime [N=88, 80, 82, 82, 160, 178]     | -0.41 (± 0.6)   | -2 (± 0.63)      | 0.08 (± 0.63)    | 0.71 (± 0.63)    |

| End point values                                    | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|-----------------------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                                  | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed                         | 176                                 | 189                                 |  |  |
| Units: mmHg                                         |                                     |                                     |  |  |
| least squares mean (standard error)                 |                                     |                                     |  |  |
| Week 4 24-hour mean [N=76, 66, 67, 72, 141, 157]    | 0.03 (± 0.37)                       | 0.38 (± 0.35)                       |  |  |
| Week 4 mean daytime [N=72, 60, 62, 60, 129, 147]    | -0.4 (± 0.4)                        | 0.07 (± 0.37)                       |  |  |
| Week 4 mean nighttime [N=82, 74, 75, 72, 147, 161]  | 0.93 (± 0.44)                       | 0.47 (± 0.42)                       |  |  |
| Week 12 24-hour mean [N=67, 62, 63, 60, 121, 139]   | -0.37 (± 0.41)                      | 0.31 (± 0.39)                       |  |  |
| Week 12 mean daytime [N=65, 56, 55, 53, 106, 116]   | -0.06 (± 0.46)                      | -0.18 (± 0.44)                      |  |  |
| Week 12 mean nighttime [N=75, 64, 71, 65, 132, 146] | 0.23 (± 0.49)                       | 0.49 (± 0.47)                       |  |  |
| EoT 24-hour mean [N=80, 73, 76, 78, 150, 168]       | -0.02 (± 0.37)                      | 0.25 (± 0.35)                       |  |  |

|                                                 |               |                |  |  |
|-------------------------------------------------|---------------|----------------|--|--|
| EoT mean daytime [N=78, 67, 69, 69, 137, 153]   | -0.18 (± 0.4) | -0.36 (± 0.38) |  |  |
| EoT mean nighttime [N=88, 80, 82, 82, 160, 178] | 0.56 (± 0.45) | 0.61 (± 0.43)  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Pulse Rate

|                 |                                                                                                      |
|-----------------|------------------------------------------------------------------------------------------------------|
| End point title | Change from Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Pulse Rate |
|-----------------|------------------------------------------------------------------------------------------------------|

End point description:

Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. The analysis population was the ABPMAS. N is the number of participants analyzed with data available at each time point. LOCF for EOT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 12

| End point values                                    | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|-----------------------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                                  | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed                         | 92              | 85               | 87               | 86               |
| Units: beats per minute (bpm)                       |                 |                  |                  |                  |
| least squares mean (standard error)                 |                 |                  |                  |                  |
| Week 4 24-hour mean [N=76, 66, 67, 72, 141, 157]    | -0.83 (± 0.63)  | 1.14 (± 0.68)    | 2.32 (± 0.67)    | 0.36 (± 0.65)    |
| Week 4 mean daytime [N=72, 60, 62, 60, 129, 147]    | -0.7 (± 0.73)   | 1.19 (± 0.79)    | 3.52 (± 0.78)    | 0.37 (± 0.8)     |
| Week 4 mean nighttime [N=82, 74, 75, 72, 147, 161]  | -0.72 (± 0.68)  | 0.98 (± 0.71)    | 1.77 (± 0.7)     | 1.09 (± 0.72)    |
| Week 12 24-hour mean [N=67, 62, 63, 60, 121, 189]   | 0.7 (± 0.72)    | 0.38 (± 0.74)    | 1.19 (± 0.74)    | 0.12 (± 0.76)    |
| Week 12 mean daytime [N=65, 56, 55, 53, 106, 116]   | 0.89 (± 0.82)   | 0.25 (± 0.88)    | 2.12 (± 0.89)    | -0.13 (± 0.9)    |
| Week 12 mean nighttime [N=75, 64, 71, 65, 132, 146] | 0.34 (± 0.71)   | 0.21 (± 0.77)    | 0.19 (± 0.73)    | 0.06 (± 0.76)    |
| EoT 24-hour mean [N=80, 73, 76, 78, 150, 168]       | 0.41 (± 0.65)   | 0.63 (± 0.68)    | 1.67 (± 0.67)    | 0.02 (± 0.66)    |
| EoT mean daytime [N=78, 67, 69, 69, 137, 153]       | 0.45 (± 0.74)   | 0.37 (± 0.8)     | 2.64 (± 0.79)    | -0.07 (± 0.79)   |
| EoT mean nighttime [N=88, 80, 82, 82, 160, 175]     | 0.39 (± 0.66)   | 0.82 (± 0.69)    | 0.75 (± 0.68)    | 0.45 (± 0.68)    |

| End point values | Solifenacin 5 mg + mirabegron 25 | Solifenacin 5 mg + mirabegron 50 |  |  |
|------------------|----------------------------------|----------------------------------|--|--|
|------------------|----------------------------------|----------------------------------|--|--|

|                                                     | mg              | mg              |  |  |
|-----------------------------------------------------|-----------------|-----------------|--|--|
| Subject group type                                  | Reporting group | Reporting group |  |  |
| Number of subjects analysed                         | 176             | 189             |  |  |
| Units: beats per minute (bpm)                       |                 |                 |  |  |
| least squares mean (standard error)                 |                 |                 |  |  |
| Week 4 24-hour mean [N=76, 66, 67, 72, 141, 157]    | 0.4 (± 0.46)    | 0.69 (± 0.44)   |  |  |
| Week 4 mean daytime [N=72, 60, 62, 60, 129, 147]    | -0.05 (± 0.54)  | 0.61 (± 0.51)   |  |  |
| Week 4 mean nighttime [N=82, 74, 75, 72, 147, 161]  | 0.86 (± 0.5)    | 0.86 (± 0.48)   |  |  |
| Week 12 24-hour mean [N=67, 62, 63, 60, 121, 189]   | 0.94 (± 0.53)   | 1.44 (± 0.5)    |  |  |
| Week 12 mean daytime [N=65, 56, 55, 53, 106, 116]   | 0.84 (± 0.64)   | 1.36 (± 0.61)   |  |  |
| Week 12 mean nighttime [N=75, 64, 71, 65, 132, 146] | 0.76 (± 0.53)   | 1.52 (± 0.51)   |  |  |
| EoT 24-hour mean [N=80, 73, 76, 78, 150, 168]       | 0.85 (± 0.47)   | 1.52 (± 0.45)   |  |  |
| EoT mean daytime [N=78, 67, 69, 69, 137, 153]       | 0.32 (± 0.56)   | 1.24 (± 0.53)   |  |  |
| EoT mean nighttime [N=88, 80, 82, 82, 160, 175]     | 1.21 (± 0.49)   | 1.64 (± 0.47)   |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to Weeks 4, 12 and EoT in Mean SBP 4 to 6 Hours Postdose

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                               |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Change from Baseline to Weeks 4, 12 and EoT in Mean SBP 4 to 6 Hours Postdose |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                               |
| Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax (time to maximum concentration) window of mirabegron and solifenacin was from 4-6 hours postdose. The analysis population was the ABPMAS. N is the number of participants analyzed with data available at each time point. LOCF for EOT was used. |                                                                               |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Secondary                                                                     |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                               |
| Baseline and Weeks 4, 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                               |

| End point values                     | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|--------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                   | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed          | 92              | 85               | 87               | 86               |
| Units: mmHg                          |                 |                  |                  |                  |
| least squares mean (standard error)  |                 |                  |                  |                  |
| Week 4 [N=77, 63, 73, 72, 142, 160]  | -2.71 (± 1.68)  | 0.34 (± 1.86)    | -1.03 (± 1.72)   | -1.77 (± 1.74)   |
| Week 12 [N=72, 60, 64, 59, 130, 131] | -4.86 (± 1.78)  | -2.13 (± 1.95)   | -1.64 (± 1.88)   | -3.15 (± 1.96)   |
| EoT [N=83, 75, 79, 78, 157, 169]     | -4.4 (± 1.6)    | -2.19 (± 1.68)   | -1.94 (± 1.64)   | -3.64 (± 1.65)   |

| End point values                     | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|--------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                   | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed          | 176                                 | 189                                 |  |  |
| Units: mmHg                          |                                     |                                     |  |  |
| least squares mean (standard error)  |                                     |                                     |  |  |
| Week 4 [N=77, 63, 73, 72, 142, 160]  | -1.55 (± 1.23)                      | -1.47 (± 1.17)                      |  |  |
| Week 12 [N=72, 60, 64, 59, 130, 131] | -0.26 (± 1.32)                      | 0.6 (± 1.32)                        |  |  |
| EoT [N=83, 75, 79, 78, 157, 169]     | -0.61 (± 1.16)                      | -0.98 (± 1.12)                      |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to Weeks 4, 12 and EoT in Mean DBP 4 to 6 Hours Postdose

|                 |                                                                               |
|-----------------|-------------------------------------------------------------------------------|
| End point title | Change from Baseline to Weeks 4, 12 and EoT in Mean DBP 4 to 6 Hours Postdose |
|-----------------|-------------------------------------------------------------------------------|

End point description:

Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax (time to maximum concentration) window of mirabegron and solifenacin was from 4-6 hours postdose. The analysis population was the ABPMAS. N is the number of participants analyzed with data available at each time point. LOCF for EOT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 12

| End point values                     | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|--------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                   | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed          | 92              | 85               | 87               | 86               |
| Units: mmHg                          |                 |                  |                  |                  |
| least squares mean (standard error)  |                 |                  |                  |                  |
| Week 4 [N=77, 63, 73, 72, 142, 160]  | -1.24 (± 0.84)  | 0.09 (± 0.93)    | -0.65 (± 0.86)   | -0.48 (± 0.87)   |
| Week 12 [N=72, 60, 64, 59, 130, 131] | -1.74 (± 0.92)  | -0.45 (± 1)      | -0.31 (± 0.97)   | -1.49 (± 1.01)   |
| EoT [N=83, 75, 79, 78, 157, 169]     | -1.85 (± 0.84)  | -0.71 (± 0.88)   | -0.71 (± 0.85)   | -1.22 (± 0.86)   |

| End point values | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|------------------|-------------------------------------|-------------------------------------|--|--|
|------------------|-------------------------------------|-------------------------------------|--|--|

|                                      |                 |                 |  |  |
|--------------------------------------|-----------------|-----------------|--|--|
| Subject group type                   | Reporting group | Reporting group |  |  |
| Number of subjects analysed          | 176             | 189             |  |  |
| Units: mmHg                          |                 |                 |  |  |
| least squares mean (standard error)  |                 |                 |  |  |
| Week 4 [N=77, 63, 73, 72, 142, 160]  | -0.22 (± 0.62)  | -0.71 (± 0.58)  |  |  |
| Week 12 [N=72, 60, 64, 59, 130, 131] | 0.48 (± 0.68)   | -0.03 (± 0.68)  |  |  |
| EoT [N=83, 75, 79, 78, 157, 169]     | 0.44 (± 0.61)   | -0.8 (± 0.59)   |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to Weeks 4, 12 and EoT in Mean Pulse Rate 4 to 6 Hours Postdose

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Change from Baseline to Weeks 4, 12 and EoT in Mean Pulse Rate 4 to 6 Hours Postdose |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                      |
| Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax (time to maximum concentration) window of mirabegron and solifenacin was from 4-6 hours postdose. The analysis population was the ABPMAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used. |                                                                                      |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Secondary                                                                            |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                      |
| Baseline and Weeks 4, 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                      |

| End point values                     | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|--------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                   | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed          | 92              | 85               | 87               | 86               |
| Units: bpm                           |                 |                  |                  |                  |
| least squares mean (standard error)  |                 |                  |                  |                  |
| Week 4 [N=77, 63, 73, 72, 142, 160]  | 0.02 (± 1.08)   | 2.39 (± 1.19)    | 3.68 (± 1.1)     | 0.47 (± 1.11)    |
| Week 12 [N=72, 60, 64, 59, 130, 131] | 0.1 (± 1.1)     | 1.22 (± 1.2)     | 1.87 (± 1.16)    | 0.37 (± 1.21)    |
| EoT [N=83, 75, 79, 78, 157, 169]     | -0.43 (± 1.05)  | 0.82 (± 1.1)     | 3.41 (± 1.07)    | -1.25 (± 1.08)   |

| End point values                     | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|--------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                   | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed          | 176                                 | 189                                 |  |  |
| Units: bpm                           |                                     |                                     |  |  |
| least squares mean (standard error)  |                                     |                                     |  |  |
| Week 4 [N=77, 63, 73, 72, 142, 160]  | -0.91 (± 0.79)                      | 0.67 (± 0.75)                       |  |  |
| Week 12 [N=72, 60, 64, 59, 130, 131] | 0.15 (± 0.81)                       | 1.39 (± 0.81)                       |  |  |
| EoT [N=83, 75, 79, 78, 157, 169]     | 0.34 (± 0.76)                       | 1.25 (± 0.73)                       |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maximum 1-hour Change from Time-matched Baseline in SBP at Weeks 4, 12 and EoT

|                 |                                                                                |
|-----------------|--------------------------------------------------------------------------------|
| End point title | Maximum 1-hour Change from Time-matched Baseline in SBP at Weeks 4, 12 and EoT |
|-----------------|--------------------------------------------------------------------------------|

End point description:

Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. The analysis population was the ABPMAS. N is the number of participants analyzed with data available at each time point. Only participants with an increase (i.e., maximum 1-hour change from time-matched baseline  $\geq 0$  mmHg) were included in the analysis. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 12

| End point values                     | Placebo              | Mirabegron 25 mg     | Mirabegron 50 mg     | Solifenacin 5 mg     |
|--------------------------------------|----------------------|----------------------|----------------------|----------------------|
| Subject group type                   | Reporting group      | Reporting group      | Reporting group      | Reporting group      |
| Number of subjects analysed          | 92                   | 85                   | 87                   | 86                   |
| Units: mmHg                          |                      |                      |                      |                      |
| least squares mean (standard error)  |                      |                      |                      |                      |
| Week 4 [N=76, 66, 67, 72, 141, 157]  | 34.05 ( $\pm 2.06$ ) | 31.14 ( $\pm 2.2$ )  | 38.2 ( $\pm 2.19$ )  | 35.16 ( $\pm 2.11$ ) |
| Week 12 [N=67, 62, 63, 60, 121, 139] | 33.21 ( $\pm 2.3$ )  | 30.68 ( $\pm 2.38$ ) | 32.88 ( $\pm 2.36$ ) | 35.11 ( $\pm 2.42$ ) |
| EoT [N=80, 73, 76, 78, 150, 168]     | 34.98 ( $\pm 2.11$ ) | 30.65 ( $\pm 2.2$ )  | 33.53 ( $\pm 2.16$ ) | 34.95 ( $\pm 2.14$ ) |

| End point values                     | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|--------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                   | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed          | 176                                 | 189                                 |  |  |
| Units: mmHg                          |                                     |                                     |  |  |
| least squares mean (standard error)  |                                     |                                     |  |  |
| Week 4 [N=76, 66, 67, 72, 141, 157]  | 32.88 ( $\pm 1.51$ )                | 32.8 ( $\pm 1.43$ )                 |  |  |
| Week 12 [N=67, 62, 63, 60, 121, 139] | 33.53 ( $\pm 1.7$ )                 | 32.82 ( $\pm 1.59$ )                |  |  |
| EoT [N=80, 73, 76, 78, 150, 168]     | 34.7 ( $\pm 1.54$ )                 | 32.55 ( $\pm 1.45$ )                |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maximum 1-hour Change from Time-matched Baseline in DBP at Weeks 4, 12 and EoT

|                 |                                                                                |
|-----------------|--------------------------------------------------------------------------------|
| End point title | Maximum 1-hour Change from Time-matched Baseline in DBP at Weeks 4, 12 and EoT |
|-----------------|--------------------------------------------------------------------------------|

End point description:

Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. The analysis population was the ABPMAS. N is the number of participants analyzed with data available at each time point. Only participants with an increase (i.e., maximum 1-hour change from time-matched baseline  $\geq 0$  mmHg) were included in the analysis. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 12

| End point values                     | Placebo              | Mirabegron 25 mg     | Mirabegron 50 mg     | Solifenacin 5 mg     |
|--------------------------------------|----------------------|----------------------|----------------------|----------------------|
| Subject group type                   | Reporting group      | Reporting group      | Reporting group      | Reporting group      |
| Number of subjects analysed          | 92                   | 85                   | 87                   | 86                   |
| Units: mmHg                          |                      |                      |                      |                      |
| least squares mean (standard error)  |                      |                      |                      |                      |
| Week 4 [N=76, 66, 67, 72, 141, 157]  | 18.78 ( $\pm 1.27$ ) | 19.15 ( $\pm 1.36$ ) | 20.41 ( $\pm 1.35$ ) | 20.02 ( $\pm 1.31$ ) |
| Week 12 [N=67, 62, 63, 60, 121, 139] | 19.68 ( $\pm 1.23$ ) | 19.52 ( $\pm 1.28$ ) | 20.41 ( $\pm 1.27$ ) | 21.18 ( $\pm 1.3$ )  |
| EoT [N=80, 73, 76, 78, 150, 168]     | 20.29 ( $\pm 1.16$ ) | 19.29 ( $\pm 1.22$ ) | 20.71 ( $\pm 1.19$ ) | 20.47 ( $\pm 1.18$ ) |

| End point values                     | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|--------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                   | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed          | 176                                 | 189                                 |  |  |
| Units: mmHg                          |                                     |                                     |  |  |
| least squares mean (standard error)  |                                     |                                     |  |  |
| Week 4 [N=76, 66, 67, 72, 141, 157]  | 20.74 ( $\pm 0.93$ )                | 20.27 ( $\pm 0.88$ )                |  |  |
| Week 12 [N=67, 62, 63, 60, 121, 139] | 19.26 ( $\pm 0.92$ )                | 20.01 ( $\pm 0.85$ )                |  |  |
| EoT [N=80, 73, 76, 78, 150, 168]     | 20.29 ( $\pm 0.85$ )                | 20.36 ( $\pm 0.8$ )                 |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maximum 1-hour Change from Time-matched Baseline in Pulse Rate at Weeks 4, 12 and EoT

|                 |                                                                                       |
|-----------------|---------------------------------------------------------------------------------------|
| End point title | Maximum 1-hour Change from Time-matched Baseline in Pulse Rate at Weeks 4, 12 and EoT |
|-----------------|---------------------------------------------------------------------------------------|

End point description:

Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. The analysis population was the ABPMAS. N is the number of participants analyzed with data available at each time point. Only participants with an increase (i.e., maximum 1-hour change from time-matched baseline  $\geq 0$  bpm) were included in the analysis. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4,12

| End point values                     | Placebo              | Mirabegron 25 mg     | Mirabegron 50 mg     | Solifenacin 5 mg     |
|--------------------------------------|----------------------|----------------------|----------------------|----------------------|
| Subject group type                   | Reporting group      | Reporting group      | Reporting group      | Reporting group      |
| Number of subjects analysed          | 92                   | 85                   | 87                   | 86                   |
| Units: bpm                           |                      |                      |                      |                      |
| least squares mean (standard error)  |                      |                      |                      |                      |
| Week 4 [N=76, 66, 67, 72, 141, 157]  | 22.34 ( $\pm 1.35$ ) | 23.86 ( $\pm 1.44$ ) | 25.12 ( $\pm 1.43$ ) | 24.28 ( $\pm 1.38$ ) |
| Week 12 [N=67, 62, 63, 60, 121, 139] | 22.63 ( $\pm 1.42$ ) | 23.54 ( $\pm 1.47$ ) | 26.03 ( $\pm 1.46$ ) | 23.52 ( $\pm 1.5$ )  |
| EoT [N=80, 73, 76, 78, 150, 168]     | 23.01 ( $\pm 1.31$ ) | 24.12 ( $\pm 1.37$ ) | 26.23 ( $\pm 1.34$ ) | 23.33 ( $\pm 1.33$ ) |

| End point values                     | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|--------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                   | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed          | 176                                 | 189                                 |  |  |
| Units: bpm                           |                                     |                                     |  |  |
| least squares mean (standard error)  |                                     |                                     |  |  |
| Week 4 [N=76, 66, 67, 72, 141, 157]  | 21.48 ( $\pm 0.99$ )                | 21.8 ( $\pm 0.94$ )                 |  |  |
| Week 12 [N=67, 62, 63, 60, 121, 139] | 22.6 ( $\pm 1.05$ )                 | 24.08 ( $\pm 0.98$ )                |  |  |
| EoT [N=80, 73, 76, 78, 150, 168]     | 22.66 ( $\pm 0.96$ )                | 24.14 ( $\pm 0.9$ )                 |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline to Weeks 4, 12 and EoT in SBP Peak/Trough Difference

|                 |                                                                           |
|-----------------|---------------------------------------------------------------------------|
| End point title | Change from Baseline to Weeks 4, 12 and EoT in SBP Peak/Trough Difference |
|-----------------|---------------------------------------------------------------------------|

End point description:

Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference is defined as the difference between the highest 1-h to lowest 1-h average per participant per visit. The analysis population was the ABPMAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Weeks 4, 12

| End point values                     | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|--------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                   | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed          | 92              | 85               | 87               | 86               |
| Units: mmHg                          |                 |                  |                  |                  |
| least squares mean (standard error)  |                 |                  |                  |                  |
| Week 4 [N=76, 66, 67, 72, 141, 157]  | -0.71 (± 1.86)  | 0.14 (± 1.99)    | -0.69 (± 1.98)   | 0.85 (± 1.91)    |
| Week 12 [N=67, 62, 63, 60, 121, 139] | 1.18 (± 1.98)   | -2.45 (± 2.05)   | -4.55 (± 2.03)   | -1.63 (± 2.08)   |
| EoT [N=80, 73, 76, 78, 150, 168]     | 1.15 (± 1.83)   | -1.38 (± 1.91)   | -2.3 (± 1.87)    | -0.97 (± 1.85)   |

| End point values                     | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|--------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                   | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed          | 176                                 | 189                                 |  |  |
| Units: mmHg                          |                                     |                                     |  |  |
| least squares mean (standard error)  |                                     |                                     |  |  |
| Week 4 [N=76, 66, 67, 72, 141, 157]  | -1.61 (± 1.36)                      | 0.41 (± 1.29)                       |  |  |
| Week 12 [N=67, 62, 63, 60, 121, 139] | 0.68 (± 1.47)                       | 0.62 (± 1.37)                       |  |  |
| EoT [N=80, 73, 76, 78, 150, 168]     | 0.25 (± 1.33)                       | 0.68 (± 1.26)                       |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline to Weeks 4, 12 and EoT in DBP Peak/Trough Difference

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                           |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Change from Baseline to Weeks 4, 12 and EoT in DBP Peak/Trough Difference |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                           |
| Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference is defined as the difference between the highest 1-h to lowest 1-h average per participant per visit. The analysis population was the ABPMAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used. |                                                                           |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Secondary                                                                 |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                           |
| Baseline and Weeks 4, 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                           |

| End point values                     | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|--------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                   | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed          | 92              | 85               | 87               | 86               |
| Units: mmHg                          |                 |                  |                  |                  |
| least squares mean (standard error)  |                 |                  |                  |                  |
| Week 4 [N=76, 66, 67, 72, 141, 157]  | -0.76 (± 1.31)  | -1.08 (± 1.4)    | -0.2 (± 1.39)    | -1.6 (± 1.34)    |
| Week 12 [N=67, 62, 63, 60, 121, 139] | 0.53 (± 1.3)    | 0.15 (± 1.34)    | -1.9 (± 1.33)    | -0.66 (± 1.36)   |
| EoT [N=80, 73, 76, 78, 150, 168]     | 0.87 (± 1.23)   | 0.27 (± 1.28)    | -0.96 (± 1.26)   | -1.67 (± 1.24)   |

| End point values                     | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|--------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                   | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed          | 176                                 | 189                                 |  |  |
| Units: mmHg                          |                                     |                                     |  |  |
| least squares mean (standard error)  |                                     |                                     |  |  |
| Week 4 [N=76, 66, 67, 72, 141, 157]  | 0.39 (± 0.96)                       | -0.56 (± 0.91)                      |  |  |
| Week 12 [N=67, 62, 63, 60, 121, 139] | -1.24 (± 0.96)                      | 0.46 (± 0.9)                        |  |  |
| EoT [N=80, 73, 76, 78, 150, 168]     | -0.98 (± 0.89)                      | 0.52 (± 0.85)                       |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline to Weeks 4, 12 and EoT in Pulse Rate Peak/Trough Difference

|                 |                                                           |
|-----------------|-----------------------------------------------------------|
| End point title | Change from Baseline to Weeks 4, 12 and EoT in Pulse Rate |
|-----------------|-----------------------------------------------------------|

## End point description:

Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference is defined as the difference between the highest 1-h to lowest 1-h average per participant per visit. The analysis population was the ABPMAS. N is the number of participants analyzed with data available at each time point. LOCF for EoT was used.

## End point type

Secondary

## End point timeframe:

Baseline and Weeks 4, 12

| End point values                     | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg | Solifenacin 5 mg |
|--------------------------------------|-----------------|------------------|------------------|------------------|
| Subject group type                   | Reporting group | Reporting group  | Reporting group  | Reporting group  |
| Number of subjects analysed          | 92              | 85               | 87               | 86               |
| Units: bpm                           |                 |                  |                  |                  |
| least squares mean (standard error)  |                 |                  |                  |                  |
| Week 4 [N=76, 66, 67, 72, 141, 157]  | 1.16 (± 1.38)   | 0.46 (± 1.48)    | 1.54 (± 1.46)    | 0.78 (± 1.41)    |
| Week 12 [N=67, 62, 63, 60, 121, 139] | 3.35 (± 1.45)   | -0.04 (± 1.5)    | 1.15 (± 1.49)    | 3.49 (± 1.53)    |
| EoT [N=80, 73, 76, 78, 150, 168]     | 2.48 (± 1.32)   | 0.45 (± 1.37)    | 1.14 (± 1.35)    | 3.16 (± 1.33)    |

| End point values                     | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |  |  |
|--------------------------------------|-------------------------------------|-------------------------------------|--|--|
| Subject group type                   | Reporting group                     | Reporting group                     |  |  |
| Number of subjects analysed          | 141                                 | 157                                 |  |  |
| Units: bpm                           |                                     |                                     |  |  |
| least squares mean (standard error)  |                                     |                                     |  |  |
| Week 4 [N=76, 66, 67, 72, 141, 157]  | -0.68 (± 1.01)                      | -0.51 (± 0.96)                      |  |  |
| Week 12 [N=67, 62, 63, 60, 121, 139] | -0.53 (± 1.07)                      | 1.48 (± 1)                          |  |  |
| EoT [N=80, 73, 76, 78, 150, 168]     | -0.02 (± 0.96)                      | 1.8 (± 0.91)                        |  |  |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first dose of double-blind study drug up to 30 days after last dose of double-blind study drug (up to 16 weeks)

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 16.0 |
|--------------------|------|

### Reporting groups

|                       |         |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Participants who received matching placebo once a day for 12 weeks.

|                       |                  |
|-----------------------|------------------|
| Reporting group title | Mirabegron 25 mg |
|-----------------------|------------------|

Reporting group description:

Participants who received mirabegron 25 mg once a day for 12 weeks.

|                       |                  |
|-----------------------|------------------|
| Reporting group title | Mirabegron 50 mg |
|-----------------------|------------------|

Reporting group description:

Participants who received mirabegron 50 mg once a day for 12 weeks.

|                       |                  |
|-----------------------|------------------|
| Reporting group title | Solifenacin 5 mg |
|-----------------------|------------------|

Reporting group description:

Participants who received solifenacin 5 mg once a day for 12 weeks.

|                       |                                     |
|-----------------------|-------------------------------------|
| Reporting group title | Solifenacin 5 mg + mirabegron 25 mg |
|-----------------------|-------------------------------------|

Reporting group description:

Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.

|                       |                                     |
|-----------------------|-------------------------------------|
| Reporting group title | Solifenacin 5 mg + mirabegron 50 mg |
|-----------------------|-------------------------------------|

Reporting group description:

Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.

| Serious adverse events                                              | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg |
|---------------------------------------------------------------------|-----------------|------------------|------------------|
| Total subjects affected by serious adverse events                   |                 |                  |                  |
| subjects affected / exposed                                         | 8 / 429 (1.86%) | 6 / 423 (1.42%)  | 5 / 422 (1.18%)  |
| number of deaths (all causes)                                       | 0               | 0                | 0                |
| number of deaths resulting from adverse events                      |                 |                  |                  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                 |                  |                  |
| Benign neoplasm of thyroid gland                                    |                 |                  |                  |
| subjects affected / exposed                                         | 0 / 429 (0.00%) | 0 / 423 (0.00%)  | 0 / 422 (0.00%)  |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 0            | 0 / 0            |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0            | 0 / 0            |
| Plasma cell myeloma                                                 |                 |                  |                  |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Prostate cancer                                 |                 |                 |                 |
| subjects affected / exposed                     | 1 / 429 (0.23%) | 0 / 423 (0.00%) | 1 / 422 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Squamous cell carcinoma                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Vascular disorders                              |                 |                 |                 |
| Hypertension                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hypertensive crisis                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hypovolaemic shock                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 1 / 422 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Surgical and medical procedures                 |                 |                 |                 |
| Renal stone removal                             |                 |                 |                 |
| subjects affected / exposed                     | 1 / 429 (0.23%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Immune system disorders                         |                 |                 |                 |
| Hypersensitivity                                |                 |                 |                 |
| subjects affected / exposed                     | 1 / 429 (0.23%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Reproductive system and breast disorders        |                 |                 |                 |
| Menorrhagia                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Respiratory, thoracic and mediastinal disorders |                 |                 |                 |
| Apnoea                                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Chronic obstructive pulmonary disease           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hiccups                                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Psychiatric disorders                           |                 |                 |                 |
| Depression                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 1 / 423 (0.24%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Injury, poisoning and procedural complications  |                 |                 |                 |
| Hip fracture                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Laceration                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ligament rupture                                |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Lower limb fracture                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 1 / 423 (0.24%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Upper limb fracture                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac disorders                               |                 |                 |                 |
| Angina pectoris                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 1 / 423 (0.24%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Atrial flutter                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac failure                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Palpitations                                    |                 |                 |                 |
| subjects affected / exposed                     | 1 / 429 (0.23%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Supraventricular tachycardia                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Nervous system disorders                        |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Cerebral haemorrhage                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cerebrovascular disorder                        |                 |                 |                 |
| subjects affected / exposed                     | 1 / 429 (0.23%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Grand mal convulsion                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 1 / 422 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hydrocephalus                                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Radiculopathy                                   |                 |                 |                 |
| subjects affected / exposed                     | 1 / 429 (0.23%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Subarachnoid haemorrhage                        |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Transient ischaemic attack                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ear and labyrinth disorders                     |                 |                 |                 |
| Otorrhoea                                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 1 / 423 (0.24%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastrointestinal disorders                      |                 |                 |                 |

|                                                                     |                 |                 |                 |
|---------------------------------------------------------------------|-----------------|-----------------|-----------------|
| Diverticulum intestinal haemorrhagic<br>subjects affected / exposed | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to<br>treatment / all                  | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to<br>treatment / all                       | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastrointestinal haemorrhage<br>subjects affected / exposed         | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to<br>treatment / all                  | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to<br>treatment / all                       | 0 / 0           | 0 / 0           | 0 / 0           |
| Haemorrhoids<br>subjects affected / exposed                         | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to<br>treatment / all                  | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to<br>treatment / all                       | 0 / 0           | 0 / 0           | 0 / 0           |
| Rectal haemorrhage<br>subjects affected / exposed                   | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to<br>treatment / all                  | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to<br>treatment / all                       | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatobiliary disorders                                             |                 |                 |                 |
| Cholecystitis<br>subjects affected / exposed                        | 1 / 429 (0.23%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to<br>treatment / all                  | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to<br>treatment / all                       | 0 / 0           | 0 / 0           | 0 / 0           |
| Cholelithiasis<br>subjects affected / exposed                       | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 1 / 422 (0.24%) |
| occurrences causally related to<br>treatment / all                  | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to<br>treatment / all                       | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatitis toxic<br>subjects affected / exposed                      | 0 / 429 (0.00%) | 1 / 423 (0.24%) | 0 / 422 (0.00%) |
| occurrences causally related to<br>treatment / all                  | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to<br>treatment / all                       | 0 / 0           | 0 / 0           | 0 / 0           |
| Skin and subcutaneous tissue disorders                              |                 |                 |                 |
| Pruritus<br>subjects affected / exposed                             | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to<br>treatment / all                  | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to<br>treatment / all                       | 0 / 0           | 0 / 0           | 0 / 0           |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Renal and urinary disorders                     |                 |                 |                 |
| Renal colic                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Urinary retention                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Musculoskeletal and connective tissue disorders |                 |                 |                 |
| Rotator cuff syndrome                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Spondylolisthesis                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Infections and infestations                     |                 |                 |                 |
| Appendicitis                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 1 / 422 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Bronchitis                                      |                 |                 |                 |
| subjects affected / exposed                     | 1 / 429 (0.23%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Bronchopneumonia                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pneumonia                                       |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Post procedural infection                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pyelonephritis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 1 / 423 (0.24%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pyelonephritis acute                            |                 |                 |                 |
| subjects affected / exposed                     | 1 / 429 (0.23%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Scrub typhus                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Septic shock                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 1 / 423 (0.24%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Metabolism and nutrition disorders              |                 |                 |                 |
| Intervertebral disc protrusion                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 429 (0.00%) | 0 / 423 (0.00%) | 0 / 422 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

| <b>Serious adverse events</b>                     | Solifenacin 5 mg | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |
|---------------------------------------------------|------------------|-------------------------------------|-------------------------------------|
| Total subjects affected by serious adverse events |                  |                                     |                                     |
| subjects affected / exposed                       | 3 / 423 (0.71%)  | 12 / 853 (1.41%)                    | 19 / 848 (2.24%)                    |
| number of deaths (all causes)                     | 0                | 0                                   | 0                                   |
| number of deaths resulting from adverse events    |                  |                                     |                                     |

|                                                                     |                 |                 |                 |
|---------------------------------------------------------------------|-----------------|-----------------|-----------------|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                 |                 |                 |
| Benign neoplasm of thyroid gland                                    |                 |                 |                 |
| subjects affected / exposed                                         | 1 / 423 (0.24%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0           | 0 / 0           |
| Plasma cell myeloma                                                 |                 |                 |                 |
| subjects affected / exposed                                         | 0 / 423 (0.00%) | 1 / 853 (0.12%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0           | 0 / 0           |
| Prostate cancer                                                     |                 |                 |                 |
| subjects affected / exposed                                         | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0           | 0 / 0           |
| Squamous cell carcinoma                                             |                 |                 |                 |
| subjects affected / exposed                                         | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0           | 0 / 0           |
| Vascular disorders                                                  |                 |                 |                 |
| Hypertension                                                        |                 |                 |                 |
| subjects affected / exposed                                         | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 0           | 1 / 1           |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0           | 0 / 0           |
| Hypertensive crisis                                                 |                 |                 |                 |
| subjects affected / exposed                                         | 0 / 423 (0.00%) | 1 / 853 (0.12%) | 2 / 848 (0.24%) |
| occurrences causally related to treatment / all                     | 0 / 0           | 1 / 1           | 1 / 2           |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0           | 0 / 0           |
| Hypovolaemic shock                                                  |                 |                 |                 |
| subjects affected / exposed                                         | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0           | 0 / 0           |
| Surgical and medical procedures                                     |                 |                 |                 |
| Renal stone removal                                                 |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Immune system disorders                         |                 |                 |                 |
| Hypersensitivity                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Reproductive system and breast disorders        |                 |                 |                 |
| Menorrhagia                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Respiratory, thoracic and mediastinal disorders |                 |                 |                 |
| Apnoea                                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 1 / 853 (0.12%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Chronic obstructive pulmonary disease           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 1 / 853 (0.12%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hiccups                                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Psychiatric disorders                           |                 |                 |                 |
| Depression                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Injury, poisoning and procedural complications  |                 |                 |                 |
| Hip fracture                                    |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 423 (0.00%) | 1 / 853 (0.12%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Laceration                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ligament rupture                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Lower limb fracture                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Upper limb fracture                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 1 / 853 (0.12%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac disorders                               |                 |                 |                 |
| Angina pectoris                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Atrial flutter                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac failure                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 1 / 853 (0.12%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Palpitations                                    |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Supraventricular tachycardia                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 1 / 853 (0.12%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 2 / 2           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Nervous system disorders                        |                 |                 |                 |
| Cerebral haemorrhage                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cerebrovascular disorder                        |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Grand mal convulsion                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hydrocephalus                                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Radiculopathy                                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Subarachnoid haemorrhage                        |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Transient ischaemic attack                      |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 423 (0.00%) | 1 / 853 (0.12%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ear and labyrinth disorders                     |                 |                 |                 |
| Otorrhoea                                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastrointestinal disorders                      |                 |                 |                 |
| Diverticulum intestinal haemorrhagic            |                 |                 |                 |
| subjects affected / exposed                     | 1 / 423 (0.24%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastrointestinal haemorrhage                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 1 / 853 (0.12%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Haemorrhoids                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rectal haemorrhage                              |                 |                 |                 |
| subjects affected / exposed                     | 1 / 423 (0.24%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatobiliary disorders                         |                 |                 |                 |
| Cholecystitis                                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cholelithiasis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Hepatitis toxic                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Skin and subcutaneous tissue disorders          |                 |                 |                 |
| Pruritus                                        |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Renal and urinary disorders                     |                 |                 |                 |
| Renal colic                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 1 / 853 (0.12%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Urinary retention                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Musculoskeletal and connective tissue disorders |                 |                 |                 |
| Rotator cuff syndrome                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Spondylolisthesis                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Infections and infestations                     |                 |                 |                 |
| Appendicitis                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Bronchitis                                      |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Bronchopneumonia                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pneumonia                                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 1 / 848 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Post procedural infection                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 1 / 853 (0.12%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pyelonephritis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pyelonephritis acute                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Scrub typhus                                    |                 |                 |                 |
| subjects affected / exposed                     | 1 / 423 (0.24%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Septic shock                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 423 (0.00%) | 0 / 853 (0.00%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Metabolism and nutrition disorders              |                 |                 |                 |
| Intervertebral disc protrusion                  |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 423 (0.00%) | 1 / 853 (0.12%) | 0 / 848 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                     | Placebo         | Mirabegron 25 mg | Mirabegron 50 mg |
|-------------------------------------------------------|-----------------|------------------|------------------|
| Total subjects affected by non-serious adverse events |                 |                  |                  |
| subjects affected / exposed                           | 8 / 429 (1.86%) | 17 / 423 (4.02%) | 14 / 422 (3.32%) |
| Gastrointestinal disorders                            |                 |                  |                  |
| Dry mouth                                             |                 |                  |                  |
| subjects affected / exposed                           | 8 / 429 (1.86%) | 17 / 423 (4.02%) | 14 / 422 (3.32%) |
| occurrences (all)                                     | 8               | 18               | 14               |

| <b>Non-serious adverse events</b>                     | Solifenacin 5 mg | Solifenacin 5 mg + mirabegron 25 mg | Solifenacin 5 mg + mirabegron 50 mg |
|-------------------------------------------------------|------------------|-------------------------------------|-------------------------------------|
| Total subjects affected by non-serious adverse events |                  |                                     |                                     |
| subjects affected / exposed                           | 25 / 423 (5.91%) | 72 / 853 (8.44%)                    | 60 / 848 (7.08%)                    |
| Gastrointestinal disorders                            |                  |                                     |                                     |
| Dry mouth                                             |                  |                                     |                                     |
| subjects affected / exposed                           | 25 / 423 (5.91%) | 72 / 853 (8.44%)                    | 60 / 848 (7.08%)                    |
| occurrences (all)                                     | 27               | 73                                  | 61                                  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date              | Amendment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 09 September 2013 | <p>Substantial amendment 1, dated 09 Sep 2013, is summarized as follows:</p> <ul style="list-style-type: none"><li>• Inclusion criterion 3 relating to female patients of childbearing potential and inclusion criterion 14 relating to the number of urgency episodes/24 h, respectively, were clarified.</li><li>• The sample size justification for change from baseline in mean number of incontinence episodes/24 h was modified to accommodate the 7-day diary period.</li><li>• The efficacy analyses were modified. The adjustment for multiplicity was changed from a hierarchical testing procedure to a sequential Bonferroni-based testing procedure to control the type 1 error across the variables. Additional sensitivity analyses for the coprimary and key secondary efficacy endpoints were added.</li><li>• Expected adverse drug reactions (ADRs) and expected risks were updated in line with the company core data sheets.</li><li>• Antidepressant drugs with anticholinergic ADRs were moved from the list of restricted medications to prohibited medications as these drugs sometimes are used to treat OAB.</li><li>• Nonsubstantial changes were implemented in addition to the substantial changes mentioned above.</li></ul> |
| 12 November 2014  | <p>Substantial amendment 2, dated 12 Nov 2014, is summarized as follows.</p> <ul style="list-style-type: none"><li>• The number of screened patients was increased to meet the target of 3392 randomized patients.</li><li>• The number of patients to be randomized in the ABPM substudy was increased to ensure the number of 608 evaluable patients. In addition, the investigator was allowed to repeat the baseline (directly) and week 4 (at week 8) ABPM assessments to increase the number of evaluable patients in the ABPM substudy.</li><li>• Exclusion criteria 4, 10 and 24 relating to neurological cause for detrusor overactivity, QTcF interval (QT interval corrected using Fridericia's correction formula) and urinary tract infection (UTI), respectively, were clarified.</li><li>• The list of prohibited or restricted medications was removed from Appendix 1 of the protocol and was provided to investigational sites via separate communications.</li></ul>                                                                                                                                                                                                                                                                     |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported